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Abbreviations 
 
 
NMR  nuclear magnetic resonance 
MRI   magnetic resonance imaging 
NIRF  near infrared fluorescence 
FRI  fluorescence reflectance imaging 
PET  positron emission tomography 
CT  computed tomography 
CNS   central nervous system  
BBB  blood brain barrier  
MS   multiple sclerosis 
EAE  experimental autoimmune encephalomyelitis  
ROI   region of interest 
MTR   magnetization transfer ratios 
CA  contrast agent 
Gd-enh gadolinium enhancement 
FeO  ferumoxides  
SPIO  small particles of iron oxide 
USPIO  ultra small particles of iron oxide 
IHC   immuno-histochemistry 
TAs  transfection agents 
PLL   poly-L-lysin 
PEI  poly-ethylene-imine 
Tat   trans-activator peptide derived from the HIV virus 
NIRF  Near-Infrared Fluorescence 
Cy5.5  1H-Benz[e]indolium, 2-[5-[3-(5-carboxypentyl)-1,3-dihydro-1,1-dimethyl-6,8- 
disulfo-2H-benz[e]indol-2-ylidene]-1,3-pentadienyl]-3-ethyl-1,1-dimethyl-6,8- 
disulfo-, inner salt 
dpi   Days post immunization 
AT  Activated T cells coming from EAE animals 
NT  Non-activated T cells coming from naïve animals 
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Summary 
 
 
 
SUMMARY 
 
MS was first described in 1868 by Charcot noting the accumulation of inflammatory cells in a 
perivascular distribution within the white matter of the brain and the spinal cord of patients. 
The autoimmune demyelination process causing the disease was first established by Thomas 
Rivers in 1933 with the repeated injection of rabbit and spinal cord fragment into primates to 
induce an EAE model. The main lesson from the use of the EAE model is that the minimal 
requirement for inducing inflammatory, autoimmune CNS demyelinating disease is the 
activation of myelin-reactive T cells in the peripheral immune system.  
First applications of MR imaging to MS in the early 1980s, increased the reliability of 
the diagnosis and enhanced the understanding of lesion development. MR imaging with the 
help of contrast agents (CAs) provided new tools (e.g. T1 and T2 relaxation based methods, 
magnetization transfer) for detecting newly forming lesions, to differentiate them from other 
lesions not specific for MS, and even evaluate BBB breakdown and edema formation, as well 
as visualizing immune cells in the EAE model. Contrast agents such as Gd complexes or iron-
based nanoparticles can be used to precisely localize zones of BBB impairment  or 
macrophages infiltration in the brain parenchyma.  
 
By focusing on the neuroinflammatory demyelinating processes in a rat model of EAE, the 
general purpose of this thesis was to develop new methods to label immune cells to identify 
immunological events characteristic of EAE. Macrophages and T lymphocytes are immune 
cells that play a major role in brain impairment. These cells have been tagged with new-
generation contrast agents (CA) for monitoring their migration non-invasively using MRI and 
near infra-red fluorescence imaging (NIRF).  
Our first goal was to label macrophages for MRI and determine their role in the three 
characteristic phases of the EAE model (i.e. acute, remitting and relapsing phases). As 
macrophages are typical phagocytotic cells, ultra small particles of iron oxide (USPIOs) have 
been injected intravenously in the tail vein of animals in order to be internalized by 
monocytes in blood circulation. Circulating monocytes loaded with iron migrated to 
inflammation areas in parenchymal brain tissues. MR measurement have been preformed on 
EAE animals and we determined iron-rich region as hypointense areas in T2-weighted images 
as region of interest (ROIs) for further investigations.  
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In addition to macrophage localization, the opening of the blood brain barrier (BBB) 
as well as demyelination processes have been measured by MRI mapping gadolinium (Gd) 
related signal enhancement and magnetic transfer (MT), respectively. By successively 
applying this protocol at different time points during the EAE model progression, we were 
able to analyse the interdependence of immuno-cellular processes leading to axonal damage 
as well as the longitudinal evolution of pathological hallmarks of EAE.  
Furthermore, these techniques have been used to validate and quantify the anti-inflammatory 
effect of EDG-1 inhibitor FTY720 on EAE symptoms. Repeated USPIO administrations and 
MRI measurements combining the analysis of MT ratios and Gd-enhancement have been 
performed on vehicle and FTY720 treated animals. This study demonstrates that FTY720 can 
prevent inflammatory events in EAE rats by sequestrating immune cells in lymphoid organs 
during acute inflammation episodes.  
The third goal, was to translate the iron-labeling protocol from macrophages to T 
lymphocytes. As T cells are initiators of the immune cascade leading to the occurence of 
symptoms in the EAE model, it would be highly relevant to visualize T lymphocytes prior to 
the onset of symptoms. Yet, as lymphocytes have no natural phagocytotic activity, in vivo 
tagging with CA was not feasible. We decided to label them in vitro with ferumoxides (FeO) 
and then, transfer iron-presenting cells adoptively to EAE animals intravenously. Different 
techniques have been used to evaluate the efficiency of lymphocytes labeling combining iron 
oxide particles with commonly available transfection agents (TAs) and the feasibility of 
labeling T lymphocytes in vitro has been demonstrated. However, the adoptive transfer of  
iron-tagged T cells to EAE rats did not lead to the detection of these cells by MRI.  
As MR detection of iron-tagged cell in vivo was unsuccessful probably due to the 
inherent lack of sensitivity of the MRI technique for molecular changes and the dilution of 
labeled cells in the blood, we decided to switch to a more sensitive technique. Thus, the goal 
of the last part of the thesis was to label primary cultured T lymphocytes with a fluorescent 
dye: cyanine 5.5 (Cy5.5). The Tat peptide from the HIV virus chemically has been bound to 
the Cy5.5 to cargo the dye across T cells membrane. The ability of this probe to penetrate T 
cells and its potential toxicity has been evaluated in vitro. Subsequently, Cy5.5-Tat labeled 
lymphocytes were transferred to EAE rats in order to monitor their bio-distribution during 
EAE. Prominent signals have been obtained from rat brain and histological experimentation 
using confocal microscopy analysis have been performed to confirm the localization of Cy5.5 
within the brain parenchyma.  
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1 NMR AND IMAGE CONTRAST  
 
The first section gives an overview of the physical principles governing the phenomenon of 
nuclear magnetic resonance (NMR). A short definition of the proton spin precedes the 
description of the NMR event: the interaction of an external magnetic field with nuclear spins 
(chapters 1.1). Different modalities of spin relaxation (1.2) and principal pulse sequences used 
for MR imaging (MRI) (1.3) are presented before discussing contrast mechanisms that allow 
tissue discrimination by MRI (1.4). Specific methods for mapping animal brain by contrast 
enhancement (1.5) and commonly used contrast agents  are described in the chapter 1.6. A 
brief description of both T1 and T2 sensitive contrast agents is given in chapters 1.6 and 1.7 
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1.1 Interaction of Magnetization with a Magnetic Field, the 
NMR Experiment 
 
The intrinsic angular moment (spin) is a fundamental property of elementary particles such as 
protons, neutrons and electrons. These particles called fermions possess a net spin of  1/2. In 
atoms, pairs of neutrons and protons align to cancel out their spins. Nuclei with an odd 
number of protons and/or neutrons have a non-zero nuclear moment characterized by integer 
or half-integer nuclear spin quantum number I. Almost every element has an isotope with a 
non-zero nuclear spin (Table 1.1). NMR can only be performed on isotopes whose natural 
abundance is high enough to be detected. For biological applications, the most relevant nuclei 
are the 1H, 13C, 19F and 31P. 
 
Table 1.1    
Nuclei Unpaired Protons Unpaired Neutrons Net Spin 
1H 1 0 1/2 
2H 1 1 1 
13C 0 1 1/2 
14N 1 1 1 
19F 1 0 1/2 
23Na 1 2 3/2 
31P 1 0 1/2 
List of the principal natural compound of biological tissues a non-zero net 
nuclear spin. 
 
When placed in a magnetic field, nuclear magnets arrange themselves in the direction of the 
main magnetic field B0. Nuclear magnets align themselves in a discrete (quantized) manner: 
(2I+1) energy levels are observed for a nuclear spin I. Hence, for I=1/2 two orientations 
occur, either parallel or anti-parallel to the applied field B0 (i.e. mI = ±1/2). The energy of the 
two states depends on the type of nucleus characterized by the so-called gyromagnetic ratio γ 
and on the magnetic flux B0:  
 
     II mBmE ⋅⋅⋅−= 0)( hγ     [1] 
 
With  being the Plank constant.  h
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For nuclei with γ > 0 (e.g. proton) the state with the z-component of the spin aligned parallel 
to the magnetic field has a lower energy. The macroscopically observable magnetization is the 
vector sum of the individual nuclear magnets, 
 
           [2] ∑
=
=
N
i
iIM
1
0
rr
 
which is oriented along the static magnetic field B0 which shall be oriented along the z-axis. 
The z-component of the magnetization is 
 
           [3] ∑
=
=
N
i
iIz mM
1
,0,
 
With  = -I, -I+1, …,+I  i.e. 2I+1 values. For magnetic field strengths of the order of few 
Tesla, the energy difference between the two levels is small as compared to the thermal 
energy, i.e. 
iIm ,
     kTEEE <<−−=∆ )()( 2121      [4] 
 
with k being the Boltzmann constant and T the absolute temperature in Kelvin.  
As a consequence, for a field strength of 4-8 T, every 105 nuclei, there is about one extra 
aligned with the B0 field as opposed to the field i.e. the excess population of the lower energy 
state is only approximately 10 ppm (part per million). This explains the inherently low 
sensitivity of nuclear magnetic resonance experiments. 
Application of an oscillating electromagnetic field perpendicular to the main field axis (z) will 
deflect the magnetization from its equilibrium position, provided that its frequency 
corresponds to the resonance frequency, the so-called Larmor frequency, defined by 
 
    00 /)}()1({/ BmEmEE II ⋅=−+=∆= γω hh    [5] 
 
For commonly used magnetic field strengths the resonance frequency is in the radiofrequency 
(RF) domain of the order of 100-500 MHz.  
 
 
  19 
 
Chapter 1.1 The NMR Experiment 
 
 
 
Application of an RF field induces  
a) transitions between the two energy states involved (in both directions) and  
b) coherences among the individual nuclear spins.  
While in the absence of the of the RF field the individual spins have random phases, there 
transverse component aligns along the RF field leading to an observable transverse 
magnetization (Figure 1.1). This oscillating, hence time dependent transverse magnetization 
induces a voltage in a pick-up coil, the nuclear magnetic resonance (NMR) signal. 
The oscillating field is commonly decomposed into two counter-rotating fields, 
 
  { })sin(cos)sin(coscos)( 21111 tittitBtBtB ⋅⋅−⋅+⋅⋅+⋅⋅⋅=⋅⋅= ωωωωω  
      { })exp()exp(211 titiB ⋅⋅−+⋅⋅+⋅⋅= ωω     [6] 
 
It is well known that only the component that rotates in phase with the Larmor precession will 
lead to observable signals, while the anti-phase component can be neglected in a good 
approximation. This is the basis of the so-called rotating frame description of NMR 
experiments: the magnetic moments are randomly distributed on a surface of two cones with 
the axis parallel to the static magnetic field. During equilibrium for nuclei with γ > 0, the 
position parallel to the field requires less energy than the antiparallel one , there is an excess 
off dipoles in the less energetic state. The total sum of all longitudinal projections is positive 
and represents the equilibrium magnetization 0M
r
 (Figure 1.1A). There is, however, no 
transverse equilibrium magnetization. 
 
This M0 net magnetization is pointing in the direction of the main magnetic field B0. In a 
coordinate system rotating at the Larmor frequency around the main magnetic field axis, the 
RF field can be considered a static vector B1 e.g. along the y-axis of the rotating frame (Figure 
1.1B). The interaction with the equilibrium magnetization causes the net magnetization 0M
r
to 
spiral away from the B0 field axe in the y-z plane. 0M
r
 rotates from a longitudinal position  a 
distance proportional to the time length of the RF pulse. If the RF field is applied for a 
sufficiently long time, the component will be tilted by π/2 leading to a maximal transverse 
magnetization (  in Figure 1.1).  1M
r
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Hence. the duration tp of the RF-pulse determines the flip angle β  by which the magnetization 
vector(s) will be tilted, 
     ptB ⋅⋅⋅= 1hγβ       [7] 
 
Once the RF field is switched off the only interaction experienced by the magnetization is that 
with the static field B0, around which it would precess undamped in the absence of any further 
interactions.  
Yet in a physical system, the magnetization is embedded in an environment (in a lattice), with 
which energy will be exchanged. This process will force the system back to equilibrium. It is 
phenomenologically described by introducing relaxation times. 
 
Figure 1.1 
At the equilibrium, the majority of proton process aligned in the direction of the main field B0. After 
applying a 90° pulse with the main B1 field, the net magnetization M1 process in the x-y plane at 
the Larmor frequency. 
A z 
 
B0 
M0 
y
x 
B z
B0
M1 B1(90° y 
x
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1.2 Relaxation 
 
The nonequilibrium magnetization state, when left undisturbed, always returns to equilibrium 
after a sufficient period of time. This is named: relaxation. 
 
1.2.1 Description of the T1, T2 and T2* relaxation times 
T1 relaxation: time that characterizes the recovery of the longitudinal magnetization to its 
equilibrium value M0.  
The return of excited nuclei (after applying B1 field) from the high energy state to the low 
energy or ground state (a jump the lower cone to upper cone in the Figure 1) is associated 
with loss of energy to the environment i.e. surrounding nuclei or lattice. The longitudinal 
relaxation is also called a spin-lattice relaxation.  
It is a tissue-specific time constant for protons, a measure of the time taken to realign 
with the external magnetic field. The T1 constant will indicate how quickly the spinning 
nuclei will emit their absorbed RF into the surrounding tissue.  
 
T2 relaxation: time that characterizes the decay of the transverse magnetization M1 is known 
as transverse relaxation time T2.  
Microscopically, T2 relaxation or spin-spin relaxation occurs when spins in the high and low 
energy state exchange energy but does not loose energy to the surrounding environment. It 
happens when two spins jump at the same time: one jump upwards, the other one jump from 
the upper cone to the lower cone (see Figure 1.1). No energy is released to the lattice and no 
net change in the longitudinal magnetization occurs. Because this involves two spins, such a 
process is called a spin-spin relaxation. T2 is the decay of 1M
r
magnetization in an ideal 
homogeneous field. 
  
In a different way from T2, T2* is the spin-spin relaxation time constant that describes 
the decay of transverse magnetization taking into account inhomogeneities in static 
magnetic fields i.e. in magnetic susceptibility. 
It is characterized macroscopically by loss of transverse magnetization at a rate greater than 
T2. The relation T2*≤T2 is always hold. Under in vivo imaging (and spectroscopy) 
conditions, the decay of transverse magnetization is governed by T2*.  
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Effects due to static susceptibility are deterministic. That means that the signal lost due 
to T2* relaxation can be recovered (see spin echo sequences section 1.4.3) 
Relaxation times depend on the microphysical environment of the spins and, hence, are  
tissue-specific. They form a principal source of contrast in MR images (Table 2).  
 
Table 1.2 
Material T1(msec) T2(msec) 
Pure water 2000-3000 2000-3000 
CSF 800-20 000 110-2000 
White matter 760-1080 61-100 
Grey matter 1090-2150 61-109 
Meninges 500-2200 50-165 
Muscle 950-1820 20-67 
Fat 200-750 53-94 
The hydrogen T1 and T2 values at 1.5 T for common brain tissues are 
listed in the following table. In biological materials, the T2 time is 
considerably shorter than the T1 time. 
 
For example, due to the slow molecular motion of lipid molecules, longitudinal relaxation 
occurs rather rapidly and longitudinal magnetization is regained quickly leading to a short T1 
time for fat. Water relaxes not as efficient as fat due to the high mobility of the water 
molecules. Water nuclei do not give up their energy to the lattice as quickly as fat, and 
therefore take longer to regain longitudinal magnetization resulting in a long T1 time. This 
illustrates that the composition of tissue has a pronounced effect on the longitudinal 
relaxation, i.e. T1. 
 
Via a spin-spin interaction, spins loose their phase coherence, which results in a loss of 
transverse magnetization. T2 relaxation is temperature dependent. At a lower temperature 
molecular motion is reduced and the decay times are reduced. Fat has a very efficient energy 
exchange and therefore it has a relatively short T2. Water is less efficient than fat in the 
exchange of energy, and therefore it has a long T2. 
 
Relaxation can be strongly influenced by administration of contrast agents, i.e. compounds 
with unpaired electron spins, which possess a magnetic moment that is two to three orders of 
magnitude larger than that of proton spins (see section 1.6). Before discussing contrast agents 
we will address methods that allow the measurement of relaxation times. 
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The inverse of relaxation time is called relaxation rate or relaxivity and has a unit of [s-1 ].  
  
1
11
T
R =  [8]   
2
12
T
R =  [9]   
 
 
1.2.2 Measurement of T1 
Of T1 measurements, the longitudinal magnetization is not detectable. The basic principle is 
to generate non-equilibrium longitudinal magnetization, wait for relaxation to occur and then 
apply a RF pulse to generate observable transverse magnetization. The two classical methods 
are the application of a saturating pulse or of an inversion pulse. Immediately after the pulse 
the longitudinal magnetization is given by 0)0( =zM  or 0)0( MM z −= , respectively. The system 
will return to equilibrium as a function of the time T evolved after the pulse,  
 
⎭⎬
⎫
⎩⎨
⎧ −⋅−−⋅= )/exp()0(1)( 1
0
0
0 TtM
MMMtM z     [10] 
which becomes 
 
{ })/exp(1)( 10 TtMtM z −−⋅=      [11] 
 
for the saturation recovery and  
 
{ })/exp(21)( 10 TtMtM z −⋅−⋅=      [12] 
 
for the inversion recovery experiment provide the application of ideal saturation and inversion 
pulses. For the saturation recovery experiment, T1 is the time at which the magnetization has 
recovered to 1-e-1 = 0.67. 
 
An alternative method to assess T1 values is rapid pulsing, with the inter-pulse delay (= 
repetition delay) TR << T1. The transverse magnetization then becomes  
 
)/exp(cos1
)/exp(1sin)0(
1
1
0 TT
TTMM
R
R
xy −⋅−
−−⋅⋅= ββ    [13] 
 
where β being the pulse angle.  
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The optimal pulse angle is given by the Ernst angle  
 
)/exp(cos 1TTRopt −=β       [14] 
 
which for short TR values is much smaller than π/2. The principle of rapid pulsing is applied 
in the so-called gradient-recalled imaging or FLASH imaging methods [Haase et al., 1987]. 
 
1.2.3 Measurement of T2 
T2 accounts for the loss of phase coherence due to spin-spin interaction. It is measured using 
spin-echo pulse sequences, which compensate for the signal loss due to differences in 
magnetic susceptibility. 
A basic spin echo sequence is the Carr-Purcell-Meiboom-Gill (CPMG) sequence (see chapter 
1.4.3). T2 values are derived from the decay of the echo envelope in a CPMG sequence, 
which is governed by 
)/exp()0()( 2TtMtM −⋅=     [15] 
 
At a time t = T2 the signal amplitude has decayed to 1/e = 0.33 of the original value. 
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1.3 Principles of Imaging 
 
1.3.1 Magnetic Field Gradient  
A gradient in the magnetic field is what will allow to distinguish each spin from his neighbor 
image his position in the magnetic field. A magnetic field gradient is a variation in the 
magnetic field with respect to position. The most useful gradient in MRI is a one-dimensional 
linear magnetic field gradient. For example, when applied along the x-axis, the effective field 
seen by a proton at location X is defined as the sum of the static field B0 plus the 
corresponding gradient field Gx, i.e.  
 
XGBxB x ⋅+= 0)(  
 
The magnetic gradient along the three x, y, and z directions are commonly labeled Gx, Gy, and 
Gz. 
Figure 1.2 
 
The gradient in the magnetic field along the x axe allow a frequency 
encoding of all protons spin present in the gradient Gx. The same 
encoding process can be apply to the y and z directions. (Adapted 
from M. Rudin e
x x 
B(x)=B0 B(x)=B0 + Gx 
t al.) 
 
 
1.3.2 Frequency Encoding  
The isocenter of the magnet is the point in the center of the magnet where (x,y,z) =0,0,0. The 
magnetic field at the isocenter is Bo and the resonant frequency is ωo. If a linear magnetic 
field gradient is applied to different spin containing regions, each regions experience different 
magnetic fields. Hence the NMR signal is dispersed along to the gradient field. The amplitude 
of the signal is proportional to the number of spins in a plane perpendicular to the gradient. 
frequency 
Water  
frequency 
signal 
f(x)= γ f(x)= γB0 + γGx 
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This procedure is called frequency encoding and causes the resonance frequency to be 
proportional to the position of the spin (see Figure 1.2). 
 
1.3.3 Pulse sequences 
Pulse sequences are a preselected set of defined RF and gradient pulses, usually repeated 
many times during a scan, wherein the time interval between pulses, the amplitude and shape 
of the gradient waveforms will control NMR signal reception and affect the characteristics of 
the MR images. 
 
A recommended shorthand designation of inter-pulse times and excitation pulse used to 
generate a particular image is to list the repetition time (TR), the echo time (TE) and, if 
using inversion recovery, the inversion time (TI) with all times given in milliseconds and if 
using a gradient echo sequence the flip angle.  
Variations in the value of TR and TE have an important effect on the control of image 
contrast characteristics. Short values of TR (less than e.g. 1000 ms) and TE (less than 
e.g. 25 ms) are common in images exhibiting T1 contrast. Long values of TR (greater 
than e.g. 1500 ms) and TE (greater than e.g. 60 ms) are common in images exhibiting T2 
contrast. Middle TR values (e.g. from 1000 to 1500 ms) and middle TE values (e.g. from 
25 to 60 ms) are common for density weighted contrast. The values are depending on the 
field strength. TR is also a major factor in total scan time. As a rule, if the TR is 
sufficiently short, all tissues will show a range of only partial recovery of longitudinal 
magnetization (M0), which will maximize T1 differences. As TR is increased, the overall 
signal increases, but T1-weighted contrast decreases. When inserting a delay between signal 
excitation and detection, signal from all tissues will be associated with varying degrees of T2-
related spin dephasing. As TE is increased, the overall signal decreases, but T2-weighted 
contrast increases.  
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Inversion recovery (IR) This sequence involves a 180°. The inversion recovery sequence 
is specified in terms of three parameters, inversion time, TR and TE. The inversion 
recovery sequence has the advantage, that it can provide very strong contrast between tissues 
having different T1 relaxation times or to suppress tissues like fluid or fat (Figure 1.3).  
 
Figure 1.3 
Pulse sequence timing diagram of an 
“Inversion Recovery” sequence. 
 
 
The Carr-Purcell-Meiboom-Gill sequence A basic spin echo sequence is the Carr-Purcell-
Meiboom-Gill (CPMG) (see Figure 1.5) sequence [Wehrli et al., 1984].  
 
Figure 1.5 
The Carr-Purcell-Meiboom-Gill sequence. 
 
This type of sequence consist of a 90° RF pulse followed by  successive 180° pulses and 
is useful for measuring T2 weighted images. It is a modification of the Carr-Purcell RF 
pulse sequence, with 90° phase shift in the rotating frame of reference between the 90° 
pulse and the subsequent 180° pulses in order to reduce accumulating effects of 
imperfections in the 180° pulses. Suppression of effects of pulse error accumulation can 
alternatively be achieved by switching phases of the 180° pulses by 180°. 
 
RF 
Slice 
Phase 
Frequency 
Echo 
T
T
90
180
TR
RF pulse 
Slice selection
Phase encoding
Frequency encoding
Echo signal 
TE
90°
180° 180° 180°
TI
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Spin-echo sequence The spin echo pulse sequence is a commonly used pulse sequence. The 
pulse sequence timing can be adjusted to give T1-weighted, proton density, and T2-weighted 
images. The two variables of interest in spin echo sequences are the TR and the TE. All spin 
echo sequences include a slice selective 90 degree pulse followed by one or more 180 degree 
refocusing pulses. 
 
Figure 1.4 
Pulse sequence timing diagram of an 
“Spin Echo” sequence. 
 
 
Gradient echo sequence The gradient echo sequences show a wide range of variations 
compared to the spin echo sequences. Not only is the basic sequence varied by adding 
dephasing or rephasing gradients at the end of the sequence, but there is a significant extra 
variable to specify in addition to things like the TR and TE. This variable is the flip or tip 
angle of the spins. The flip angle is usually at or close to 90 degrees for a spin echo sequence 
but commonly varies over a range of about 10 to 80 degrees with gradient echo sequences. 
This so-called Ernst-angle is an angle less than 90° optimized to have the best signal-to-noise 
ratio considering a given TR.  For the basic gradient echo sequence the larger tip angles give 
more T1 weighting to the image and the smaller tip angle give more T2* weighting to the 
images. 
Figure 1.6 
 
Pulse sequence timing diagram of an 
“Gradient Echo” sequence. 
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1.4 Contrast Mechanisms in MRI 
 
Image contrast in MRI is based on differences in magnetic resonance signal between tissues. 
The determinants of signal and contrast in MRI are numerous. Spin density, magnetic 
susceptibility, diffusive properties of water, proton/spin exchange and all characteristics of the 
tissue that influence NMR signal are the parameters that can be manipulated for the purpose 
of contrast enhancement.  
 
1.4.1 Spin density – Water proton density (ρ) 
This is the number of resonating spins (protons) per unit volume in an NMR experiment. The 
maximum potential signal coming from any one given tissue is directly proportional to the 
fraction of protons that contribute to this signal. Most protons in human tissues are associated 
with water and most tissues typically consist of 60% to 80% water. Moreover, water protons 
outnumber by far other protons in organic components. As the tissue-water content is 
relatively constant, each tissue has its respective signal intensity. Yet, contrast among 
different tissues is weak 
An alteration of the spin density to enhance the contrast would require significant changes in 
the water content. Hence, the diagnostic value of spin-density contrast is generally low. 
 
1.4.2 The magnetic susceptibility (χ)  
The magnetic susceptibility is the degree of magnetization of a material in response to a 
magnetic field. All forms of the matter like solid liquid or gaz, possess the macroscopic 
property of magnetic susceptibility. From a general point of view, diamagnetic compounds 
have small negative susceptibility, paramagnetic substances have positive susceptibilities and 
superparamagnetic and ferromagnetic materials have large positive susceptibilities.  
 
Daimagnetic material Most of biological or organic tissues as well as inorganic materials are 
diamagnetic. Diamagnetism is a very weak form of magnetism that is only exhibited in the 
presence of an external magnetic field. It is the result of changes in the orbital motion of 
electrons due to the external magnetic field. Diamagnetic substance do not have unpaired 
electrons; the magnetic moment of paired electrons is essentially zero. Therefore, diamagnetic 
susceptibility by itself has little effect in NMR and is of little interest as a contrast magnet. 
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Materials like water, copper, nitrogen, barium sulfate and most of the tissue constituents are 
diamagnetic.  
 
Paramagnetic material Substances with positive susceptibility are known as paramagnetic 
and are attracted by magnets. Paramagnetism is the tendency of atomic magnetic dipoles, in a 
material that is otherwise non-magnetic to generate individual magnetic moments when an 
external magnetic field is applied. When the external field is turned off, magnetic moments 
will loose their alignment. Paramagnetic materials include oxygen and ions of various metals 
like aluminum, calcium, platinum and sodium. These ions have unpaired electrons, resulting 
in a positive magnetic susceptibility. The effect of paramagnetic materials on MRI is increase 
in the T1 and T2 relaxation rate.  
 
Ferromagnetic material There is a third, rather broad class of materials that have extremely 
high, positive susceptibility. These materials are known as ferromagnetic. Ferromagnetism is 
a phenomenon by which a material can exhibit a spontaneous magnetization, and is one of the 
strongest forms of magnetism. Ferromagnetic materials generally contain iron, nickel, cobalt. 
When placed in a magnet field, the field strength is much stronger inside the material than 
outside. Ferromagnetic materials are also characterized by being made up of clusters (1017 to 
1021 atoms) called magnetic domains, that all have their magnetic moments pointing in the 
same direction. The ability to remain magnetized in absence of magnetic field is a 
distinguishing factor compared to diamagnetic, paramagnetic materials. 
 
Superparamagnetic material Superparamagnetic material consists of individual ferromagnetic 
domains of an elements that have paramagnetic properties in bulk. Their magnetic 
susceptibility is between that of ferromagnetic and paramagnetic materials. In an applied field 
these domains align with the field, setting up a very large and positive magnetization; but, in 
absence of external field, they lose the magnetization and return to random orientations 
similar to paramagnetic substances. Examples of a superparamagnetic material include iron 
containing contrast agents for bowel, liver, lymph nodes and brain imaging. 
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1.4.3 Diffusive properties of water 
Diffusion is the process by which water molecules or molecular substances mix and 
migrate due to their random thermal motion. These diffusive processes mean that 
particles move from areas of high to areas of low concentration, leveling out 
concentration gradients. The distribution of vessels including capillaries within tissues is 
such that transport over macroscopic distances is accomplished by the blood circulation, 
while intercapillary distances are covered by molecular diffusion. 
MRI provides a sensitive technique for measuring diffusion of some substances in 
particular water. MR imaging is sensitive to diffusion, because the diffusion of water 
molecules along a field gradient reduces the MR signal. In areas of lower diffusion the 
signal loss is less intense and the display from this areas is brighter. 
 
1.4.4 Proton/Spin exchange 
In MRI, signal strength is directly proportional to the total concentration of water protons 
(proton density). Protons in macromolecules and water molecules that are bound to 
macromolecules are normally not visible due to their very short T2 relaxation times. T2 
relaxation time in macromolecules is much shorter than that of bulk water. In order to 
get a signal from these protons, magnetization transfer contrast techniques have to be 
applied, which saturates the magnetization of macromolecule-bound water protons, but 
ideally does not affect the magnetization of the protons of bulk water [Balaban et al., 1992]. 
During the pulse sequence, the saturated protons may enter the free pool of protons of 
bulk water, or may transfer their longitudinal magnetization to free water protons which 
lead to a decrease of the MR signal of the bulk water. Any water molecules in contact 
with the protein might be capable of exchanging magnetization with the protein. 
Therefore saturating water molecules bound to the protein will affect the signal and the 
contrast between water in contact and not in contact with the protein. 
One use of magnetization transfer is to increase the visibility of areas of demyelination 
(e.g. multiple sclerosis). In this case, protons bound to myelin will transfer their 
magnetization to bulk water, leading to a localized loss of signal proportional to the 
amount of myelin present in this area.   
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1.5  Contrast Enhancement using Contrast Agents 
 
1.5.1  General requirement for contrast agent 
Contrast agent (CA): the principle aim to use contrast agents in MR imaging is to enhance 
the contrast between different anatomical regions otherwise undistinguishable to the MR 
imaging techniques.  
This often occurs when a lesion is too small and is lost because of partial-volume averaging 
with other tissues or if its tissue properties are too similar to these of surrounding tissues 
[Okuhata, 1999]. The presence of paramagnetic or superparamagnetic material affects the T1 
and/or T2 relaxivity of the protons in water. Physiological and structural differences of 
neighboring tissues allow or prevent the accessibility of CA to these tissues. As a result, the 
concentration of CA will vary amongst tissues, resulting in an enhanced contrast [Gibby, 
1988]  [Sobol, 1994; Lauffer, 1990].  
The first requirement for a good CA is the ability to interact magnetically with hydrogen 
nuclei (of water molecules) to influence their magnetic properties [Hendrick and Haacke, 
1993]. This is related to the number of unpaired electrons in the outer electron shell of an 
atom that overwhelmingly determines its effect as a relaxation CA (see Table 1.3). 
The second requirement is that MR contrast agent be capable of reversibly binding water 
molecules in order to provide a rapid exchange of water molecules between binding sites 
close to the CA and bulk water [Kirsch, 1991]. This rapid exchange of magnetic properties 
between near water molecule and bulk water is at the origin of the enhanced contrast.  
 
 
 
 
 
 
 
 
 
Table 1.3 
Element Unpaired electrons  Net magnetization moment (magneton)  
Electron spin    
Relaxation time 
(sec) 
Transition metals    
Cr2+ 4 4.9 10-11-10-12 
Mn3+ 4 4.9 10-10-10-11 
Fe3+ 5 5.9 10-9-10-10 
Fe2+ 4 5.1 10-10-10-11 
Lanthanides metals    
Gd3+ 7 7.6 10-8-10-9 
Eu2+ 7  10-12-10-13 
Tb3+ 6 9.5 10-12 
Metals which have unpaired electrons that interact with water molecules to enhance the 
magnetic relaxation of protons. The unit generally used for net magnetization moment is the 
magneton. 1 magneton = magnetic moment of one proton H+. [Hendrick and Haacke, 1993] 
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1.5.2 Theoretic consideration of relaxivity enhancement 
Paramagnetism The large local fields of the moments of magnetic dipoles in paramagnetic 
substances can potentially enhance the relaxation rates of water protons bound to or in the 
vicinity of ions [Mendonca-Dias et al., 1983; Lauffer, 1987]. It is the coupled interaction 
between the ions (lattice) and the protons that leads to changes in the relaxation. This provide 
a direct effect on T1 (energy exchange between spin and lattice) but also in the T2 (see Table 
1.4). 
 Table 1.4 
CA Effect on T1 Effect on T2 or T2* 
Number of atomic 
dipoles per molecule or 
particle 
Paramagnetic material Decrease Decrease 1 
Superparamagnetic 
particles Little change Marked decrease 10
10 
Ferromagnetic particles Little change Dramatic decrease 1012 
The following table sums up the ability of different CA to influence the T1 or T2 relaxation 
time. (Adapted from [Hendrick and Haacke, 1993]) 
 
 
 
 
 
 
 
Superparamagnetism For superparamagnetic substances, a much greater influence occurs 
compared to paramagnetic materials due to the significantly larger magnetic moment [Wood 
and Hardy, 1993]. This results in more inhomogeneities (compared to paramagnetism) in the 
magnetic field that lead to a shortening of  T2 and T2* that far exceed any degree of T1 
reduction [Pochon et al., 1997]. 
The theoretical explanation for the effect of contrast agents on tissue relaxation rates (R1 and 
R2) was given first by Solomon [Solomon, 1955] and Bloembergen [Bloembergen et al., 
1948]. The effect of a CA on tissue relaxation rates is in direct linear proportion to the 
concentration of the CA ([CA] in millimole per liter): 
 
   ][111 CArRR inherentobserved ×+=      [16] 
][222 CArRR inherentobserved ×+=      [17] 
 
where observed and inherent denotes tissue relaxation properties with CA and without CA 
and r1 and r2 being the molar relaxivity of the contrast agent in the respective tissue.  
The Solomon-Bloembergen equations are presented and described in detail in other articles 
[Kucharczyk et al., 1991]. 
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1.5.3 Inner sphere and outer sphere relaxation 
When a small amount of  paramagnetic compound is dissolved in water, water molecules 
exchange between three different molecular environments [Lauffer, 1987]. 
First, there is the bulk water, or regions sufficiently far from the CA which are not effected by 
the magnetic properties of the agent. The dipole-dipole intermolecular behavior between 
paramagnetic centers of the CA and hydrogen atoms of water molecules decreases rapidly as 
the distance separating the dipole increase. Any proton attached to a water molecule that is 
separated from the paramagnetic center by more than three other water molecules is 
practically unaffected by the magnetic moment of the paramagnetic material (C in the Figure 
1.7). Other water molecules bind close enough to paramagnetic material have an ion-dipole 
interaction that have a very short half-life. This interaction lasts however long enough to 
ensure a strong interaction of proton with the electronic dipole. The water molecule binds to 
the paramagnetic ligand and the water is said to be coordinated and belongs to a hydration 
sphere (inner-sphere) (Figure 1.7A).  
The third environment, often labeled as outer sphere, is defined as the transition region 
between the inner-sphere and the bulk water. This environment describes water molecules that 
diffuse close enough to interact with the paramagnetic center via intermolecular dipole-dipole 
coupling but are not otherwise bound to the paramagnetic agent (Figure 1.7B).  
 
Figure 1.7 
C
B
A
 
Adaptation from [Sobol, 1994]. The three water environment in the vicinity of a 
paramagnetic ligand. A=hydration (inner-sphere) environment; B=outer-sphere 
environment; C=bulk water 
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It is clear that the hydration water, being close to  the paramagnetic center, would interact 
strongly with the electronic dipole, and thus its relaxation rate of these molecules should be 
greatly enhanced. The rapid exchange of water molecules bound to the CA and bulk water 
molecules enhances the paramagnetic effect beyond the volume of the CA.  
 
1.5.4 In vivo stability, excretability and toxicity 
After the intravenous injection, the concentration of the contrast agent increases, then 
starts to decrease as it is eliminated from the tissues. In general, a contrast enhancement 
is obtained by one tissue having a higher affinity or vascularity than another.  
The CA must be absolutely non toxic for the patient [Oksendal and Hals, 1993]. The acute or 
chronic toxicity for an metal complex CA is related to its stability in vivo and its tissue 
clearance behavior. At doses required for MR relaxation rate changes, transition metals and 
the lanthanide ions are relatively toxic [Lauffer, 1990].  
Therefore, these ions have to be chelated (see definition) in order to form an inert non-toxic 
complex for the organism. The chelation between the metal ion and ligand neutralizes the 
avidity of each partner for binding to proteins, enzymes, or membranes via electrostatic, 
hydrogen bonding interaction or covalent bonds.  
 
Chelation: process of reversible binding of an organic ligand, the chelator or chelating agent, 
to a metal ion, forming a metal complex, the chelate.  
 
A diagnostic agent should be efficiently eliminated from the body within minutes or few 
hours after administration and the stability is therefore required only for this period of time 
[Luckey and Venugopal, 1977]. With chelation of these ions, elimination rate is increased 
thereby reducing the chance of long term toxicity. 
 
1.5.5 CA in vivo distribution 
The in vivo distribution of CA is another approach to categorize the substances. Historically, 
the first class of CA distributed into the intravascular and interstitial space. These unspecific 
agents allow the evaluation of physiological parameters such as the status of BBB or the renal 
function. However, to improve diagnostic accuracy, compounds with tissue-specific 
distribution are needed [Oksendal and Hals, 1993]. Due to their physico-chemical properties, 
each CA has a specific behavior within the body. 
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Intravascular agents, also known as blood pool agents, remain in the blood for extended 
periods of time rather than diffusing quickly into the interstitial spaces [Okuhata, 1999]. The 
renal-specific agent accumulate in the kidneys due to their glomerular filtration [Rusinek et 
al., 2004]. CA designed for hepatic imaging can be divided into nonspecific, extracellular 
space directed, reticuloendothelial system- (RES) selective, and hepatocyte-selective 
compounds. Based on their specificity, these CA provide either information on 
vascularization and perfusion or more "functional" information (RES CA) [Helmberger and 
Semelka, 2001]. For lymph-nodes imaging, many CA are available either to discriminate 
tumoral and normal parenchyma or to see cells of the immune system [Ishikawa and Anzai, 
2002; Weissleder et al., 1990]. Finally, using MRI to localize malignant tumors need the use 
of specific agent that accumulates only in malignant tissues [Shahbazi-Gahrouei et al., 2001]. 
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1.6 T1 Contrast Agents 
 
T1 contrast agents enhance contrast by shortening T1 relaxation. Because they increase 
signal intensity in T1 weighted images they are therefore also called “Positive contrast agent”. 
They are typically small molecular weight compounds containing paramagnetic substances 
which make them good T1 relaxation agents (see section 1.3.1). Most T1 agents in use are 
Gadolinium (Gd) chelates.  
These agents produce predominantly spin-lattice relaxation effects because of the fast 
exchange of the water molecules from a close vicinity to the bulk water [Lauffer, 1987]. 
However, paramagnetic materials causes both T1 and T2 shortening (see Table 1.4), but at 
low concentrations, the T1 shortening dominates the signal intensity.   
 
1.6.1 Gadolinium compounds  
All Gd chelates are paramagnetic compounds which shorten mainly the T1 relaxation time of 
local water molecules increasing their intensity on T1-weighted images [Caravan et al., 1999]. 
 
Structure Gd chelates associated with proper ligands actually remain chelated in the body and 
are excreted intact. Ligands such as DTPA (diethylenetriamine pentaacetic acid) or DOTA 
(1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid) form complexes stable 
enough so that, for the period that the agent is in the body, there is no detectable dissociation 
(see Figure 1.8).  
Due to the large size of the metal ion, lanthanides favor high coordination numbers with water 
molecules. All gadolinium(III)-based chelates approved for use in MRI are nine-coordinate 
complexes with the chelating ligand occupying eight binding sites at the metal center, the 
ninth coordination site is accessible by a solvent water molecule. 
 
Stability and toxicity The free gadolinium ion is unsuitable for clinical use due to high 
toxicity, however, the metal chelate is metabolically inert. Gd chelates are hydrophilic and 
thus do not penetrate cells. There are no nitrogen groups or intercalating groups to attack 
DNA molecules. The metal ion is buried in the cage protected by the multidentate ligand; it is 
unlikely to bind to donor groups in proteins and enzymes. The structure is not susceptible to 
nucleophile or electrophile attack [Lauffer, 1987].  
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Figure 1.8 
  
H
H
Commonly, the chelation of Gd(III) with diethylenetriamine pentaacetic acid (DTPA) or 1.4.7.10-
tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid (DOTA), form a strongly paramagnetic, stable 
complex. The interaction between the Gd atom and a free water molecule is illustrated with colors. 
 
 
1.6.2 Dendrimers 
Dendrimers are three-dimensional (not planar), oligomeric structures prepared by reiterative 
reaction sequences starting from smaller “core” molecules, as shown schematically in Figure 
1.9. The highly branched, nearly monodisperse structure of dendrimers has led to a number of 
interesting molecular attributes for this relatively new class of macromolecule [Kobayashi and 
Brechbiel, 2004].  
The potential advantages of Gd chelate dendrimer conjugates include the fact that dendrimers, 
such as the Starburst polyamidoamine (PAMAM) dendrimers (see Figure 1.9C), have uniform 
surface chemistry, narrow molecular weight distribution and minimal shape variation.  
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Figure 1.9 
A 
 
B 
 
C 
 
A represents the core molecule. B is a dendrimer of first generation. C is a schematic representation of the 4th 
generation on which Gd compounds have been fixed. 
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1.6.3 In vivo distribution 
This class of T1 contrast agents represents the dominant use of MRI contrast media in 
radiology. After intravenous injection, the bolus rapidly distributes into the entire blood 
plasma pool and distribute nonspecifically throughout the plasma and interstitial space of the 
body [Hendrick and Haacke, 1993] with the exception of the brain where the agent does not 
penetrate the intact BBB and thus stays entirely in the plasma compartment of the capillary 
bed  [Oksendal and Hals, 1993]. The agents are excreted by the kidneys with an elimination 
half-life of 1.5h. Concerning the best known extracellular Gd-containing CA, Gd-DTPA, 
standard doses are 0.1 mmol/kg of body weight. Regardless of the type of Gd-based 
extracellular CA, these compounds have a relatively low rate of side effects, and all of them 
can be bolus injected. 
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1.7 T2 Contrast Agents 
 
SPIOs and USPIOs: Small Particles of Iron Oxide and Ultra Small Particles of Iron Oxide 
They are commercially available small particulate aggregates of iron oxides. These T2 CAs 
lead to a loss of signal intensity due to increased transverse relaxation. Areas with high CA 
contents appear dark on MR images, they are therefore also called “negative contrast agents”. 
 
 
1.7.1 Ferumoxides  
Structure Iron cores are composed of magnetically active iron oxide crystals which range 
from about 1 to about 50 nm in diameter [Groman et al., 1989]. The core may be alternatively 
coated or associated by the mean of hydrogen bonds with a polysaccharide (e.g. dextran), a 
protein or a polypeptide [Bulte et al., 1993] [Bach-Gansmo, 1993]. With coating, the overall 
particle diameter ranges from about 1 to about 500 nm. The coating can serve as a base to 
which various biological molecules can be attached. Polymer coatings grafted onto the iron 
oxide core during synthesis are necessary to provide stability of the iron oxide in aqueous 
solutions and in vivo [Nicolle et al., 2002]. The type of surface coating and the geometric 
arrangement of the polymer on the iron oxide core determine not only the overall size of the 
colloid, but also play a significant role in biokinetics and biodistribution (Figure 1.10). 
 
Figure 1.10 
 
Dextran-Coated superparamagnetic iron oxide particles induce 
microscopic magnetic field inhomogeneities that lead to a rapid 
dephasing of proton spins (red dots) and loss of imaging signal. 
 
B0 
Proton of bulk water 
Dextran 
Iron core 
Disturbed proton 
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Stability and toxicity Surface charge is know to play an important role in blood half-lives of 
colloids and polymers [Oksendal and Hals, 1993]. It is generally agreed that a strong positive 
and negative charge decrease circulation time. The biodistribution of iron oxide preparations 
is also determined by particle size. Most iron oxides have a relatively short blood half-life 
(minutes) and their primary application is for imaging of liver, spleen and the gastro-intestinal 
tract [Helmberger and Semelka, 2001]. Long-circulating iron oxides (hours) [Pochonet al. , 
1997], however, are very useful for imaging of the vascular compartment (magnetic 
resonance angiography), and for perfusion imaging [Ostergaard, 2004], neurofunctional 
imaging [Bradley, 2004], imaging of lymph nodes, receptor imaging, and target specific 
imaging [Laurent et al., 2004] (Table 1.5). 
Iron oxides have been shown to degrade in vivo with iron mobilization and utilization 
according to natural iron pathways [Emerit et al., 2001]. Iron is a useful component of 
cytochromes, oxygen-binding  molecules (hemoglobin, myoglobin) and some enzymes 
[McCord, 1998]. 
 
 
Table 1.5 
Property AMI-25/ENDOREM AMI-227/SINEREM MION 
Fe (mg/ml) 11 20 8.25 
Mean particle size 60-150 11.5 8 
R1 in buffer (mM./s) 24 21 16.5 
R2 in buffer (mM/s) 107 44 34.8 
Plasma Half-life 10 min* >24 h (human) >4 h 
Properties of various Superparamagnetic Iron-oxide based Contrast agents 
* Proposed value in man; no information was available about the plasma half-life of Endorem in rodents 
 
However, iron can also damage tissues by catalyzing the conversion of superoxide and 
hydrogen peroxide to free radical species that attack cellular membranes, proteins and DNA 
[Gutteridge et al., 1982]. Once inside the cells, particles are clustered within lysosomes. 
Degradation of iron oxides into iron and oxygen is presumed to occur in intracellular 
lysosomes of macrophages under the influence of a variety of hydrolytic enzymes, low pH 
and proteins participating to iron metabolism.  
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1.7.2 In vivo distribution 
Medium sized and large particles (> 30nm diameter) tend to accumulate in the spleen and 
lung while small particles (< than 30nm) accumulate preferably in the liver, bone marrow and 
lymph nodes. USPIO have a potential to improve differentiation of metastatic from 
inflammatory lymph nodes while normal lymph nodes appear black on T2* weighted images 
due to a massive uptake of USPIO [Ishikawa and Anzai, 2002] [Shah et al., 2003]. 
Metastatic lymph nodes remain unchanged in signal intensity due to the lack of phagocytotic 
activity. Another application is liver imaging: CAs are either specifically targeted to 
hepatocytes (Mg or Gd-based compounds) or are accumulated in the reticuloendothelial 
system (RES) of the liver (Kupffer cells) and the spleen (e.g. SPIO) to allow discrimination 
between normal tissues and tumors.  
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2 NEAR INFRARED IMAGING  
 
The second section is firstly dedicated to fluorescence optical imaging in general and then 
focuses on the applications of using near infrared light. General fluorescence principles such 
as light excitation and fluorescence emission are described in the chapter 2.1 followed by their 
implication in experimental protocols to monitor fluorescence in vivo (2.2). The description of 
cyanine dyes, which are commonly used contrast agents for near infra-red imaging, is the 
subject of chapter 2.3. 
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 2.1 Fluorescence  
 
2.1.1 Excitation-Emission 
Fluorescence is a property of molecules that involves electronic transitions. Absorption of 
photon of the appropriate energy causes a transition from the molecular ground state E0(v=0) 
which for the majority of molecules is a singlet state, to an excited state E1(v=n), 
correspondingly also a singlet state (Fig.2.1).  
 
Figure  2.1 
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Light excitation at wavelength λ1 provoke the energy absorption by 
electrons which jump from the energy state E0 to E1. After a certain 
time (pico sec) the loss of energy occurs in two steps: a non radiative 
loss toward E1’and the fluorescence emission when returning to the 
ground state E0. The photon emission occurs always with a 
wavelength λ2 > λ1. 
 
 
Energy is dissipated via radiation less transitions to the vibrational ground state of E1(v=0). 
Relaxation to the ground state occurs by emission of a light photon, which is lower energy 
(longer wavelength) than the exciting photon, i.e. the amount of energy emitted as 
fluorescence is always less than the amount of energy absorbed. The energy difference 
between the absorbed and emitted photons ends up as molecular vibrations (heat). In 
fluorescent materials, the excited state has always the same spin as the ground state (singlet). 
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The excitation and fluorescence frequencies νex and νfl are defined as 
 
 )()( 0vEnvEh 01ex =−==⋅ν  
and 
)()( 0vE0vEh 01efl =−==⋅ν  
 
respectively, where h is Planck's constant and v the vibrational quantum number 
 
The quantum yield of a fluorescent substance is defined by  
 
# photons re-emitted
# photons absorbed
Quantum yield =
 
 
The absorption and emission of energy can only occur at precise wavelengths, which are 
characteristic for a given molecule. Thus, each fluorescent molecule is defined by its own 
distinct absorption and emission energy spectrum. The distribution of wavelength-dependent 
intensities that cause fluorescence is known as the fluorescence excitation spectrum, and the 
distribution of wavelength-dependent intensities of emitted energy is known as the 
fluorescence emission spectrum.  
 
 2.1.2 Interaction of NIR radiation with biological tissues 
Infrared (IR) radiation is electromagnetic radiation of a wavelength longer than visible light, 
but shorter than microwave radiation. Infrared radiation has wavelengths between 700 nm and 
1 mm. Infrared is absorbed more strongly than microwaves (wavelength from 10-3 to 0.1 m), 
but less strongly than visible light. The result of infrared absorption is heating of the tissue 
since it increases molecular vibrational activity. Because of its longer wavelength and the low 
absorbance of tissue intrinsic chromophores such as oxy- and deoxyhemoglobin, melanin and 
fat, infrared radiation penetrates tissue further than visible light and propagates by multiple 
scattering through several centimeters of tissue, enabling deep (> 1cm) tissue imaging [Sevick 
et al., 2002]. Moreover, working at near-infrared (NIR) wavelengths between 700 and 1100 
nm limits biological tissues autofluorescence [Frangioni, 2003]. Figure 2.2 is showing the 
autofluorescence spectra of the principal components of biological tissue upon illumination 
with NIR radiation.  
  47 
 
Chapter 2.1 Fluorescence  
 
 
 
Figure 2.2 
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NIR fluorescence of major tissue components. To 
avoid problems of tissue unspecific autofluorescence, 
the NIR tissue optical window is between 700 and 
900 nm.  
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2.2  In Vivo NIRF Imaging 
 
Fluorescence has proven to be a versatile tool for many applications. It is a powerful 
technique for studying molecular interactions, biochemistry, cell biology and physiology. 
Fluorescence detection has three major advantages over other light-based investigation 
methods: high sensitivity, high speed, and safety: 
- The point of safety refers to the fact that samples are not affected or destroyed in the 
process, and no hazardous byproducts are generated.  
- Sensitivity is an important issue because the fluorescence signal is proportional to the 
concentration of the substance being investigated. Using fluorescence, one can monitor very 
rapid changes in concentration.  
- Because it is a non-invasive technique, fluorescence does not interfere with a sample. The 
excitation light levels required to generate a fluorescence signal are low, reducing the effects 
of photo-bleaching; and living tissue can be investigated with no adverse effects on its natural 
physiological behavior. 
Although the spatial resolution (1mm) is limited when compared with other imaging 
modalities e.g. MRI, NIRF tomography provides access to a variety of physiological 
parameters that otherwise are not accessible [Hielscher et al., 2002]. 
 
Main optical imaging technologies currently used are fluorescence reflectance imaging (FRI) 
and fluorescence mediated tomography (FMT).  
 
 2.2.1 Fluorescence Reflectance Imaging 
FRI is the simplest method: a NIR light source with the appropriate spectral intensity 
illuminates the specimen and the reflected fluorescence is detected. Optical bandpass filter are 
installed to avoid spectral overlap between the excitation and the emission wavelengths 
[Mahmood et al., 1999]. These systems allow potentially simultaneous imaging of two or 
more dyes [Mahmood et al., 2002] and real-time quantitative assessment of the fluorescent 
signal.  
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 2.2.2 Fluorescence Mediated Tomography 
FMT is a tomographic imaging modality capable of quantitatively displaying deep near-
infrared fluorescence (NIRF) signals in three-dimensional volume [Ntziachristos et al., 2003]. 
The emitted fluorescence that propagated through tissues is collected, quantified and then 
combined to obtain the distribution of fluorophores in deep tissues. A tomographic image is 
reconstituted after the data are mathematically processed. Recent results show that NIRF 
signal from tumor like structures can propagate about 10 cm in breast or lung tissues and 
more than 5 cm in the adult brain [Ntziachristos et al., 2002]. 
 
2.2.3 Elements for fluorescence detection 
Four essential elements of fluorescence detection systems can be identified: 1) an excitation 
source, 2) a fluorophore, 3) wavelength filters to isolate emission photons from excitation 
photons, and 4) a detector that registers emission photons and produces a recordable output, 
usually as an electrical signal or a photographic image. Regardless of the application, 
compatibility of these four elements is essential for optimizing fluorescence detection.  
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2.3  NIRF Contrast Agent 
 
Because there is little NIR fluorescence contrast generated by most tissues, most of in vivo 
studies administer exogenous contrast agent (CA). All of the techniques are based on the same 
concept: expose the specimen to NIR light, detect the emitted fluorescence coming out of the 
tissue and use the absorption spectra of the light absorbing molecules present in the tissue to 
interpret the detected light levels as changes in CA concentrations. 
 
2.3.1 Theory 
For successful in vivo imaging with NIR contrast agents, careful attention must be paid to 
parameters, which can influence the signal to background ratio including [Sevick et al., 
2002]: 
- selection of excitation/emission wavelengths and quantum yield: optimal excitation and 
detection wavelength have to be determined; excitation and detection wavelength have to be 
chosen such that the best fluorescence quantum yield of the probe is reached. Studying 
carefully the excitation spectrum can also avoid problem of tissue autofluorescence (see 
Figure 2.2).  
- photo bleaching threshold: under high-intensity illumination conditions, the irreversible 
destruction or photo bleaching of the excited fluorophore becomes the factor limiting 
fluorescence detectability. The most effective remedy for photo bleaching is to maximize 
detection sensitivity, which allows the excitation intensity to be reduced. Detection sensitivity 
is enhanced by low-light detection devices such as CCD cameras, as well as by high–
numerical aperture objectives and the widest bandpass emission filters compatible with 
satisfactory signal isolation. Alternatively, a less photo labile fluorophore may be substituted 
in the experiment.  
- biodistribution and target binding affinity: In vivo imaging requires that the contrast agent is 
delivered to the target and is retained by the target while non-bound material is cleared from 
the circulation [Frangioni, 2003]. 
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 2.3.2 Cyanine dyes 
Structure Cyanine dyes are structurally defined by a conjugated chain of an odd number of 
carbon atoms linked between two nitrogen centers forming a polymethine chromophore: 
 
Figure 2.3 
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With cyanine dyes, a broad chemical derivatization is possible. By varying the number of odd 
carbon atoms, the spectrum of the probe changes and the whole spectral range between visible 
to NIR wavelengths can be covered.  Moreover, these dyes show high absorbance coefficients 
and very good fluorescence efficiency (i.e. high quantum yield). The most commonly used 
dye for NIRF imaging is the Cyanine 5.5 (see Figure 2.4). 
 
Figure 2.4 
Molecular structure of the cyanine 5.5 
 
Toxicity After intravenous injection, the dye is stable and remains in the blood circulation 
until excretion. It seems there is no renal elimination of the initially absorbed dye in an 
unchanged form. Apparently the dye accumulates in the liver and kidneys for detoxification 
and elimination, causing no inconsiderable damage to the fine structures of these organs 
[Uhlenbroock, 1965]. 
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3 ORGANIZATION OF THE NERVOUS SYSTEM 
 
In order to better understand the sections on mechanisms of brain inflammation, chapter three 
describes the general organization and function of the central nervous system. Neurons that 
generate and conduct nervous impulse (3.1) and glial cells that permit neurons to work in 
optimal conditions are described. The role of the blood brain barrier is discussed in the 
chapter 3.2 by detailing endothelium architecture and the function of tight junctions. 
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3.1  Cells of the Central Nervous System 
 
 3.1.1 Neurons 
Neurons are the main compound of the central nervous system (CNS) and the peripheral 
nervous system (PNS). Neurons vary considerably in structure and size throughout the 
nervous system and within a given brain region. Its task is to relay signals to a specifically 
targeted cell [Ramón y Cajal, 1995]. The neuron cell body contains the nucleus and other 
intracellular organelles common to non-neuronal as well as neuronal cells. Neurons have 
branches (dendrites) to which other neurons form synapses and axons that make connections 
with other neurons. They often look likes branches or spikes extending out from the cell 
body.  It is primarily the surfaces of the dendrites that receive chemical messages from other 
neurons. Dendrites act like as receiving stations for excitation and inhibition signals. One 
extension is different from all the others: the axon.  Although in some neurons, it is hard to 
distinguish from the dendrites, in others it is easily distinguished by its length. The purpose of 
the axon is to transmit an electro-chemical signal to other neurons, sometimes over a 
considerable distance. At the very end of the axon is a synapse. It is there that the electro-
chemical signal that has traveled the length of the axon is converted into a chemical message 
that activates the next neuron. 
 
 3.1.2 Myelin and nerve conduction 
To analyze events in the outside world or within the body, and to transmit information from 
cell to cell, nerve cells use electrical and chemical signals. Myelin is the material that 
insulates axons and speeds the conduction of nerve impulses. The nerve that transmits the 
impulse can be compared to an electrical wire with the myelin sheath being the insulation 
around the wire. The myelin chemical composition is very particular and vary from the CNS 
to the PNS. This is a substance rich in protein (15-30%), lipids (70-85%) that forms layers 
around the nerve fibers and acts as an electrical insulation due to its lipophilic composition, 
thereby excluding polar and conducting particles such as water and ions. The Table 3.1 give 
an idea about the several lipidic compounds of the rat myelin. The most frequent proteins 
encounter in the CNS are PLP (ProteoLipid Protein), MBP (Myelin Basic Protein) and MAG 
(Myelin Associated Glycoprotein).  
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Table 3.1 
Substance Myelin White matter Grey matter 
Lipid (% dry) 70% 55% 33% 
Cholesterol (% lipid) 28% 28% 22% 
Cerebroside (% lipid) 23% 20% 5% 
Galactopeptids (% lipid) 28% 29% 7% 
Plasmalogens (% lipid) 12% 11% 9% 
Phospholipids (% lipid) 43% 46% 70% 
Composition of myelin in the white and grey matter of human CNS. (The Human Brain 
by Nolte J. 5th Edition) 
 
Myelin is present in both the CNS and the PNS. Myelin is formed in the PNS by Schwann 
cells and in the CNS by oligodendrocytes.  
The myelin layer is segmented and there are small areas or “nodes” that are naturally 
unmyelinated (nodes of Ranvier).  As chemical ions pass in and out of the axons membrane, 
the electrical current they generate is conducted down the nerve, and jumps from node to 
node. Myelin prevents the current from leaking out of the nerve at inappropriate points and 
decreases the electrical resistance of the nerve. This helps make sure the nerve impulse is 
conducted efficiently. 
 
 3.1.3 Glial cells 
Glial cells were first described in 1846 [Virchow, 2005]. In subsequent years, Ramón y Cajal 
focused his attention on glial cell functions like secretion of trophic molecules and the current 
spread during conduction of nerve impulse [Ramón y Cajal, 1995]. During these 
investigations, he draw precise figures of different glial cells, their distribution throughout the 
nervous system and their morphology. Glial cells act as a supporting system for the neurons 
and their dendritic and axonal processes; they also have a primary role in a wide range of 
normal functions and reactions to injury, including inflammation repair, fluid balance, and 
energy metabolism. In the CNS among the neurons, glial cells are usually subdivided into 
several distinct categories [Ketteman and Ransom, 1995] [Ransom, 1991].   
Macroglia comprise: 
Astrocytes make contact with capillaries and neurons. The major astrocytic processes are 
directed toward neurons and their process and synapses, where they are believed to act as 
metabolic buffer or detoxifiers and suppliers of nutrients. Astrocytes play a significant role 
during infectious and autoimmune disease and are the principal cells responsible for repair 
and scar formation in the brain. 
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Oligodendrocytes are predominant in the white matter. Oligodendroglial cytoplasmic 
processes wrap around the axons of neurons to form myelin in a manner analogous to the 
Schwann cells in the PNS (Figure 3.1). Injury to oligodendrial cells is a feature of acquired 
demyelinating disorders (e.g. multiple sclerosis) 
Radial glial cells play an essential role in the developing mammalian CNS by guiding 
neurons growth. 
 
 
Figure 3.1 
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Structure of an myelin-insulated axon. Oligodendrocytes synthesize myelin 
which  surround axons to form Schwann cells.  
 
 
Microglia is represented only by microglial cells resembling macrophages in the blood and 
probably arise from them. They serve as a CNS macrophage system.  
The distribution of neurons and glial cells through the nerve system is well organized. 
The CNS (the brain, spinal cord and optic nerves) is made up of several different components:  
·        The gray matter contains the cell bodies of the nerves. 
·        The white matter contains nerve fibers coated with myelin.  
·        The glial cells that form a supporting network.  
PNS nerve cells perform two major functions: 
·        Sensory neurons collect information about the body’s internal and external environment  
      and convey it to the CNS. 
·        Motor neurons carry instructions on what to do from the CNS to the glands and muscles
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3.2 Blood Vessels and Blood Brain Barrier 
 
Blood vessel and capillaries are formed by endothelial cells. These cells are organized in a flat 
epithelium (endothelium) and form a cylindrical structure: the capillary lumen (see Figure 
3.2).  
 
3.2.1 Endothelium 
Blood Brain Barrier: zone that delineates the vascular lumen from brain parenchyma. The 
barrier layers consist of endothelial cells with adjacent cells forming the tight junctions 
(zonulae occludentes). In addition, the BBB is composed of the basement membrane and 
astrocytic end-feet contacting the tight junctions from the abluminal side.  
In contrast to vessel walls in the periphery, only a few molecules can cross the intact BBB 
freely by diffusion [Abbott, 2002]. While water and lipophilic substrates such as O2 and CO2 
can diffuse freely along their concentration gradient, uptake of nutrients like glucose and 
amino acids depends on transporter systems, while other larger molecules might be taken up 
by specific receptor mediated transcytosis [Ballabh et al., 2004; Gloor et al., 2001].  
Thus, a particular ephithelium is lining all blood vessel in the body: the endothelium. 
Endothelium is the largest “organ” in the body, its surface is equivalent to 6 tennis court in a 
70kg man and weight about 1800g (> liver) with a mass that approximates five normal hearts. 
The trillion cells that compose the endothelium are in close contact and form a slick layer that 
prevents blood cell interaction with the vessel wall as blood moves through the vessel lumen 
(see Figure 3.2). The endothelium plays a critical role in the mechanics of blood flow, the 
regulation of coagulation, leukocyte adhesion, and vascular smooth muscle cell growth, and 
also serves as a barrier to the transvascular diffusion of liquids and solutes. For years the 
endothelium was thought of as an inert single layer of cells that passively allowing the 
passage of water and other small molecules across the vessel wall. However, this dynamic 
tissue performs many other active functions, such as the secretion and modification of 
vasoactive substances and the contraction and relaxation of vascular smooth muscles.  
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Endothelial cell 
Nucleus 
Junction 
Red blood cells 
Basement membrane 
Figure 3.2 
a)  
 
b) 
 
 
c) 
 
a) Continuous capillaries, including most tissues, such as muscle, lung, and skin 
b) Fenestrated capillaries,  including kidney, intestine, and some endocrine and exocrine glands 
c) Sinusoid capillaries, including liver, spleen, and bone marrow. It is noted that this illustration expresses only the 
morphological pores contributing to diffusive permeability. Actual trans-capillary exchanges are modified by 
vesicular transports with variable sizes up to 20–30 nm 
Adapted from [Okuhata, 1999] 
Endothelial cell Nucleus 
Junction ∼ 6 nm 
Junction ∼ 50-60 nm 
Parenchymal cell 
Junction ∼ 100-10000 nm 
 
 
 
Within the brain, the association between blood vessel endothelium and astrocyte membrane 
form together the so-called blood-brain barrier (BBB). This is the specialized system of 
capillary endothelial cells and astrocytes that protects the brain from foreign substances or 
harmful substances like hormones or neurotransmitters in the blood stream, while supplying 
the brain with the required nutrients for proper function. Unlike peripheral capillaries that 
allow relatively free exchange of substance across cells, the BBB strictly limits transport into 
the brain through both physical (tight junctions) and metabolic (enzymes) barriers [Huber et 
al., 2001]. Proteins, ions and hydrophilic molecules cannot pass trough the BBB; lipophilic 
molecules such as alcohol and gases can [Mayhan and Heistad, 1985]. Thus the BBB is often 
the rate-limiting factor in determining permeation of therapeutic drugs into the brain 
[Robinson, 1987]. BBB breakdown is assumed to be a key component in CNS associated 
pathologies [Perry et al., 1997]. 
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The BBB barrier can be damaged by the following events: 
 - hypertension (high blood pressure)  
 - hyperosmolarity (a high concentration of a substance in the blood) 
 - exposure to microwave as well as radiation  
 - exposure to infectious agents  
- injury to the brain like trauma, ischemia, inflammation and pressure  
 
3.2.2 Tight junctions 
Tight junctions are the connections between epithelial and endothelial cells that comprise 
various tissues of the body [Huber et al., 2001]. They regulate the passage of molecules 
across these natural barriers [Mayhan, 2001]. As part of the body's normal activity, tight 
junctions selectively open and close in response to various signals both inside and outside of 
cells. This allows the passage of large molecules or even entire cells across the tight junction 
barrier. Large molecular weight drugs need to pass through these tissue barriers in order to get 
to their sites of action [Rapoport, 2000]. 
Tight junctions consist of proteins, (e.g. claudins, occludins) and junctional adhesion 
molecules that are anchored in the membranes of two adjacent cells and interact with each 
other to hold the cells together and prevent other molecules from passing between them 
[Wolburg and Lippoldt, 2002].  
Tight junctions are found in all tissues, but those of particular relevance to drug delivery 
include: nasal tissue, gastrointestinal tissue, blood vessels and blood-brain barrier. 
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4  INFLAMMATION IMMUNE MECHANISMS 
 
Basic mechanisms of inflammation leading to immune responses are the topic of the section 
four. Following a general description of cells of the immune system and the way they interact 
(4.1), processes of acute and chronic inflammation are discussed (4.2). The importance of 
chemical mediators involved in cell communication that permit coordination of the immune 
response is explained in the chapter 4.3. 
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4.1 Basis of the Immune System 
 
 4.1.1 Cells of the immune system 
T lymphocytes are the mediators of the cellular immunity (≠ humoral immunity cf. B 
lymphocytes). They contribute to the immune defenses in two major ways. Some help 
regulate the complex workings of the immune system, while others are cytotoxic and directly 
contact infected cells and destroy them.  
The regulatory T cells are "helper/inducer" T cells. They are needed to activate many immune 
cells, including B cells and other T cells. Another subset of regulatory T cells acts to turn off 
or suppress immune cells. Cytotoxic T cells help the body in eliminating cells that have been 
infected by viruses as well as cells that have been transformed by cancer. They are also 
responsible for the rejection of tissue and organ grafts. 
T cells constitute 60 to 70% of peripheral lymphocytes. But T lymphocytes are also found in 
lymph nodes and the spleen. Each T cell is genetically programmed to recognize a specific 
cell-bound antigen by means of an antigen-specific T cell receptor (TCR). This TCR receptor 
is always noncovalently linked to a cluster of polypeptide chains: the CD3 molecular 
complex. Some other co-receptors expressed in the membrane of T cells are linked to a 
specific function: CD4+ for helper T cells and CD8+ for cytotoxic T cells.  
T cells cannot be activated by soluble antigens; presentation of processed, membrane-bound 
antigens by macrophages or other antigen-presenting cells (APCs) is mandatory for induction 
of cell-mediated immunity. 
 
B lymphocytes B cells work mainly by secreting soluble substances known as antibodies 
(immunoglobulins). On antigenic stimulation, B cells form large plasma cells that secrete 
immunoglobulins, which are the mediators of humoral immunity.  
B lymphocytes constitute 10 to 20% of the circulating peripheral circulating population. They 
are also present in bone marrow, lymph nodes and spleen, and extralymphatic organs such as 
the gastrointestinal tract. B cells recognizes antigens via the B cell antigen receptor complex. 
Immunoglobulin M (IgM), present on the surface of B cells constitutes the antigen-binding 
component of the B cell receptor. As with T cell, each B cell get activated by binding a 
soluble unique antigen on their receptor and is programmed to make one specific antibody.  
 
  61 
 
Chapter 4.1 Basis of the Immune System 
 
 
 
Phagocytes are large white cells that can engulf and digest foreign invaders. They include 
monocytes, which circulate in the blood, and macrophages, which are found in tissues 
throughout the body, as well as neutrophils, cells that circulate in the blood but move into 
tissues where they are needed.  
Macrophages are versatile cells; they act as scavengers, they secrete a wide variety of 
powerful chemicals, and they play an essential role in activating T cells. Neutrophils are not 
only phagocytes but also granulocytes: they contain granules filled with potent chemicals. 
These chemicals, in addition to destroying microorganisms, play a key role in acute 
inflammatory reactions. Macrophages play important roles both in the induction and in the 
effector phase of immune responses: 
 - they are first required to process and present the antigen to immunocompetent T cells 
 - they are important effector cells in certain form of cell-mediated immunity 
 - they can also play a role in the humoral immunity by phagocyting microbes  
  that are cover by IgG 
 
Natural killer cells (NK cells) At least two types of lymphocytes are killer cells: cytotoxic T 
cells (CD8+) and NK cells. To attack, cytotoxic T cells need to recognize a specific antigen, 
whereas NK cells do not. Both types contain granules filled with potent chemicals, and both 
types kill on contact. The killer binds to its target, aims its weapons, and delivers a burst of 
lethal chemicals. 
These cells represent approximately 10 to 20% of the peripheral blood lymphocytes and do 
not bear TCR or cell surface immunoglobulins. NK cells do not present the CD3 receptor. 
 
4.1.2 Cytokines, messengers of the immune system 
The induction and regulation of the immune responses involve multiple interactions among all 
the immune cells. Some interactions depend on cell-to-cell contact some others are mediated 
by short-acting soluble mediators, called cytokines. Cytokines are diverse and have a wide 
spectrum of effects. Despite several different cells produce cytokines, these molecules are the 
principal instrumentation of T cells.  
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Cytokines: small protein molecules that are the core of communication between immune 
system cells, and even between immune system cells and cells belonging to other tissue types. 
They are actively secreted by immune cells. Their action is often local, but sometimes can 
have global effects on the whole body.  
There are a lot of known cytokines that have both stimulating and suppressing action on 
lymphocyte cells and immune response (see Table 4.1). Cytokines act by binding to their cell-
specific cytokine receptor. This receptor is located in the cell membrane and allows a signal 
cascade to start in the cell that eventually will lead to biochemical and phenotypical changes 
in the target cell. 
A chemokine is a cytokine that has a chemoattractant effect for monocytes and may also 
cause cellular activation of specific functions related to host defense. 
 
Binding to specific receptors on target cells, cytokines recruit many other cells and substances 
to the site of immune activity. Cytokines encourage cell growth, promote cell activation, 
direct cellular traffic, and destroy target cells.  
 
 
Table 4.1  
Names Abbreviation Examples 
Interleukins IL IL-1, IL-2, etc 
Interferons IFN IFNα , IFNβ , IFN γ 
Tumor Necrosis Factors TNF TNFα , TNFβ  
Growth Factors GF NGF, EGF 
Colony stimulating Factors CSF M-CSF, G-CSF, GM-CSF 
Chemokines - RANTES, MCP-1, MIP-1α 
The nomenclature of cytokines partly reflects their first-described function and also the 
order of their discovery. There is no single unified nomenclature, and individual cytokines 
may belong to two groups (e.g. the chemokine IL-8)  [Roitt et al., 2005]. 
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4.2  Mechanisms of Inflammation 
 
 4.2.1 Acute inflammation process 
The cause of acute inflammation may be due to physical damage, chemical substances, micro-
organisms or other agents. The acute inflammatory response is a very common, complex and 
stereotyped response to recent or ongoing injury. Three main processes occur: 
- Increased blood flow due to dilation of blood vessels (arterioles) supplying the region. This 
implies that acute inflammation can just take place in vascularized tissues.   
- Increased permeability of the capillaries, allowing fluid and blood proteins (exudate) to 
move into the interstitial spaces. The exudate carries proteins, fluid and cells from local blood 
vessels into the damaged area to mediate local defenses.  
- Migration of neutrophils (and perhaps a few macrophages) out of the venules and into 
interstitial spaces. 
These events are essentially the same whatever the cause and wherever the site. However, it is 
important to notice that they do not only lead to beneficial effects. Desired aspects of fluids 
exudates are dilution of toxins by removing them, entry of antibodies and/or drugs  in the 
wound, fibrin formation to trap pathogens, more efficient supply of nutrients and oxygen to 
neutrophils and finally the drainage of the fluid exudates into the lymphatics organs allowing 
the stimulation of the immune response. On the other hand, the release of lysosomal enzymes 
by inflammatory cells may also have harmful effect such as digestion of healthy tissues; the 
swelling of damaged tissues can arm normal tissues surrounding the inflammation area and 
sometimes, the excessive inflammatory response (e.g. hypersensitivity) provokes more tissue 
destructions than the pathogen itself. 
Acute inflammation is short-lasting, only a few days. Longer lasting processes are referred to 
as chronic inflammation.  
 
4.2.2 Chronic inflammation 
If the agent causing acute inflammation is not removed, the acute inflammation may progress 
to the chronic stage. In this case, the character of the cellular exudate changes, with 
lymphocytes, plasma cells and macrophages replacing the neutrophils. Chronic inflammation 
is a complex response to prolonged problems, orchestrated by T-helper lymphocytes. It 
involves recruitment and activation of T and B lymphocytes, macrophages, eosinophils, 
and/or fibroblasts.  
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4.3 Chemical and Cellular Mediators of Inflammation 
 
 4.3.1 Chemicals mediators 
The spread of the acute inflammatory response following injury to a small area of tissue 
suggests that chemical substances are released from injured tissues, spreading outwards into 
uninjured areas. These chemicals, called endogenous chemical mediators, cause 
vasodilatation, emigration of neutrophils, chemotaxis and increased vascular permeability (see 
Table 4.2).  
 
 
Table 4.2  
Chemical mediator Source Effect 
Histamine Mast cells, leukocytes and platelets Increase vascular dilatation and  permeability  
Lysosomal compounds Neutrophils Increase vascular permeability and activate complement system 
Prostaglandins Many cell types Increase vascular permeability and platelet aggregation 
Serotonin Mast cells Potent vasoconstrictor 
Lymphokines Lymphocytes Chemotactic 
Complement system Plasma Chemotactic, cytolytic activity, opsonisation* 
Kinin system Plasma Increase vascular permeability, vasodilatation and smooth muscle contraction 
Coagulation system Plasma Conversion of fibrinogen to fibrin promoting clotting of blood 
List of chemical mediators playing a role in the inflammation process. 
* process whereby opsonins make an invading microorganism more susceptible to phagocytosis 
 
 
 4.3.2 Leukocytes activation and extravasation 
An other critical function of inflammation is the delivery of leukocytes to the site of injury. 
The sequence of events from the lumen of a blood capillary to the interstitial tissue, called 
extravasation, can be divided into the following steps: see Figure 4.1. 
Leukocytes first roll on the inner part of the endothelium. The adherence is due to the affinity 
between the selectin molecules, present on the surface of leukocytes, to their respective 
selectin ligands which are situated on the surface of endothelial cells.  
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Figure 4.1  
 
Different steps of recruitment of leukocytes on an inflammation site. 
(Derived from “Pathologic basis of disease”, Cotran Kumar Collins, Ed. Robbins). 
Rolling Activation Adhesion Transmigration 
Selectins 
(P, L, E ) 
 
 
Leukocytes then become activated. The slowed leukocytes have now the opportunity to 
respond the signaling molecules held at the endothelial surface. Particularly important are the 
large group of chemokines, which activate certain populations of leukocytes that have the 
appropriate receptors. 
Activation upregulates the affinity of the leukocytes integrins which engage the cellular 
adhesion molecules on the endothelium (e.g. ICAM-1) to cause first adhesion and initiate a 
programme of migration.  
Then leukocytes transmigrate across the endothelium. This is an active process  which involve 
both cell types (leukocytes and endothelial cells) and occurs near the junctions between 
endothelial cells. By the help of enzyme secretion, leukocytes can digest and pierce the 
basement membrane to migrate into the tissue toward chemoattractants coming from the 
source of injury.  
It is important to notice that in specialized tissues such as the brain, in case of non-damaged 
BBB where the endothelium is connected by continuous tight junctions, it is clear that 
lymphocytes migrates across the endothelium vacuoles, and the junctions do not break apart 
[Roitt, Brostoff, and Male, 2005].  
Integrins / Immunoglobulins 
( LFA 1 MAC 1/ ICAM-1 VCAM-1) 
Leukocyt 
PECAM-1 
Chemo attractants Endotheliu 
Basement  
membran 
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 4.3.3 Phagocytosis 
Phagocytosis is mediated by macrophages and polymorph nuclear leucocytes. Phagocytosis 
consist on the ingestion and digestion of microorganisms, insoluble particles, damaged or 
dead host cells, cell debris, activated clotting factors. There are several stages of 
phagocytosis:  
Chemotaxis: movement of cells against a concentration gradient of chemotactic factors.  
Adherence: receptor-ligand interaction that guide the extension of macrophage’s pseudopods 
around the particle (bacteria for instance)  
Pseudopodium formation:  protrusion of membranes to flow round the "prey".  
Phagosome formation: fusion of the pseudopodium with a membrane enclosing the "prey" 
leads to the formation of a structure termed a phagosome.  
Phago-lysosome formation: the phagosome moves deeper into the cell, and fuses with a 
lysosome, forming a phago-lysosome. These contain hydrogen peroxide, active oxygen 
species (free radicals), peroxidase, lysozyme and hydrolytic enzymes. This leads to digestion 
of the phagolysosomal contents, after which they are eliminated by exocytosis. The speed of 
phagocytosis can be increased by coating the organisms by molecules termed opsonins, this is 
the phenomenon of opsonization. 
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5 MULTIPLE SCLEROSIS AND EAE MODEL 
 
Under healthy conditions, the immune system has no access to the normal brain. Autoimmune 
neurodegeneration processes occurring in multiple sclerosis (MS) are particular cases. The 
pathology as well as the etiology of the disease are discussed in chapter 5.1. To study this 
disease and evaluate potential treatments, an animal model of experimental autoimmune 
encephalomyelitis (EAE) has been developed (5.2). Brain inflammation processes occurring 
in EAE that reflect changes observed in MS are summarized in chapter 5.3. 
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5.1  Multiple Sclerosis 
 
5.1.1 Definition 
Multiple sclerosis (MS) is an inflammatory disease of the CNS of unknown etiology 
characterized pathologically by the occurrence of areas of destruction of the myelin 
(demyelination) followed by gliosis throughout the brain.  
In many cases, early disease manifestations are phasic with relapses during which patients 
often present episodes of neurological and/or cognitive dysfunction and followed by phases of 
improvement or even apparent complete clinical recovery [Miller, 1998]. In case of a 
progressive disease course, some deficits might persist and even aggravate with time. In fact, 
MS is a complex and heterogeneous disease with a phenotype that is not unitary. Not only 
disease courses vary among relapsing remitting, primary progressive and secondary 
progressive, but also clinical symptoms as well as domains of cognitive dysfunction [Julien 
and Ferrer, 1989]. 
Gliosis: The production of a dense fibrous network of neuroglia; includes astrocytosis, which 
is a proliferation of astrocytes in the area of a degenerative lesion. 
 
5.1.2 Pathology 
The pathological hallmark in MS is a circumscribed lesion beginning with destruction of the 
myelin sheaths of the nerve fibers and ending with the formation of a sclerotic plaque. These 
plaques occur predominantly in the white matter of the brain and spinal cord. They are 
sometimes found in the grey matter of the CNS but rarely in the grey matter of the PNS 
[Allen et al., 1981].  
Characteristic histological features are perivascular inflammation, demyelination and axonal 
loss. Cellular analysis of lesions show evidences that the inflammatory cells present in MS 
plaques play an important role in the lesion development. These cells are mainly T 
lymphocytes [Babbe et al., 2000] [Huseby et al., 2001] [Calopa et al., 1995] [Hellings et al., 
2002] but some B cells, macrophages and plasma cells may also be found [Prineas and 
Connell, 1978; Prineas and Wright, 1978] [Nyland et al., 1982]. Many immunoglobuline-
containing cells are found in the plaques [Esiri, 1977; Esiri, 1980]. There is also good 
evidences to indicate that circulating immune complexes [Tachovsky et al., 1976] [Goust et 
al., 1978] and circulating T cells sensitized to proteins of the myelin are of importance 
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[Traugott et al., 1979] [Traugott et al., 1983a] [Turner et al., 1980] and similar cells may be 
found in the CSF [Kam-Hansen, 1980]. 
However, as demonstrated by Trapp and colleagues [Trapp et al., 1999], different 
demyelinating processes can be distinguished. These processes can range from demyelination 
caused by inflammatory process [Bitsch et al., 2000] that is followed by remyelination 
[Lassmann et al., 1997], to inflammatory demyelination with irreversible axonal death. The 
latter process is known as Wallerian degeneration. Demyelination followed by regeneration 
may lead to compromised or even failing nerve conduction [Raine and Wu, 1993] that can be 
related to a slowing of the physical or mental abilities of patients. In the case of axonal loss, 
deficits may persist. 
 
 5.1.3 Etiology 
Auto-immune disease MS is more and more believed to be an autoimmune disease. The prefix 
“auto” means “self.”  Autoimmunity means that the immune system is reacting against 
normally occurring antigens in the person’s body, as if these antigens were foreign [Bruck and 
Stadelmann, 2003]. It is not known what, in patients with MS, causes T cells to become 
activated but it is postulated that viral infections, genetic predisposition, environmental 
factors, and autoimmunity are all considered as contributing factors in the etiology of MS 
[Julien and Ferrer, 1989].  
In the case of MS, the target of the immune attack is believed to be a component of myelin in 
the central nervous system, probably one or few of main protein composing the myelin (see 
section 3.1.2). Certain T cells become sensitized to myelin and enter the CNS [Steinman, 
2001] [Stinissen and Raus, 1999] [Neumann et al., 2002]. Once in the CNS, these T cells not 
only injure myelin, but secrete chemicals that damage nerve fibers (axons) and recruit more 
damaging immune cells to the site of inflammation [Barnett and Prineas, 2004]. During active 
disease, demyelination is associated with an inflammatory reaction that is orchestrated by 
activated lymphocytes, macrophages and endogenous glial cell (astrocytes and microglia) 
[Benveniste, 1997] [Minagar et al., 2002] [Raivich and Banati, 2004]. 
 
Symptoms and distribution As mentioned previously, myelin not only protects nerve fibers, 
but is also essential for their proper function. When myelin sheath of the nerve fiber is 
destroyed or damaged, the ability of the nerves to conduct electrical impulses to and from the 
brain is disrupted, producing the various symptoms of MS such as abnormal sensations, 
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vision problems, and weakness [Berg et al., 2000] [Barnett and Prineas, 2004]. Symptoms of 
MS are unpredictable and vary from person to person and from time to time in the same 
person. Symptoms can vary widely because the damage can occur anywhere in the brain, 
spinal cord or optic nerve. The principal consequences of these hallmarks are motor weakness 
and incoordination of the lower limbs. Other characteristics like sensory symptoms, ataxia 
and bladder symptoms appear in respectively 87, 82 and 71% of  the cases. Patients generally 
complain because of fatigue and cramps. The affection of the optic nerve lead to visual 
symptoms in 49% of the patients.  
This demyelinating disease of the CNS generally afflicts persons between 20 and 50 years 
old, affecting more women than men. 
 
Therapy and areas of research There is currently no cure for MS.  However, over the past 
several years, first effective treatments for the disease have become available.  In contrast to 
non-specific immunosuppression [Hauser et al., 1982] [Kanwar, 2005], which was the 
mainstay of MS treatment for many years, these newer medications, called immune 
modulators, target various components of the immune attack in MS [Fujino et al., 2003]. 
While these treatments have shown promise, they are still only partially effective at 
decreasing the incidence of recurrent attacks that characterize relapsing-remitting MS; yet 
they have minimal effects, if any, on the progressive forms of the disease. 
Efforts to reverse the damage caused by MS and restore function in people with MS must 
focus on the repair of myelin, oligodendrocytes, and neurons in the CNS.  Some neural repair 
occurs naturally [Billinghurst et al., 1998]. Spontaneous healing of MS lesions has been 
observed following stimulation of oligodendrocytes in the area, or recruiting young 
oligodendrocytes from more distant area, in order to synthesize new myelin at the damaged 
site.  Researchers are now working to identify the molecular players that are used by the body 
to activate the oligodendrocytes in order to stimulate additional repair. Similarly the role of 
growth factors (proteins) for myelin repair is being evaluated.  
Replacement of damaged cells is an alternative approach to treat MS [Bulte et al., 2002].  
Possible cell sources include: skin-derived cells, bone marrow and umbilical-cord blood cells, 
fetal cells, adult brain cells, and Schwann cells from the PNS. The usefulness of these 
replacement cells will depend on finding or creating the signals needed to stimulate their 
transformation and growth into healthy new cells. 
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These efforts will not be successful, however, unless a way is found to stop the immune 
system from damaging the CNS tissue in the first place.  Much of the ongoing research in MS 
is directed towards finding answers to questions about the role of the immune system in the 
development of MS. Scientists have begun to identify the sites or receptors on the T cells that 
bind to the myelin. The precise identification of these receptor sites may help lead to the 
development of more specific immunosuppressant therapies that destroy only these sensitized 
T cells while leaving other cells intact. That is why, method to image in vivo T cells 
localization during the course of MS would be extremely informative on the illness 
development and evolution.   
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5.2 The EAE Rodent Model  
 
EAE (experimental autoimmune encephalomyelitis): is an animal models for MS which 
has been developed to elucidate the underlying mechanisms of neuro-inflammation. 
Established animal models of acute and chronic-relapsing EAE have led to important insight 
into the pathophysiology of the immune disease. 
 
5.2.1 Description 
EAE and related demyelinating diseases affect the brain and spinal cord, similar in many 
aspects to MS. Like MS, EAE is a demyelinating disease: it destroys the myelin.  EAE can be 
induced in rats, mice, guinea pigs, rabbits, and monkeys [Gold R. et al., 2000]. Like MS, it 
takes several clinical forms, including relapsing-remitting and progressive-relapsing. The time 
course and pathology of the disease depend on the species and the type of antigen. 
  
5.2.2 Inoculation 
EAE can be induced only in specific species by injecting homogenized spinal cord or myelin 
fragments. In the Lewis rat, at least three myelin proteins can induce EAE, myelin basic 
protein (MBP) [Ben Nun et al., 1981], proteolipid protein (PLP) [Yamamura et al., 1986], or 
myelin-oligodendrocyte glycoprotein (MOG) [Linington et al., 1993] in combination with an 
immune-exciting agent, called an adjuvant (an agent which, while not having any specific 
antigenic effect in itself, may stimulate the immune system, increasing the response to a 
vaccine). Alternatively, EAE can be induced by injection of CD4+ T cells that have been 
activated in vitro (adoptive transfer EAE) [Zamvil et al., 1985]. In this case, the time course 
of the disease runs in a more synchronous mode. Moreover, this protocol highlights the 
importance of T cells for disease induction. 
Although not being identical to all pathophysiological aspects of the human disease, EAE 
models nevertheless reproduce many aspects of MS [Gold et al., 2000]. While active EAE in 
Lewis rats induces a strong inflammatory response, it does not lead to chronic axonal damage 
as found in human MS. Active immunization of congenic Lewis rats (DA, BN strains) or  
mice (SJL, C57/Bl6 strains) leads to a relapsing-remitting time course and persistent damage 
of  axons and is therefore more similar to the human pathology. Therefore, EAE models can 
be used to streamline the development and validation of novel imaging approaches suited for 
patient/therapy management and for testing novel therapeutic strategies.  
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5.2.3 EAE animal studies inform about MS 
Much of our current knowledge about the disease damage (pathology) and immune responses 
underlying MS has been gained from studies of animals with EAE. Information derived from 
microscopic and biochemical examination of the brain, blood, and spinal cord of animals with 
EAE includes: 
- identifying sites in the central nervous system that are more likely to develop MS lesions 
(damaged areas) also known as plaques 
- finding out which immune cells are involved in the formation of plaques and how they 
interact 
- developing experimental treatments or manipulations that can stop or reverse the 
demyelinating process  
In the past, MRI has been employed as a valuable tool to detect and characterize clinical or 
neurological changes. Unfortunately, conventional MRI provides only low pathological 
specificity and correlations between lesion volume, atrophy, and lesion localization and 
clinical symptoms or cognitive measures are only moderate [Berg, et al., 2000] [Rovaris et 
al., 1998].  
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5.3 Brain Inflammation in MS and EAE 
 
Several diseases of the central nervous system (CNS) are caused or at least accompanied by 
inflammatory processes. These processes comprise acute inflammatory events, which are 
supported by infiltration of brain tissue by different types of leucocytes but also by the 
transformation of brain residing microglia to an activated form and later also to macrophages. 
Immune defense in the CNS generally follows a typical layout in which the different cells of 
the immune system play their specific role. Immune responses are generally induced by the 
presence of a foreign antigen.  
 
5.3.1 Immune privilege of the normal brain 
The CNS presents some differences in comparison to other organs. First, due to the BBB, 
immune cells, antibodies and immunological mediators have little access to the normal brain 
[Hickey, 1991]. Yet, there are some hematogenous cells (see definition), in particular 
monocytes/macrophages and T lymphocytes, present in the CNS under normal conditions 
[Hauser et al., 1983b]. T lymphocytes can traverse the normal BBB, when they are in an 
activated state [Wekerle et al., 1991] [Hickey et al., 1991]. These data suggest that it is a 
small pool of peripheral activated T cells that enter the CNS for immune survey and are, thus, 
allowed to search for specific antigens or pathogens.  
Hematogenous cells: originating in the blood or spread through the bloodstream 
 
Another factor promoting an immune response in the CNS is the active suppression of the 
expression of major histocompatibility (MHC) antigens in the nervous system. Antigen 
recognition by T lymphocytes requires the presentation of the small peptides of the antigenic 
protein by antigen presenting cells in the context of MHC antigen. Thus, in the absence of 
MHC-antigens T lymphocytes cannot recognize their target and thus, do not activate the 
mechanisms would lead to inflammation [Vass et al., 1986]. 
Thirdly, other molecules like adhesion molecules, that are essential to in the cell-cell contacts 
during the migration of inflammatory cells [Bevilacqua, 1993; Springer, 1994] have a low 
expression on endothelial cells of cerebral vessels as well as on local tissue elements 
[Lassmann et al., 1986].  
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Finally the CNS is equipped with a particular tissue macrophage, the microglia [Gehrmann et 
al., 1995] [Gehrmann et al., 1993]. In the normal brain microglia seems to be 
immunologically inert. Microglia can become activated by a variety of immunological and 
non-immunological stimuli. Different levels of activation appear to exist, which may 
transform the cells in pure scavengers of fully activated immunological effector cells 
[Lassmann, 1997]. Furthermore these cells can produce both, immunostimulatory as well as 
immunosuppressive cytokines [Kiefer et al., 1995]. 
 
5.3.2 Induction of initial brain inflammation  
In the case of EAE, immune system has to recognize the pathogen or autoantigen that is 
sequestrated in the nervous system. That implies, that immune cells have to get access to the 
normal nervous system or that the antigens have to be presented in a way that allows 
recognition.  
In the first hypothesis, activated T cells can pass the normal BBB. Thus, peripheral 
stimulation of the immune system will allow a selected population of T cells to enter the CNS 
and to search for their respective antigen. To enter the CNS, activated T cell are slowed down 
and attached to endothelium wall due to adhesion. When the antigen or a cross reactive 
antigen is present in the CNS compartment, it will be presented to the T lymphocytes on a 
population of meningeal and perivascular tissue macrophages, which constitutively express 
MHC antigen even normal conditions [Vass et al., 1986] [Hickey et al., 1991]. If we admit 
that T cells cannot pass the normal BBB,  astrocyte and microglia should be involved to 
present the antigen to circulating T cells. The initial antigen recognition in the perivascular 
space triggers a cascade of secondary events that lead to the development of the brain 
inflammation. A key role in this process is played by cytokines that are produced by either 
hematogenous cells or by local tissue elements. 
In any hypothesis, the initiation of the immunological/inflammatory response is initiated by 
antigen presenting cells (APC) (e.g. pericytes) that present characteristic peptide-motifs of the 
antigen together with other surface signals to cells of the immune system. The antigen-
specific autoimmune T cells first contact a naive intact BBB and are able to extravasate 
through the BBB due to their activated status. This is the first step of BBB disruption.  The 
cells which initiate disease are predominantly myelin-reactive CD4+ T-helper cells 
[Swanborg, 1995]. These cells are retained in the CNS due to presentation of appropriate 
antigen (most likely by endogenous microglia) and undergo further activation. When antigen 
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is recognized a cascade of events is started which leads to inflammation and elimination of the 
pathogen, however which may be associated with additional tissue damages. This lead to the 
recruitment of non-antigen-specific lymphocytes and activated macrophages from the blood 
into this site, accompanied by further disruption of the BBB. 
 
5.3.3 Amplification of the inflammatory response  
The recruitment of immune cells is mediated by a variety of chemotactic factors (chemokines) 
secreted into the circulation and of adhesion proteins (selectins, integrins) presented at the 
luminar surface of activated endothelial cells (see section inflammation). Chemokines play an 
important role in the secondary recruitment of leukocytes into the established inflammatory 
focus [Baggiolini and Dahinden, 1994]. In brain, inflammatory chemokines are not only 
produce by hematogenous cells but also and predominantly by local cells such as astrocytes 
[Tani and Ransohoff, 1994]. Liberated in the extracellular and perivascular space, they 
apparently modulate the inflammatory reaction by attracting additional monocytes. In 
comparison to cytokines, the synthesis of chemokines in the lesion is much more prominent 
and less controlled [Schluesener and Meyermann, 1993]. 
 
5.3.4 Mechanisms of immune-mediated tissue damage in brain lesion 
Infiltrating macrophages and intrinsic microglia take part in the inflammatory process by 
phagocytosis of myelin, leading to demyelination [Gehrmann et al., 1993; Bauer et al. 1994]. 
Immune effector cells, such as monocytes/macrophages, granulocytes or cytotoxic T cells also 
produce a variety of toxic factor, that are required for the destruction and elimination of 
foreign pathogens (myelin in our example of EAE). These include cytotoxic cytokines (TNF-
α, lymphotoxin) perforin or complement factors, proteolytic and lipolytic enzymes and 
oxygen radicals. These toxic factors, however, not only destroy foreign pathogens but may 
also damage local tissue elements. In the CNS the myelin/oligodendroglia complex appears to 
be particularly vulnerable to the action of these toxic inflammatory mediators [Griot et al., 
1990] [Scolding et al., 1990] [Selmaj and Raine, 1988].  
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5.3.5 Physiopathology of MS brain lesions 
The earliest change observed in the lesions examined in our model was widespread 
oligodendrocyte apoptosis in tissue in which macrophages, activated microglia, reactive 
astrocytes, and neurons appeared normal [Barnett and Prineas, 2004]. However, the local 
accumulation of activated CD4+ and CD8+ T cells around small venules, with CD4+ cells 
predominating is relevant of a starting inflammation [Hauser et al., 1986]. The primary 
demyelination observed in MS results from damage to the myelin sheath and/or 
oligodendrocytes. Macrophage/microglia are active participants in myelin breakdown; 
phagocytosis of myelin proteins in the lesions by these cells is a reliable indicator of ongoing 
demyelinating activity [Bauer et al., 1994]. At a later stage in the disease process myelin 
degeneration is associated with perivascular inflammation involving of T cells, B cells, 
plasma cells and activated macrophages [Prineas and Wright, 1978] [Prineas, 1975]. 
 
Gliosis is also a predominant feature of MS, and is characterized by astrocyte proliferation, 
hypertrophy and increase synthesis of glial fibrillary acidic protein, an astrocyte-specific 
protein [Bignami et al., 1972]. This reaction is thought to contribute to the formation of dense 
glial scars in the CNS, leading to motor and sensory impairment. Recent findings with 
magnetic resonance imaging indicate that considerable subclinical disease occurs, and BBB 
breakdown is an early event in lesion development [Thompson et al., 1992] [Gay and Esiri, 
1991], which may be a crucial for the pathogenesis of new lesions in MS. 
A typical relapse is characterized by an abrupt loss of oligodendrocytes throughout a 
circumscribed and relatively small volume of tissue. The formation of these new lesions occur 
within hours: oligodendrocytes throughout the affected tissue appear apoptotic and ramified 
microglia with thickened processes appear in increased numbers [Gay et al., 1997]. Although 
apoptosis typically allows dead cells to be removed without inciting an inflammatory reaction, 
[Henson et al., 2001] [Fadok et al., 1998] [De Simone et al., 2003] the multiple sclerosis 
lesion might be an exception in view of the relatively huge quantity of apoptotic plasma 
membrane, in the case of this altered myelin, generated by each dying oligodendrocyte. 
Inflammation is associated with postapoptotic necrosis, which occurs when normal clearance 
mechanisms of apoptotic cells are overwhelmed [Henson et al., 2001] [Barnett and Prineas, 
2004]. T cell, early activated macrophages [Aboul-Enein et al., 2003] and myelin phagocytes 
are rare or absent in the apoptotic zone but are present elsewhere in the lesion. After 1 or 2 
days, oligodendrocytes disappear, most presumably phagocytized by the now amoeboid 
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microglia present in the tissue. The tissue appears vacuolated because of the presence of 
widespread intramyelinic edema, which usually accompanies oligodendrocyte loss [Graeber 
Blakemore, Graham DI, Lantos PL, eds. Greenfield’s Neuropathology.7th ed. London: Arnold 
2002]. 
 
5.3.6 Clearance of inflammation 
Finally during clearance of inflammation, inflammatory cells, that have entered the brain 
during inflammation, have to be removed from the lesion during recovery. Most of the 
apoptotic cells are T lymphocytes and the peak of T cells apoptosis correlates well with the 
clearance of the inflammatory lesion [Schmied et al., 1993]. There is some evidences that the 
population of autoantigen-specific T lymphocyte that is removed by programmed cell death in 
the brain [Tabi et al., 1994; Bauer et al., 1995]. 
Lassman et al., have studied recently that migration routes of macrophages that have taken up 
brain proteins in inflammatory demyelinating lesion and found evidence for a drainage 
pathway through the spinal meninges into the epidural lymphatic vessels and the para aortal 
lymph nodes. In addition, some macrophages were also found to migrate through the walls of 
inflamed vessels through the circulation and could then be identified in the spleen. 
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6 IN VIVO MRI OF BRAIN IMPAIRMENT  
 
The noninvasive measurement of brain impairment can be performed by MRI (6.1) by 
focusing on the injuries induced by the progression of MS or EAE. The chapter 6.2 presents 
the possibilities to image structural changes such as blood brain barrier leakage or 
demylination processes. Beyond tissues imaging, new protocols in MRI allow a spatial 
resolution at the single cell level. Chapter 6.3 describes the possibilities to label specific cells 
and to visualize them by MRI. 
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6.1  MRI Visualization of Brain Inflammation 
 
Imaging of inflammatory events in the brain can be based on targeting various processes 
along the immune response. Because the CNS presents some differences compared to other 
organs, specific events of the pathophysiological cascade have to be identify and tagged. 
First, due to the BBB, immune cells, antibodies and immunological mediators have little 
access to the normal brain [Hickey, 1991]. Yet, there are some hematogenous (coming from 
the blood) cells present in the CNS under normal conditions [Hauser et al., 1983b]. T 
lymphocytes can traverse the normal BBB, when they are in an activated state [Wekerle et al., 
1991; Hickey et al., 1991; Hickey, 1991]. These data suggest that it is a small pool of 
peripheral activated T cells that enter the CNS for immune survey in search for specific 
antigens or pathogens.  
Secondly, other molecules like adhesion molecules, that are essential in the cell-cell contacts 
during the migration of inflammatory cells [Bevilacqua, 1993] [Springer, 1994] have a low 
expression on endothelial cells of cerebral vessels as well as on local tissue elements [Sobel et 
al., 1990] [Raine et al., 1990] [Lassmann et al., 1991]. 
Two ways are thus available to visualize inflammatory events in the brain either targeting 
antigens or immune cells or by targeting secondary markers of inflammation. 
Targeting antigens or immune cells: The immune cells themselves or immune chemical 
receptors (e.g. cytokine receptors) could serve as primary imaging targets, since their 
activation or presence within inflammation areas in the brain is directly linked to the disease 
process and to the damage of brain tissue.  
Targeting secondary markers of inflammation: Imaging of neuro-inflammation has 
emerged from the visualization of processes down-stream of the initial inflammatory events, 
i.e. structural/micro-structural changes in brain tissue. Markers of vascular edema, 
demyelination and blood brain barrier damage have been extensively applied both in 
preclinical and clinical studies. Despite the fact that their specificity for the pathophysiology 
of MS remains questionable, these readouts have played, and still do so, a tremendous role for 
the in vivo assessment of inflammatory diseases of the CNS due their robustness and broad 
availability. 
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6.2  Imaging of Structural Changes 
 
6.2.1 Assessment of BBB Leakage: Gd-Enhancing Lesions  
It has been detailed in the section 3.2 that the BBB play the role of a high selective filter that 
protect the brain parenchyma from circulating agent potentially dangerous for the brain and is 
responsible for the homeostatic regulation of the brain microenvironment. In the case of brain 
inflammation, BBB integrity is disturbed: transcytosis of leukocytes from the circulation into 
the brain parenchyma and their associated inflammatory processes can interfere with the 
integrity of the BBB. This damage is specific for leukocyte infiltration under inflammatory 
conditions since the trans-endothelial migration of immune cells during immune surveillance 
does not lead to BBB damage [Gloor et al., 2001]. Moreover, BBB breakdown can occur as a 
consequence of direct mechanic (hemorrhage) or ischemic damage of endothelial cells. The 
breakdown of the BBB can be visualized by MRI during early lesion development [Thompson 
et al., 1992] [Gay and Esiri, 1991], which may be a crucial event in the pathogenesis of new 
lesions in MS [Abbott et al., 1999]. In most cases, low molecular weight CAs such as Gd-
DOTA or Gd-DTPA are used, which are approved for clinical use since almost two decades. 
These CAs are administered intravenously at a typical dose of 0.1 mmol/kg (clinical single 
dose). The intact BBB is impermeable for these molecules but in areas of acute inflammation, 
CA can leak out of the blood vessels into the interstitial space, where it leads to an 
enhancement of longitudinal and transversal relaxation rates and therefore to a change in MR 
signal intensity. 
  
However, the visualization of increased BBB permeability provides a sensitive but not very 
specific marker for acute inflammatory processes. It should also be remembered that 
correlative studies of Gd-enhancement and cellular infiltration cannot provide the ultimate 
prove for a one-to-one correlation, because tissue samples are always taken from areas which 
show clear signal abnormalities in the MR images; hence the available data are biased.  The 
occurrence of inflammatory events of neurological relevance, i.e. infiltration of immune 
competent cells into brain parenchyma, might not be associated with structural damage. At 
least for the rat EAE model it was shown that areas of macrophage infiltration were not 
affected by BBB damage as measured by administration of Gd-DOTA [Rausch et al., 2003]  
or that BBB damages has occurred only transiently and the BBB has been reconstituted at the 
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time point of the measurement. Such tissue areas have been defined “normal-appearing white 
matter”.  
 
6.2.2 T2-Hyperintense Lesions and Multi-Component-T2-Mapping 
Enhanced T2 relaxation times are one of the most characteristic hallmarks of MS lesions. T2 is 
a sensitive but rather unspecific imaging readout [Barkhof and van Walderveen, 1999]. 
Combined MRI and histopathological analysis has shown that T2-hyperintensity can be 
observed during the acute, subacute and chronic demyelinated or even remyelinated state of 
lesions [Bruck et al., 1997]. Physiologically, T2-prolongation can be observed as a 
consequence of vascular edema, which results from a redistribution of water from the 
vasculature into the tissue. Occurrence of a vascular edema is an important indicator of acute 
inflammatory processes accompanied by acute or persistent BBB damage (Figure 6.1).  
 
 
Figure 6.1 
MR-images showing MS-lesions of different characteristics. (A) T2-weighted image. Two lesions are marked by 
arrows. (B) Same slice acquired with a T1-weighted sequence prior to administration and (C) after administration 
of a low molecular weight CA (Gd-DOTA). Only lesion 1 from the T2-weighted scan appears hypointense on the 
T1-weighted scan and takes up CA. Lesion 2 does not enhance CA. This set of images demonstrates the variable 
relationship of lesion type and MR parameters.  
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At least two components contribute to the overall T2-values measured in affected tissue: a 
long T2-component (70-95ms) of (bulk) water in cytoplasmic and extracellular spaces and a 
short T2-component (10-55ms) associated with water molecules bound within myelin 
membranes. Protons of cerebrospinal fluid (CSF) have T2-times of the order of 1s [MacKay et 
al., 1994]. Although not prominent in the T2-maps, the short T2-component might play the 
relevant role for the distinction between acute inflammation and persistent degeneration. As 
shown for MS lesions in patients and in animal models of EAE [Stewart et al., 1993], a 
decrease of the fast T2-component has been observed for chronic lesions; this is interpreted as 
loss of myelin and reflects a chronic impairment of tissue function. 
 
6.2.3 Magnetization Transfer Contrast 
Magnetization transfer imaging can be used to assess the degradation of myelin in the brain of 
MS patients or in animal models [Henkelman et al., 2001] [Graham and Henkelman, 1997]. 
The technique probes the transfer of longitudinal magnetization between to molecular partners 
that are coupled via chemical exchange, magnetic cross-correlation, or spin diffusion. For 
water exchange in biological tissue the process studied is the transfer of longitudinal 
magnetization between protons that are bound to immobile (macromolecular) surfaces such as 
the myelin sheath of axons (see section 3.1.2) and free protons.  
MTRs have been extensively used in clinical MS trials. Compared to BBB damage and 
edema, reduction of MTR has been associated to permanent loss of white matter integrity or 
at least to transient demyelination. Similar assumptions have been made for tissue damage 
due to ischemia [Ordidge et al., 1991]. However, as already discussed, even quantitative 
measurements of MTRs or of exchange rate constants cannot provide direct information on 
the reduction of myelin or other membrane elements. Degradation of these structures should 
be associated with a reduced amount of bound water, which, however, is invisible in MRI. 
The indirect visualization by imaging the interaction of bound and free water protons by the 
magnetization transfer effect underlies one severe limitation: changes in the empirical rate 
constant k (or in MTRs) can be due to changes in the density of the bound protons or the 
alteration of the effective exchange rate. Hence, a strict biophysical link between the 
empirical MRI-derived parameters to tissue degradation is not possible. Nevertheless, the 
assumption that reductions in MTR qualitatively reflect tissue damage is plausible, and the 
readout is considered of diagnostic value.  
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6.2.4 T1-Hypointense Lesions 
Chronic lesions can appear hypointense on post-contrast T1-weighted images [Barkhof and 
van Walderveen, 1999] [Truyen et al., 1996], and were therefore termed ’black holes’. It has 
been proposed that this signal change is associated with hypocellularity, demyelination, 
axonal loss and/or the presence of reactive astrocytes [van Walderveen et al., 1998]. Hence, 
T1-hypointensity should indicate severe, irreversible damage of brain tissue, actually neuro-
degeneration, which should be more closely related to the disability status as compared to the 
inflammation marker vascular edema or BBB damage. From a diagnostic point-of-view, 
however, T1-hypointensity is considered just a qualitative measure for the presence or absence 
of a lesion. Since several different pathological processes can lead to this form of signal loss 
(or a decrease of the T1-relaxation time corresponding to an increase in R1-relaxivity), it is 
almost impossible to measure the status of a lesion or to predict its future development. 
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6.3  Cell Labeling 
 
In the previous section we focused on visualizing aspects of immune cell recruitment, i.e. on 
the expression of antigens by endothelial cells in the affected region. In vivo tracking of 
immune cells per se would provide another relevant readout to evaluate inflammatory 
processes in the brain.  
As already discussed, there are two classes of immune-cells: lymphocytes, which orchestrate 
the tissue response to inflammation and macrophages, which eliminate the antigen expressing 
pathogen and are responsible for massive tissue destruction. The majority of in vivo labeling 
studies focused on macrophages taking advantage of their phagocytotic activity. Macrophages 
recognize nano-particles of a certain size as foreign antigens, and incorporate them into their 
lysosomes. This mechanism is rather established for labeling cells of the monocyte phagocytic 
system of the liver with SPIOs nanoparticles. Efficient labeling of the different types of 
macrophages (e.g. lymphnode or blood-borne monocytes) requires sufficient exposure time 
for phagocytotic label uptake. Nanoparticles should not be cleared rapidly by Kupffer-cells in 
the liver, circulation time should be of the order of several hours. USPIOs were originally 
designed for the demarcation of benign from malignant lymphnode lesions. However, due to 
their plasma half-life of 5 hours, it could be demonstrated that these particles also allow 
visualization of blood-borne macrophages in animal models of stroke and EAE [Rausch et al., 
2001] [Dousset et al., 1999c] [Dousset et al., 1999a] [Dousset et al., 1999b]. 
 
6.3.1 Macrophages tracking by MRI  
Visualization of infiltrating macrophages offers several advantages over imaging of 
downstream processes such as BBB damage. First, the primary demyelination observed in MS 
results from damage to the myelin sheath and/or oligodendrocytes. Macrophage/microglia are 
active participants in myelin breakdown; phagocytosis of myelin proteins in the lesions by 
these cells is a reliable indicator of ongoing demyelinating activity  [Bauer et al., 1994]. 
  
Secondly, acute inflammatory activity is a transient process. In the rat EAE model it could be 
demonstrated that the infiltration of macrophages is closely linked to behavioral disability as 
reflected by a neurological score. BBB damage, on the other hand, appears to be a more 
persistent effect, which extends over several days [Floris et al., 2004]. This suggests that the 
BBB is leaky during several phases of the inflammatory cascade including the early 
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interaction of leucocytes with endothelial cells, the opening of tight junctions due to 
transcytosis and potentially also tissue repair mechanisms. There is also experimental 
evidence that the presence of labeled macrophages is not necessarily associated with BBB 
damages (see Figure 6.2).  
 
 
Figure 6.2 
 
Comparison of parametric images from one animal of the EAE group. A) ED-1 
stain demonstrating macrophages in the cerebellum and the medulla of an animal 
with acute EAE. B) The T2 image displays hypo-intense areas, induced by 
accumulation of USPIO. C) and D) Corresponding slices from another animal 
with EAE demonstrating the mismatch of Gd- and USPIO-enhancements. 
Enhancement of Gd-DOTA is visible in structures of the midbrain. The 
discrepancy of spatial localization of USPIO and Gd-DOTA enhancement is 
demonstrated by the dotted and dashed lines. The area marked by the dotted line 
accumulated USPIO but no Gd-DOTA. The reverse situation can be observed in 
the area marked by the dashed line. 
 
 
A detailed analysis of Gd- and USPIO-enhancing lesions in a chronic relapsing rat EAE 
model has demonstrated a significant spatial mismatch between BBB permeability and 
monocyte infiltration [Rausch et al., 2003]. Qualitatively, Gd-enhancement also appeared 
more diffuse as compared to the distribution of USPIO-labeled cells, possibly because low 
molecular weight CAs passively diffuse within the interstitium. However, during the acute 
phase of EAE there was also a clear mismatch in that some areas that showed either 
accumulation of USPIO or Gd-DOTA. During the chronic phase, only USPIO-induced 
enhancement has been observed. Although the EAE model cannot be translated in a one-to-
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one fashion to human MS, these findings raise the question whether BBB damage can in fact 
serve as a reliable readout for acute-inflammation. This reservation is even more justified, 
since BBB damage as measured by Gd-extravasation is often also poorly correlated with 
neurological function and disease outcome [Kappos et al., 1999]. Whether the correlation 
between the lesion load as derived from USPIO-enhancing lesions, reflecting a high 
macrophage concentration and correspondingly high inflammatory activity, and the clinical 
status of MS patients will reveal a better prognostic value of the MRI readout remains to be 
shown. 
 
6.3.2 Non-phagocytotic cells labeling  
Non-phagocytotic immune-cells cannot be tracked in vivo using MRI as easily as 
macrophages because those do not take up nanoparticles from the circulation. Visualization of 
early forming lesion in EAE would allow to characterize the local accumulation of activated 
CD4+ and CD8+ T cells around small venules in inflamed areas [Hauser et al., 1983a]. During 
the next stages, the myelin degeneration is associated with perivascular inflammation 
consisting of T cells, B cells, plasma cells and activated macrophages [Prineas, 1975]. 
Imaging of such cells requires harvesting cells from a donor animal followed by ex vivo 
labeling. The feasibility of T cell labeling by USPIOs has been demonstrated: cells were 
incubated for several ours in medium containing the CA [Yeh et al., 1995]. However, this 
approach turned out to be not very efficient as the incorporation of CA by pinocytosis occurs 
at a rather low rate. Improved methods are based on conjugating nanoparticles with 
transfection agents, such as the trans-acting activator domain (TAT) of the human immune-
deficiency virus [Dodd et al., 2001], poly-L-lysine [Frank et al., 2002], or lipid-based 
transfection agents such as Fugene [Arbab et al., 2004a], which serve as translocation signals 
and enhance the particle uptake. Alternatively, magnetodendrimers (see section 1.7.2) can be 
used, which tightly interact with the cell membrane [Bulte et al., 2002]. Up to now, in vivo 
tracking of labeled T cells has not been used extensively. The reason for that might be the 
relatively low sensitivity of MRI itself and the complex preparation of the cell cultures. 
Several factors have to be considered in this respect: first, T cells have to be myelin-specific. 
For observation of bystander T cells, huge amounts of labeled cells must be administered 
because only a low fraction of these cells would enter the brain. Secondly, clonal expansion 
will lead to label dilution and finally, the specificity of T cells should not be affected by the 
labeling procedure. 
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Today, the advantage of the MR approach is high temporo-spatial resolution and the potential 
translatability to humans. It can be anticipated that imaging of monocyte infiltration and 
eventually also lymphocyte recruitment will have a profound influence on the diagnosis and 
management of MS patients. 
 
  89 
 
 
 
 
 
 
7 OBJECTIVES AND OUTLINE OF THE THESIS 
 
Cellular and molecular imaging is a rapidly evolving field. MR and optical approaches are 
constantly improved to explore the molecular processes of diseases. In consequence, there is a 
great need of developing new methods to make these technological advances profitable. 
Recently, it has become possible to detect single cells by NMR with the help of contrast 
agents [Dodd et al., 1999] and to monitor cell migration in vivo [Bulte and Kraitchman, 
2004]. A better understanding of immune cell migration in neuropathological diseases (e.g. 
multiple sclerosis) would allow a quicker and improved diagnosis. Being non-invasive, MR 
and optical imaging permit longitudinal studies of immune cell activity during brain 
inflammation or after treatment with anti-inflammatory drugs. 
 
7.1 Tracking tagged macrophages by MRI: a tool to evaluate drug effects 
The first objective of this thesis is to use nonspecific CAs for MR imaging to focus on the 
detection of preliminary labeled immune cells. Macrophages which are professional 
phagocytotic cells, are easily labeled by circulating iron particles and can be observed in vivo 
after rat transient ischemia [Rausch et al., 2002a] or FTY treatment of EAE [Rausch et al., 
2004]. It is known that the brain inflammation in the EAE model is initiated by T 
lymphocytes [Traugott et al., 1983b], thus the second objective is to evaluate the possibility of 
labeling T cells for in vivo tracking by MRI. As lymphocytes have no natural phagocytotic 
activity, primary cultured T cells have been labeled in vitro in order to be transferred 
adoptively in EAE animals before measurement. 
 
7.2 New methods to label T lymphocytes for MR and NIRF imaging 
As the visualization of iron-tagged T lymphocytes by MRI was not possible because of 
dilution of tagged cells in the blood and the weak inherent sensitivity of the MRI method, the 
third aim of the thesis was to visualize T cells and track them by using a more sensitive 
technique, such as near infrared imaging. Fluorescence reflectance imaging is complementary 
to MRI because it can detect fluorescent markers at the molecular level [Ntziachristos et al., 
2003]. T lymphocytes have been labeled with the cyanine 5.5 dye coupled to the Tat peptide 
and re-injected in the blood circulation of EAE animals. Before performing in vivo imaging, 
the toxicity and the pharmacology of the newly designed probe has been evaluated in vitro.  
  
 
 
 
 
 
 
7.3 Outline of the thesis 
The experimental section is composed of the following manuscripts, which have been 
published or are in preparation for submission:  
 
Berger C, Hiestand P, Kindler-Baumann D, Rudin M and Rausch M.  
Analysis of lesion development during acute inflammation and remission in a rat model of 
EAE by visualization of macrophage infiltration, demyelination and blood-brain-barrier 
damage.  
NMR Biomed, 2006 Jan 12 
 
Berger C, Hiestand P, Kindler-Baumann D, Rudin M and Rausch M.  
Longitudinal assessment of cerebral lesions by USPIO-enhanced MRI  in EAE rats: 
assessment of treatment efficacy of FTY720 in acute and chronic relapsing EAE.  
Novartis Internal Study Report (RD-2004-01566)  
 
Berger C, Rausch M, Schmidt P, and Rudin M.  
Feasibility and limits of magnetically labeling primary cultured T cells with ferumoxides 
coupled with commonly available transfection agents.  
Mol Imaging (2006) 
 
Berger C, Gremlich H-U, Schmidt P, Kneuer R, Cannet C, Rausch M and Rudin M.  
Tracking of Cy5.5-TAT labeled T lymphocytes by quantitative near-infrared imaging 
during acute brain inflammation in a rat model of experimental autoimmune 
encephalomyelitis.  
(in preparation) 
 
 
These manuscript are presented in the chapters 8.1, 8.2, 9.1 and 9.2 respectively.  
 
The aim of the chapter 10 (overall conclusion) is to present results in the general context of 
molecular imaging. It reports recent investigations in this domain and compare them to our 
results to orient further investigation related to the subject. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EXPERIMENTAL SECTION 
 
 
 
 
 
 
 
 
 
 
  
 
Chapter 8.1 Macrophage Tracking during EAE Brain Inflammation 
 
 
 
 
8 MACROPHAGES LABELING FOR MRI 
 
8.1 Macrophage Tracking during EAE Brain Inflammation 
 
 
Analysis of Lesion Development during Acute Inflammation and 
Remissionin a Rat Model of EAE by Visualization of Macrophage 
Infiltration, Demyelination and Blood-Brain-Barrier Damage 
 
 
8.1.1 Abstract 
 
In vivo tracking of macrophage migration is feasible by labeling cells with ultra small 
particles of iron oxide (USPIO). Here, we demonstrate that it is possible to monitor distinct 
patterns of macrophages migration during the early states of inflammation in a rodent model 
of chronic relapsing experimental autoimmune encephalomyelitis (EAE). As previous MRI 
studies showed that EAE inflammation processes are clearly linked to macrophages 
infiltration in the brain, a longitudinal protocol for macrophages visualization was designed, 
where USPIOs were injected repeatedly during the acute phase of the disease, the remitting 
phase and the first relapse. Besides USPIO-enhanced MRI, blood brain barrier (BBB) 
damage, magnetization transfer ratios (MTR) and neurological impairment were assessed as 
classical markers for central nervous system (CNS) inflammation and tissue damage. During 
the acute phase, animals showed severe paralysis of the hind paws, intense accumulation of 
macrophages in brain tissue and some diffuse patterns of BBB disruption. While USPIO-
accumulation completely disappeared after the acute phase, residual damage of the BBB 
remained detectable in some lesions during the remitting phase. During the first relapse, the 
accumulation of USPIO loaded cells was less pronounced but still detectable. The time course 
of MTR, which is used as a marker for myelin loss, was linked to the infiltration of 
macrophages during the acute phase.  
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8.1.2 Introduction 
 
In vivo tracking of inflammatory cells in animal models or humans is of large interest for 
diagnosis or staging of neuroinflammatory diseases such as multiple sclerosis (MS) and for 
testing new therapeutic approaches. Beyond conventional magnetic resonance based markers 
such as imaging of blood-brain-barrier (BBB) defects, edema or atrophy, readouts with 
greater pathophysiological specificity are under investigation, one being USPIO-enhanced 
MRI. USPIOs are ultra-small particles of iron-oxide that are taken up by activated 
macrophages after systemic administration [Dousset et al., 1999b] [Rausch et al., 2002a] 
[Rausch et al.,. 2002b]. This method has already been used in several experiments showing 
inflammation of the brain and other organs. Dousset et al. [Dousset et al., 1999b] have shown 
that in vivo CNS macrophage cellular imaging can be achieved on Experimental Autoimmune 
Encephalomyelitis (EAE) by using USPIOs. In particular for the brain, histological 
correlation between iron particles and perivascular macrophages showed that USPIOs are 
almost exclusively located within macrophages. In addition, after an exposure time of about 
one day, USPIO do not penetrate the intact BBB passively in EAE or stroke [Rausch et al., 
2003] [Rausch et al., 2002b].  
 
It is assumed that macrophages are to a large extent responsible for tissue damage in 
inflammatory and degenerative diseases of the Central Nervous System (CNS) [Steinman, 
1996]. Detailed analysis of their accumulation has been carried out by immuno-
histochemistry (IHC) in animal models and in patients with MS [Bruck and Stadelmann, 
2003] [Kerschensteiner et al., 2004b]. In preclinical research, the model of EAE is used to 
study the processes leading to tissue damage and the effects of anti-inflammatory drugs 
[Steinman, 1999].  
 
As demonstrated by Floris et al. [Floris et al., 2004], the time course and spatial pattern of cell 
infiltration is a highly dynamic process in EAE animals and might be used as a fingerprint for 
brain areas undergoing acute tissue damage. In the present study, we were in particular 
interested in studying whether repeated USPIO injections allow distinction of the 
inflammatory episodes from those devoid of acute cell infiltration (remitting periods) and to 
compare these data to conventional imaging readouts. Imaging macrophage infiltration in 
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EAE animals at multiple time points would also allow studying the development of individual 
lesions with respect to inflammation, demyelination and tissue repair. Such a longitudinal 
imaging protocol would allow differentiating areas, which undergo multiple episodes of 
inflammation from newly forming lesions. In the present study, USPIO were administered at 
three time points (the acute phase, the remitting phase and first relapse) in each animal to 
study ongoing infiltration of macrophages. The elimination half-life of USPIO used here is of 
about 5h [Dousset et al., 1999c] and the time during which USPIO labeled macrophages 
remain visible in MR images is in the order of two to three days post-injection [Rausch et al., 
2001]. Therefore, at intervals of 5 days between each injection, contrast in MR images is not 
sensitive to USPIO which have been injected during an earlier imaging session.  
 
USPIO accumulation was in addition compared to Gd-DOTA enhancement, allowing 
visualization of BBB damage, to magnetic transfer ratio imaging (MTR), which allows 
detection of demyelination and to neurological readouts.  
 
 
8.1.3 Material and Methods 
 
Animal Model Experimental Autoimmune Encephalomyelitis (EAE) in the Lewis rat is 
characterized by an acute monophasic attack after immunizing with xenogenic CNS proteins 
(i.e. guinea-pig spinal cord tissue). It is possible to prolong the disease course in Lewis rats 
and induce a relapsing pattern by slightly increasing the concentration of encephalitogenic 
antigens (which generate inflammation of the brain) and/or Mycobacterium tuberculosis in the 
inoculum [Feurer et al,. 1985]. In this experiment, brain inflammation is monitored only 
during the acute phase up to the first relapsing phase.  
 
Inbred (RT11) female Lewis rats (N=10) from Charles River (Sulzfeld, Germany) were kept 
in a climate-controlled room with 12 hour light/dark cycles, housed in sawdust-lined cages 
with 4 to 5 rats per cage, and given standard rodent chow and water ad libitum.  
 
Rats weighing 150-165 grams were lightly anesthetized with isoflurane (Abbott, Baar/Zug, 
Switzerland) and immunized intradermally (i.d.) into each hind foot pad with a 100 µl 
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suspension consisting of 1 part (volume:volume) guinea pig spinal cord (Gp-sc) emulsified in 
0.9% NaCl to 1 part complete Freund’s adjuvant (CFA; Difco, Detroit, MI, US) supplemented 
with M. tuberculosis strain H37RA (Difco). The final inoculum per rat consisted of about 66 
mg Gp-sc and 2 mg mycobacterium. 
 
For the MRI experiments, the rats were anaesthetized using 1.5% isoflurane in nitrous oxide 
(2:1) and the tail vein was cannulated with a catheter (0.5×25 mm) (Becton-Dickinson, Basel, 
Switzerland) for infusion of contrast agent. The animals were placed on a support where body 
temperature was maintained at 37°C using warm air. Total MRI scanning time was 45 min per 
rat. All experiments were in strict concordance to the Federal law for animal protection. 
 
All animals were scanned at three time points by MRI. MRI acquisitions were performed on 
two days during each of the three EAE phases, i.e. 11-12 days post immunization (dpi) for the 
acute phase, 18-19 dpi (remitting phase) and 24-25 dpi (first relapse). Additionally, 
neurological scoring was carried out on every day after immunization. A measurement of 
animal body weight was done at days 0, 7, 14 and 21 after immunization. 
 
Neurological scoring Neurological examination was performed daily and animals were 
graded according to disease symptoms: 0 = normal; 1 = flaccid tail; 2 = hind limb weakness 
or ataxia; 3 = complete hind limb paralysis, often accompanied by incontinence.  
 
Imaging protocol MRI experiments were carried out on a Bruker Biospec 7T/15 cm system 
(Bruker, Karlsruhe, Germany) using a birdcage head coil with 35 mm inner diameter for RF 
transmitting and receiving. The protocol comprised a T2-weighted fast-spin-echo scan 
(TR=4500, TE=73, RARE-factor=12, NEX=4, MTX=256×192) and a T1-weighted scan 
(TR=600, TE=8, NEX=4, MTX=256×128). In a third scan, T1-imaging (same parameters as 
before) was combined with magnetization transfer suppression (MTS). A Dante pulse 
sequence for MTS (pulse power = 16 T, number of pulses = 256, offset frequency = 5000 
Hz) was used. After an intravenous injection of 0.2 ml (1mmol) Gd-DOTA per animal 
(Dotarem®, Guerbet, Aulnay-sous-Bois, France), one T1-weighted scan was started five 
minutes after the contrast agent injection. The geometrical parameters were the same in all 
scans: FOV = 3.5×3.5 cm, slice thickness = 1 mm and interslice-distance = 0.28 mm. 
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For labeling of macrophages, 0.3 mL per animal of Sinerem® (AMI-227, Guerbet, Aulnay-
sous-Bois, France) was injected into the tail vein of each animal 24h prior to every MRI 
acquisition at a dose of 300 µmol Fe/kg. Each rat received this bolus of USPIO before each 
MRI measurements i.e. during acute phase (at 11 or 12 dpi), remitting phase (at 18 or 19 dpi) 
and first relapse (at 24 or 25 dpi). Every MRI sessions were performed on all animals. The 
administration and scanning protocol was adopted from previous studies on EAE and stroke 
[Rausch et al., 2002b], [Rausch et al., 2003], [Rausch et al., 2001] and was optimized to 
detect labeled cells without background signal from USPIO, which had not been captured by 
phagocytic cells.  
 
Image analysis BioMAP 3 software (developed in-house based on IDL 6, an application 
development software; Research Systems Inc., Col., USA) was used for image analysis. For 
quantitative assessment of disease-related signal changes, regions of interest (ROIs) have 
been defined, which comprised areas of hypo-intense signal in T2-weighted images during the 
acute phase. As demonstrated in our previous studies  [Rausch et al., 2003] [Rausch et al., 
2002b] [Rausch et al., 2001], dark areas correspond to lesions infiltrated by labeled 
macrophages. ROIs were only defined for the medulla oblongata since inflammation occurred 
systematically in this part of the brain. Signal alteration in Gd-DOTA enhanced maps (Enh-
maps) as well as MTR values were analyzed for these ROIs. Gd Enh-maps and MTR maps 
were calculated for the three phases of the disease (i.e. acute, remitting and first relapse) 
based on the ROIs defined for the acute phase. Due to the inherent variability of the 
immunization effect (i.e. concentration and virulence of the encephalitogenic antigens), lesion 
patterns can differ between experiments. As animal never showed USPIO enhanced areas in 
the cortex in this experiment, the parietal cortex was used as a control region for inter- and 
intra-subject comparison.  
 
To measure the lesion volume during the remitting and the first relapse phase, ROIs based on 
USPIOs hypo-intense areas were also determined for these EAE episodes. Total lesion 
volume was calculated by adding the areas of all ROIs (acute, remitting and first relapse) 
multiplied by the interslice distance. Enh-maps were calculated from the signal of the pre- 
(Spre) and post-contrast (Spost) T1-weighted scans according to 
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pre
prepost
S
SS
Enh
−=   
MTR-maps were calculated from the T1-weighted scans with (SMTR) and without MTS-
preparation (S0) by 
0
0
S
SS
MTR MTR
−=  
 
Statistical analysis Statistical comparisons were made by using Microsoft Excel applying the 
two-tailed Student t-test. Differences larger than p<0.05 were reported as significant. 
 
 
8.1.4 Results 
 
Neurological assessment Animals showed neurological impairment up to level 3 between 10 
and 12 days post immunization (dpi, Figure 1A) with 100% disease incidence paralleled by a 
loss of weight during the same period (Figure 1B). The acute phase was followed by a 
remitting phase between 15 and 20 dpi during which neurological status improved almost 
completely and body weight recovered.  
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Figure 1: A) Neurological score of animals during the different phases of EAE. Animals display neurological 
impairment during the acute phase and the first relapse, while they show almost complete remission between the 
two periods. The acute inflammatory phase ranges from 9 to 15 dpi, the remitting phase from 15 and 20 dpi, and 
the first relapse from day 21 to 26 post immunizations. B) The body weight of animals was monitored on days 0, 
7, 14 and 21. Animals display significant loss of body weight during the acute phase. Animals recovered weight 
during the remitting phase. Values are shown as mean ± standard deviation. 
 
 
During the first relapse (21 to 26 dpi), neurological impairment was characterized by an 
average level of 0.85. 
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MRI Tissue infiltrated by USPIO labeled macrophages is visible on T2-weighted images as 
hypointense areas. Representative images are shown for each EAE phase in the Figure 2. The 
lesion volume as defined by the area of macrophage infiltration in the medulla oblongata is 
shown in Figure 3A. Infiltration of labeled macrophages could be detected during the acute 
phase. During the remitting phase, no USPIO enhanced lesions became apparent in the brain. 
During the first relapse, only weak signs of USPIO enhancement were observed in 3 out of 9 
animals (one animal died during MRI scan of the first relapse), which were located in sub-
cortical areas (not shown in the Figure 2). These USPIO enhanced lesions were not 
necessarily collocated with lesions that were formed during the acute phase. Although an 
USPIO-lesion volume of 20 up to 60 mm3  produce almost constantly the same high degree of 
neurological impairment (see Figure 3A), there was no linear correlation during the first 
relapse (Figure 3B).   
 
T2 MTR Enh
Acute
12dpi
Remitting
19 dpi
Relapse
26 dpi
0 a.u.
1
 
Figure 2: MRI brain scans of EAE animals during acute phase i.e. 11,12 dpi (first row), remitting phase 18, 19 
dpi (second row) and first relapse 24, 25 dpi (third row). Left column: USPIO-enhancement. Tissue infiltrated by 
labeled macrophages appears hypo-intense on T2-weighted images. Middle column: MTR maps. There are no 
large changes visible in the images (ROI based analysis revealed only changes in the order of 10%; see Figure 
3). Right column: Enhancement of Gd-DOTA in brain tissue as a marker for BBB damage. Areas of Gd-DOTA 
extravasation in the medulla appear blue on the Enh-maps. Enhancement of Gd-DOTA in the medulla is more 
diffuse as compared to USPIO enhancement. 
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Enhancement of Gd-DOTA in brain tissue was primarily observed during the acute phase of 
the disease (Figure 2, right column). Even if areas of Gd-DOTA enhancement appeared more 
diffuse probably due to the passive diffusion of Gd-DOTA within the edema, these areas were 
matching those of USPIO-enhancement. However, in some animals (images not shown), areas 
of the medulla oblongata showed only uptake of either USPIO or Gd-DOTA. A quantitative 
analysis of BBB-damage is shown in Figure 3C. During the acute phase, the extravasation of 
Gd-DOTA was significantly increased in USPIO enhanced lesions as compared to the frontal 
cortex (p=0.003), which was used as reference. During the remitting period, the integrity of 
the BBB recovered but Gd-DOTA-extravasation was still larger than in the cortex (p=0.007). 
The first relapse was not related to a second increase of BBB permeability but a further 
recovery. 
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Figure 3: A) Lesion volume for the medulla. Values are shown for the three episodes of the disease, which are 
the acute phase, the remitting phase and the first relapse. B) Correlation among different animals between 
USPIO-lesion volume corresponding to macrophages infiltration and neurological state of EAE animals. Data 
from the acute phase (circles) and first relapse (triangles) where lesions were visible are shown (7 animals of 10 
present a lesion volume equal to zero ). Data from the remitting phase are not shown, since animals had neither 
USPIO-enhancement nor neurological symptoms. C) Quantitative analysis of Gd-enhancement from T1-
weighted MRI data. Quantitative analysis was carried out for the ROIs, which were defined on the T2-weighted 
images and represented USPIO-enhancing areas. (with * = p < 0.05 and ** = p < 0.01) D) Quantitative analysis 
of MTR data. Analysis was carried out for the same ROIs as in C. Values are shown as mean ± standard 
deviation. 
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Figure 3D shows a quantitative analysis of MTR values. MTR of the medulla is slightly 
reduced compared to MTR values in the cortex of EAE animals during the acute phase. In the 
remitting phase MTR of the medulla recovered significantly compared to acute phase and did 
not decrease again during the first relapse. Despite the fact that we have never observed 
USPIO accumulation in the cortex, a significant decrease in MTR (p = 0.00178) was found 
for the cortical ROI between the acute phase and the first relapse.  
 
 
8.1.5 Discussion 
 
MRI and neurological impairment were used to study neuro-inflammatory and neuro-
degenerative processes in EAE rats. An estimation of the body weight of EAE rats was 
relevant for the general healthy states of animals. In contrast to earlier studies [Rausch et al., 
2003] [Floris et al., 2004] which focused on a particular stage of the disease, animals have 
been scanned multiple times allowing the longitudinal observation of macrophage infiltration 
and BBB-damage during the different stages of the disease in individual animals. 
 
Animals showed the typical pattern of chronic EAE: acute phase – remitting phase – 1st 
relapse. However, unlike in human MS, episodes of active inflammation clearly decrease in 
severity after the acute phase, which was observed around day 11 after immunization. The 
three phases could clearly be identified from the neurological state of animals (weakness, hind 
limb paralysis): animals showed a loss of weight during the inflammatory episodes and a 
recovery of body weight and neurological state during the remitting phase. Infiltration of 
macrophages was also exclusively observed during episodes with active inflammation i.e. 
acute phase and first relapse: lesions showing clear signal attenuation in T2-weighted scans 
during the acute phase, which disappeared during the remitting phase. Regarding MRI data, it 
is impossible to distinguish if USPIO have been degraded within the lysosomes of 
macrophages and have lost their superparamagnetic characteristics or if labeled macrophages 
have left the area of inflammation. However, data suggest that there is no infiltration of 
macrophages during the remitting phase of the disease. This observation indicates that acute 
infiltration of macrophages can be detected by systemic administration of USPIO and that the 
elimination time of this contrast agent or labeled of macrophages is sufficiently short to 
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distinguish episodes of inflammation and remission. This non-invasive MRI readout for cell 
migration is superior to immunohistochemistry since it allows studying the fate of 
inflammatory lesions over time. In this experiment lesions within the medulla, which have 
emerged during the acute phase, did not undergo a second infiltration by macrophages during 
the first relapse. This observation suggests that infiltration by macrophages within these 
lesions ends with the onset of neurological remission. 
We attribute this decrease in the T2 signal to iron-labeled recruited blood-born macrophages 
because no free diffusion of USPIO across tight junctions can be expected. Typically, BBB 
capillaries have 4-6 nm fenestrations [Mandler, 2002]. During the acute inflammation 
processes, tight junction pores can increase to a diameter of up to 20 nm [Rapoport, 2000] 
which does not allow USPIO particles (30 nm) to cross the BBB. Even if the BBB is 
disrupted and allows serum components to passively diffuse across tight junctions (i.e. 
forming edema), the absence of neutrophils and red blood cells within the CNS suggests that 
even the impaired BBB actively controls the recruitment of inflammatory cells into the CNS 
[Wolburg et al., 2004]. Moreover, it has been shown recently that the migration of 
mononuclear cells across the BBB during EAE inflammation leaves tight junction intact 
[Wolburg et al,. 2005]. Hence, there is much evidence that USPIOs are specific markers for 
blood-born macrophages and should not freely diffuse across tight junctions followed by 
uptake by resident microglia.  
USPIO-lesion load and neurological symptoms were also analyzed on a single-subject level in 
order to assess the relevance of macrophage infiltration for the development of paresis of the 
sensory-motor system. Since spinal cord and brain stem are important structures for 
transmission of ascending and descending neuronal signals, neurological impairment should 
coincide with lesions within these sites. Although USPIO uptake coincided with neurological 
impairment on a qualitative level, no quantitative correlation was found between these 
parameters. In particular during the acute phase, high neurological impairment was found 
with a wide range of lesion load as defined by the area of USPIO enhancement. Nevertheless, 
a minimal lesion load leading to an onset of symptoms was observed, which was in the order 
of 15mm3. This threshold cannot be explained by the present imaging data. It is known, 
however, that rats display a high grade of brain plasticity, which might compensate for axonal 
damage because a certain amount of residual fibers remains intact [Wiessner et al., 2003]. 
Moreover, reorganization of corticofugal fibers was observed in a model of focal EAE of 
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spinal cord already a few days after induction of an inflammatory lesion [Kerschensteiner et 
al., 2004a]. 
 
MTR is related to the amount of myelin, which is subject to degradation by macrophages in 
EAE. Quantitative changes of this parameter indicate either demyelination or myelin re-
synthesis. In this study, the time course of MTR followed that of USPIO accumulation. 
Hence, as expected from the pathophysiology of EAE, myelin degradation seems to be closely 
linked with the infiltration of macrophages. MTR reduction was more pronounced during the 
acute phase, since the present EAE model rarely leads to pronounced relapses. Moreover, the 
fast recovery of MTR-values after the acute phase suggests a possible remyelination, which 
was also reported for MS lesions [Raine and Wu, 1993]. However, the normalization of MTR 
values during the remitting phase could be also explained by resorption of vascular edema and 
normalization of T1-values since the MTR-effect is to some extent sensitive to longitudinal 
relaxation of bulk water [Rudin and Sauter 1992].   
 
The measurement of BBB damage revealed similar results as reported earlier [Rausch et al., 
2003]: although there was a mismatch of USPIO and Gd-DOTA enhancement for some 
potential inflammatory lesions, both parameters provided useful results on the time course of 
the disease. Interestingly, USPIO-enhancing lesions disappeared after the acute inflammatory 
episode, while BBB damage of these lesions recovered more slowly. Although several studies 
have demonstrated a close link between macrophage infiltration and BBB damage, it must be 
assumed that opening of the tight junctions persists also after termination of leukocyte 
transmigration [Floris et al., 2004] [Morrissey et al., 1996]. 
 
In conclusion, this approach for in vivo cell labeling allows longitudinal monitoring of acute 
infiltration of macrophages, which are of high relevance for tissue damage in EAE and MS by 
repeated USPIO administration and MRI measurements. Combined with MTR analysis and 
Gd-enhancement mapping, USPIO administration can be used several times during the 
disease course to monitor the evolution of pathological hallmarks of EAE. As in an earlier 
study, we have found a mismatch of USPIO and Gd-DOTA enhancement, while there was a 
closer link between USPIO-accumulation and MTR reduction. 
 103 
 
Chapter 8.2 Monitoring Macrophages: a Tool to Evaluate Drug Effects 
 
 
 
 
 8.2  Monitoring Macrophage: a Tool to Evaluate Drug Effects 
 
 
 
Longitudinal Assessment of Cerebral Lesions by USPIO-Enhanced 
MRI in EAE Rats:  
Assessment of Treatment Efficacy of FTY720 in Acute and Chronic 
Relapsing EAE 
 
 
8.2.1 Abstract 
 
The efficiency of the anti-inflammatory drug FTY720 on experimental allergic 
encephalomyelitis (EAE) was evaluated using longitudinal magnetic resonance imaging 
measurements. The anti-inflammatory drug FTY720 was used for treatment of rats in a model 
of chronic relapsing EAE at a dose of 0.3mg/kg/day. MRI and neurological readouts were 
used to study the burden of disease in treated and untreated animals. Animals were studied at 
three time points: acute phase, remitting phase and first relapse. Our results show that 
untreated animals showed severe paralysis of the hind paws, intense accumulation of 
macrophages in brain tissue and areas of blood brain barrier (BBB) disruption in contrast to 
FTY720 treated animals, which displayed no signs of inflammatory activity or neurological 
impairment during the treatment period. These observations were made for the acute phase 
and the first relapse. Termination of treatment after the acute phase led to fast onset of 
symptoms. Moreover, there is some evidence that treatment with FTY720 before or during a 
relapse might cause partial loss of blood-brain-barrier integrity. We conclude that FTY720 
administration can reduce demyelization and BBB disruption during leading to prevention of 
inflammatory events in EAE rats. 
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8.2.2 Introduction 
 
Experimental allergic encephalomyelitis (EAE) is a commonly used animal model, which 
mimics in several aspects human multiple sclerosis [Steinman, 999] [Raine and Traugott, 
1984]. EAE can be induced in several species by administration of myelin antigens, most 
often myelin basic protein (MBP), or myelin reactive CD4+ cells. The immune response 
triggered in EAE involves activation of several cell types. While T lymphocytes trigger 
inflammatory process by secreting chemokines that promote leukocytes infiltration, 
monocytes are thought to be the primary cell type that causes tissue damage [Steinman, 1996; 
Izikson et al., 2000].  
 
The aim of this study was to further evaluate the in vivo immunomodulatory effects of 
FTY720, a novel sphingosine-1 phosphate (S1P) receptor agonist [Brinkmann et al., 2002] by 
conventional and target specific MRI techniques. FTY720 is a myriocin analogue that alters 
homing of lymphocytes from the peripheral blood to secondary lymphoid organs. FTY720 
acts by signaling EDG-6, a lymphoid specific G-protein coupled receptor, which increases the 
intrinsic mobility of lymphocytes [Kahan, 1998; Brinkmann et al., 2001]. Hence, the cells 
respond more readily to lymphocyte-homing chemokines, which are continuously expressed 
in secondary lymphoid organs. The homing to these lymphoid organs decreases the levels of 
freely circulating lymphocytes and hence the number of activated lymphocytes recruited by 
inflamed tissue will be reduced.   
 
MRI allows in vivo assessment of several aspects of EAE or MS related pathological 
processes including early inflammation, tissue degradation and scar formation: contrast 
enhanced T1-weighted imaging using extra cellular contrast agents allows to detect areas of 
increased blood brain barrier (BBB) permeability as an early indicator for leukocytes 
infiltration [Katz et al., 1993]. T2-weighted scans are sensitive to elevated levels of tissue 
water, as found in edematous tissue and also across sclerotic lesions [Miller et al., 1998] but 
are generally of low histo-pathological specificity [Barkhof and van Walderveen, 1999]. In 
later stages of the lesion development, magnetization transfer imaging (MTI) can provide 
specific information about demyelization. MTI is a technique based on the transfer of 
longitudinal magnetization from protons of bulk water to relatively immobile myelin-bound 
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protons by continuous or pulsed off-resonance excitation [Clark et al., 1991]. Signal 
attenuation is related to the local amount of myelin and other water macromolecules and 
hence allows to distinguish between transient edema formation and chronic degeneration of 
white matter tracts [Dousset et al., 1992]. Macrophages can be labeled by systematically 
administrated ultra small particles of iron oxide (USPIO), which will remain for multiple days 
in the lysosomes, where they induce a significant increase of the local longitudinal and 
transversal relaxation rate and hence lead to a prominent signal increase in T1 and a signal 
decreases T2 weighted images [Dousset et al., 1999b] [Rausch et al., 2002a] [Rausch, et al., 
2003].  
In vivo tracking of macrophages by MRI represents an attractive approach to study the 
efficacy of anti-inflammatory drugs. Recently, the immunosuppressive effect of FTY720 in 
the EAE model could be demonstrated by USPIO-enhanced MRI for prophylactic and chronic 
treatment regimes [Rausch et al., 2004]. In the present study, we were in particular interested 
in studying the development of individual lesions from the acute inflammatory episode over 
the remitting phase to the first relapse by USPIO-enhanced MRI. As demonstrated by Floris 
[Floris et al., 2004] and colleagues, the temporal development of pathological imprints in 
EAE is highly dynamic and appearance of lesions can be change with the state of the disease. 
The longitudinal imaging protocol employed here allows to distinguish the reoccurrence of 
lesions in areas of inflammatory history from the formation of new lesions and can therefore 
provide valuable information on the effect of anti-inflammatory drugs. 
The macrophage-tracking approach was complemented by imaging of BBB disruption and 
myelin degradation using magnetization-transfer-imaging as further biomarkers for the 
assessment of neuro-inflammatory processes. 
 
 
8.2.3 Material and Methods 
 
Animal Model Actively-induced EAE in the Lewis rat is typically characterized by an acute 
monophasic attack after immunizing with xenogenic CNS proteins and is widely exploited for 
drug evaluation using a prophylactic treatment regimen (dosing starts at immunization). To 
assess drug effects using therapeutic treatment (dosing begins during established EAE), one 
can prolong the disease course in Lewis rats and induce a relapsing pattern by slightly 
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increasing the concentration of encephalitogenic Ag and/or Mycobacterium tuberculosis in 
the inoculum [Feurer et al., 1985]. All studies were conducted in accordance with Swiss 
federal regulations for animal protection. 
 
Inbred (RT11) female Lewis rats from Charles River (Sulzfeld, Germany) were kept in a 
climate-controlled room with 12 hour light/dark cycles, housed in sawdust-lined cages with 4 
to 5 rats per cage, and given standard rodent chow and water ad libitum. After at least one 
week of adaptation, they were randomly distributed into experimental groups and individually 
numbered with a tail mark. 
Rats weighing 150-165 grams were lightly anesthetized with isoflurane and immunized 
intradermally (i.d.) at the dorsal tail root with a 100 µl suspension consisting of 1 part 
(volume:volume) guinea pig spinal cord (Gp-sc) emulsified in 0.9% NaCl to 1 part complete 
Freund’s adjuvant (CFA; Difco, Detroit, MI) supplemented with M. tuberculosis strain 
H37RA (Difco). The final inoculum per rat consisted of about 66 mg Gp-sc and 2 mg 
mycobacterium. 
FTY720 was provided as a powder (Novartis Pharma AG, Basel, Switzerland) and dissolved 
in distilled water. The drug was freshly prepared and given per os (p.o.) once daily by gavage 
at a dosing volume of 5 ml/kg body weight.  
For MRI experiments, the rats were anaesthetized using 1.5% isoflurane in nitrous oxide (2:1) 
and the tail vein was cannulated for infusion of contrast agent. The animals were placed on a 
support where body temperature was maintained at 37°C using warm air. Total MRI scanning 
time was 45 min per rat. All experiments were in strict adherence to the federal law for animal 
protection. 
 
The experimental design comprised three groups: immunized rats treated p.o. with vehicle 
(water; ‘vehicle’, n = 9) or FTY720 0.3 mg/kg per day (‘FTY-acute’; n = 7) during the acute 
phase (days 0-15) or FTY720 0.3mg/kg per day (‘FTY-chronic’; n = 7) during the chronic 
phase (days 15-27). Each of the animals was scanned at three time points in the MRI: acute 
phase (11, 12 and 13 dpi). The remitting phase was measured during days 18 and 19 dpi and 
the first relapse on day  25, 26 and 27 post immunization.  
Additionally, neurological scoring and determination of body weight was carried out on every 
day after immunization. 
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Neurological scoring Neurological examination was performed daily and animals were 
graded according to disease symptoms: 0 = normal; 1 = flaccid tail; 2 = hind limb weakness 
or ataxia; 3 = complete hind limb paralysis, often accompanied by incontinence.  
 
Imaging protocol The protocol comprised a T2-weighted fast-spin-echo scan (TR=4500, 
TE=73, RARE-factor=12, NEX=4, MTX=256×192), a T1-weighted scan (TR=600, TE=8, 
NEX=4, MTX=256×128) and a magnification-transfer-prepared T1-weighted scan with the 
same parameters. A Dante-pulse-sequence for magnetization-transfer-suppression (pulse 
power = 16 µT, number of pulses = 256, offset frequency = 5000 Hz) was used. After 
injection of 0.2 mL Gd-DOTA (Guerbet, Paris), the T1-weighted scan was prepared with a 
delay of five minutes. The geometrical parameters were the same in all scans: FOV = 3.5×3.5 
cm, slice thickness = 1 mm and interslice-distance = 0.28 mm. 
For labeling of macrophages AMI-227 (Guerbet, Paris) was injected at a concentration of 300 
µMol Fe/kg into the tail vein of the animal 24h prior to the MRI measurement. The 
administration and scanning protocol was adopted from previous studies on EAE and stroke 
]Rausch et al. 2003] [Rausch et al. 2002] [Rausch et al., 2001] and was optimized to detect 
labeled cells without background signal from USPIO, which had not yet been captured by 
phagocytotic cells.  
 
Image analysis For image analysis BioMAP 3 (in-house development based on IDL 5.4 
Research Systems Inc., Col., USA) was used. Enhancement-maps were calculated from the 
signal of the pre- and post-contrast T1-weighted scans according to 
 
pre
postpre
S
SS
Enh
−=  
MTR-maps were calculated from the T1-weighted scans with and without MTS-preparation 
by 
0
0
S
SS
MTR MTR
−=  
For quantitative assessment of EAE-related signal alteration, hypo-intense areas in T2-
weighted images reflecting accumulation of labeled macrophages were marked by region of 
interest (ROI). Those were only defined in the medulla since inflammation occurs 
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systematically in this part of the brain. For the animals of the FTY-acute group, areas of 
inflammation could not be identified during the treatment (acute phase) and ROIs have 
therefore been designed on images recorded during the remitting phase.  For the two other 
groups (vehicle and FTY-chronic), the ROIs were selected on the basis of the acute phase 
pictures.  As none of the animals showed inflammation in the cortex, a reference area for 
control measurement has been drawn in the cortex. Signal alteration in MTR- and Enh-maps 
were analyzed for these areas.  
 
Statistical analysis Statistical comparisons were made in Microsoft Excel using a two-tailed t-
test. Differences with p<0.05 were reported as significant. 
 
 
8.2.4 Results 
 
Neurological assessment Animals of the vehicle treated group showed neurological 
impairment up to level 3 between 10 and 12 dpi (black curve in Figure 1a) with 100% disease 
incidence paralleled by a loss of weight during the same period (Figure 1b). The acute phase 
was followed by a remitting phase between 15 and 20 dpi during which neurological status 
improved almost completely and body weight recovered. During the first relapse (20 to 27 
dpi), neurological impairment was characterized by an average level of 1. 
 
For the FTY-acute group, no neurological impairment (red curve in Figure 1A) and no loss of 
weight (Figure 1B) were observed during the treatment period. One day after termination of 
treatment (day 13), neurological impairment began to increase up to level 2 between 15 to 17 
dpi (red curve in Figure 1). This severe impairment was followed by a remitting phase (days 
19-20) and a relapsing phase (21 to 27 dpi), which was similar to the vehicle group. 
For the FTY-chronic group, acute and remitting phases were identical to the pattern of the 
vehicle group (Figure 1a and b). However, under FTY720 treatment from (days 16 to 27), 
animals did not enter a relapsing phase (20-27 dpi) (yellow curve in Figure 1) and all animals 
recovered weight faster as vehicle-treated animals (Figure 1b). 
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Figure 1A: Neurological state of animals during the different phases of EAE. The vehicle group displays the 
three characteristic disease episodes of EAE model: the acute inflammatory phase from 9 to 15 dpi, the remitting 
phase from 15 and 20 dpi, and the first relapse from day 20 to 27 post immunizations. FTY720 treatment leads to 
diminished symptoms during the treatment phase. Note that prophylactic treatment of the FTY720-acute group 
started already with day 0. The FTY-acute group displays delayed occurrence of symptoms starting 2 days after 
termination of treatment. B: Body weight evolution from day 0 to day 21. Animals, which were not treated 
during before and during the acute phase display significant loss of body weight during this inflammatory 
episode. Recovery of body weight is improved in the FTY-chronic group compared to vehicle treated animals. 
 
 
MRI T2-weighted scans showed areas of signal attenuation induced by USPIO labeled 
macrophages during the acute phase and first relapse. Figure 2 shows representative images of 
lesions in the medulla and cerebellum for the three experimental groups. Infiltration labeled 
macrophages became most apparent during the acute phase for the vehicle and FTY-chronic 
group. At this time point no infiltration of labeled macrophages could be seen for the FTY-
acute group. Almost no USPIO-enhancing lesions became apparent in these areas during the 
remitting phase for the vehicle and FTY-chronic group. Only animals of the FTY-acute group 
showed infiltration of labeled macrophages during this phase. Figure 3 shows a quantitative 
analysis of lesion volume, demonstrating that macrophage infiltration in the medulla is most 
prominent during the acute phase of the disease: in the vehicle treated animals lesion volume 
was largest during the acute phase. A reduction of lesion volume was found for the remitting 
period. Infiltration by macrophages was either found in sub-regions of lesions of the acute 
phase or in areas without inflammatory history. During the relapsing phase a second increase 
of lesion volume was observed for the vehicle but not for the FTY-chronic group. Only a very 
low lesion volume was observed during the treatment periods in the respective animals.   
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Figure 2: T2-weighted images and MTR-/Enh-maps showing the medulla of individual animals followed over 
the three episodes. A: Animal of the vehicle-group. Dark areas are visible during the acute phase in T2-weighted 
scans. Increased BBB-permeability can be observed in the same areas. MTR shows no prominent alterations. B: 
Animal for the FTY-acute group. A USPIO enhancing lesion can be observed during the remitting phase (note 
that the nomenclature is derived from the normal time course of the disease). C: Animal of the FTY-chronic 
group. A similar lesion pattern as in A can be observed. 
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Figure 3: Lesion volume during the different phases of EAE. The lesion size was derived from the area covered 
by USPIO labeled macrophages.  
 
 
Figure 4a shows a quantitative analysis of MTR values. During the acute phase MTR was 
significantly decreased (p<0.001, mean MTR=0.34) in the vehicle treated animals as 
compared to the FTY-acute group (mean MTR=0.39). In the remitting phase MTR of the 
vehicle treated group and the FTY-chronic recovered to MTR=0.36. However, at this time 
point a reduction (not significant at p<0.05) of MTR as compared to the treatment period was 
observed for the FTY-acute group. During the first relapse a slight decrease of MTR was 
observed for the vehicle treated group, which was significantly lower as compared to the FTY-
acute and FTY-chronic group. In particular, the FTY-chronic displayed a further recovery of 
MTR during the treatment period. 
Enhancement of Gd-DOTA (indicative for BBB disruption) was visible close to hypointense 
areas found in the T2-weighted images but there was no one-to-one correspondence. During 
the acute phase a significant increase of Gd-DOTA extravasation was observed in untreated 
rats (vehicle and FTY-chronic) as compared to the FTY-acute group. During the remitting 
period, BBB integrity recovered for the vehicle treated animals and the FTY-chronic group. 
Animals of the FTY-acute group, however, showed a clear increase of BBB disruption during 
this episode. The first relapse was not paralleled by a second increase of BBB permeability. 
Instead, a further decrease for vehicle treated animals and a clear reduction of Gd-DOTA 
extravasation was observed for the FTY-acute group. However, a slight increase of BBB 
permeability was observed for the FTY-chronic group, leading to a significant larger 
extravasation compared to the vehicle group. 
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Figure 4: Quantitative analysis of parametric MRI data. Quantitative analysis was carried out for the ROIs, 
which were defined in the T2-weighted images. A: Magnetization Transfer Ratio MTR. B: Enhancement of Gd-
DOTA.  
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8.2.5 Discussion 
 
MRI, neurological impairment and body weight were used in this study to assess the effect of 
FTY720 on neuroinflammatory and neurodegenerative processes in EAE rats. In contrast to 
prior studies, animals have been scanned multiple times allowing the longitudinal observation 
of macrophage infiltration, de- and re-myelination and BBB-damage during the different 
states of the disease in individual animals.The type of immunization (guinea pig myelin to 
Lewis rats) that has been used in this study is generally regarded as model of acute EAE, 
however, by adding a larger amount of Freund’s adjuvant to the emulsion a first relapse can 
be induced. Although inflammation is variable in its extent and location in the EAE model 
used here, previous studies have shown that the medulla is generally affected by inflammatory 
processes [Rausch et al., 2003] [Dousset et al., 1999] [Rausch et al., 2003]. For this reason, 
the analysis of FTY720 activity was focused on this brain structure.  
Animals, which were not treated at any time-point showed the typical pattern of chronic EAE: 
acute phase – remitting phase – 1st relapse. These phases could clearly be identified from the 
physiological and imaging data: animals showed a loss of weight during the inflammatory 
episodes and a regain of body weight during the remitting phase. A similar pattern was found 
for the neurological symptoms. Infiltration of macrophages was also exclusively observed 
during active inflammation: lesions showing clear signal attenuation in T2-weighted scans 
during the acute phase had normal signal intensity some days later during the remitting period 
(from a methodological perspective, this observation demonstrates that USPIO-labeling of 
macrophages is ideally suited to take multiple snapshots of ongoing cell infiltration being not 
sensitive for past inflammatory events).   
Prophylactic treatment with FTY720 in the FTY720-acute group led to a general abolishment 
of macrophage infiltration, weight loss and neurological impairment. However, after 
termination of acute treatment, all symptoms, which were observed in the vehicle-group, 
began to develop. Hence, it must be assumed that FTY720 blocks inflammatory acutely but 
does not lead to a persistent homing or desensitization of lymphocytes: activation factors that 
remain in the blood circulation might be responsible for a continuous activation of T cells, 
which can enter the brain if no homing-signals were induced. This finding does not allow the 
conclusion that termination of treatment with FTY720 in humans will lead to an immediate 
onset of symptoms after termination of treatment, since the appearance of auto-reactive T 
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lymphocytes is not necessarily linked to acute presentation of the antigen and activation 
factors in MS.  
MTR is related to the amount of myelin, which is subject to degradation by macrophages in 
EAE. Variations of this readout indicate either demyelization or myelin re-synthesis. The 
comparison between myelin quantity in the brain of treated and non-treated animals 
demonstrate, whether FTY720 can affect the activity of macrophages. The difference of 
MTR-values during the different groups and phases of the disease were lower compared to the 
results of prior studies carried on the same animal model [Rausch et al., 2003]. This might be 
due to the fact that immunization in this experiment led to a lower degree of axonal 
degeneration. In addition, the EAE model used here is primarily a model for neuro-
inflammation and not for neuro-degeneration or demyelination [Meeson et al., 1994]. 
Administration of low molecular contrast agent such as Gd-DOTA allows assessment of BBB 
disruption. As already shown before, infiltration of macrophages and damage of the BBB did 
not correlate entirely in space and time. A spatial mismatch was observed for the acute phase 
in untreated animals. A further decrease of BBB integrity was found for animals of FTY-
chronic group during the treatment phase. The physiological background of this BBB 
disruption is unclear and cannot be assigned to residual BBB damage induced during the 
acute phase und no acute inflammatory processes: the example shown in Figure 4c 
demonstrates that there is no Gd-DOTA extravasation during the remitting phase and no 
infiltration of macrophages during the first relapse. It can therefore not be excluded that 
FTY720 might interfere with BBB integrity in tissue that has already passed an initial 
inflammatory event. Methodological issues might be the reason why this effect has not been 
observed before: in the last study [Rausch et al., 2003] a large ROI has been defined for the 
medulla of the FTY-chronic group, since these animals had not been scanned during the acute 
phase and therefore the areas of macrophage infiltration were not known. Here, however, 
specific ROIs could be defined for the medulla according the distribution of lesions during the 
acute phase.   
In conclusion, the present study demonstrates that FTY720 can prevent inflammatory events 
in EAE rats and confirms the results of prior studies. In the EAE model used here, termination 
of treatment after the acute phase leads to the delayed development of symptoms. 
Furthermore, there is some evidence that FTY720 during a relapse leads to increased BBB 
disruption in areas which had already passed an inflammatory event. 
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9 TAGGING T CELLS FOR BIOMEDICAL IMAGING 
 
9.1 T Cells Labeling for MRI: an In Vitro Study 
 
 
Feasibility and Limits of Magnetically Labeling 
Primary Cultured Rat T Cells with Ferumoxides Coupled 
with Commonly Available Transfection Agents 
 
9.1.1 Abstract 
 
Visualization and quantification of inflammatory processes is of high importance for early 
diagnosis for a multitude of diseases. MR imaging using iron-oxide (FeO) nanoparticles as 
contrast agents allowed studying macrophage infiltration during inflammation in a variety of 
tissues. Macrophages are effectors of the immune response, their appearance being 
orchestrated by activated T lymphocytes. Therefore, tracking of labeled T lymphocytes, 
which initiate the immune process, should enable earlier detection of tissue inflammation. In 
this study, we investigate the feasibility of specifically labeling harvested T cells by using 
dextrane-coated FeO nanoparticles and commonly available transfection agents (TAs). 
Physico-chemical properties of the newly formed FeO/TA vesicles were determined as well 
as their cell toxicity and their T cell activation potential. Labeling efficiency of each FeO/TA 
combination was evaluated by measuring the transverse MRI relaxation rate R2, by X-ray 
spectroscopy and magnetic selection. Toxicity and labeling efficacy differed significantly 
among TAs. The best results were achieved by using poly-amine TAs an in particular by 
using poly-L-lysin at a concentration of 1.5 µg/ml administered in combination with 22.5 µg 
iron/ml. Using this protocol up to 60% of harvested T cells could be labeled. Microscopic 
investigation revealed FeO/TA nanoparticles localized within the cytoplasma of the cells but 
also sticking to the outer membrane surface. 
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9.1.2 Introduction 
 
The migration of immune-competent cells to sites of tissue inflammation is a key element in 
the immune response of the body. Visualization and quantification of these processes is 
critical from a diagnostic point of view, for the understanding of inflammatory disease, and 
for the evaluation of potential therapeutic interventions. A number of imaging approaches has 
been proposed to monitor cell migration in vivo [Bulte and Kraitchman, 2004]  [Mempel et 
al., 2004]. All of them involve specific labeling of the cells/cell types to be studied using 
either exogenous labels with radionuclides, MRI contrast agents or fluorescent dyes as 
reporter groups, or by genetically modifying cells to constitutively express a reporter gene 
[Allport and Weissleder, 2001]. Among the different imaging approaches evaluated for 
studying cell migration MRI is particularly attractive due to its superior spatial resolution, 
which is at least one order of magnitude higher than e.g. for nuclear and optical imaging. 
Inflammation involves a massive accumulation of immune-competent cells, in particular 
macrophages, in the affected tissue. The infiltration of labeled macrophages can be monitored 
noninvasively by MRI following  systemic administration of ferumoxides (FeOs), i.e. 
ultrasmall superparamagnetic iron oxide particles coated with dextran (USPIO), as 
demonstrated e.g. in the rat experimental autoimmune encephalomyelitis (EAE) model 
[Rausch et al., 2004]. Due to their high phagocytotic activity, blood-borne monocytes 
efficiently internalize nanoparticulate matter and, hence, a substantial fraction of the 
macrophages that enter the inflamed tissue are labeled. In the rat EAE model, the use of 
USPIOs, initially developed for imaging of the liver lesions [Ferrucci and Stark, 1990], 
provided an almost 100% sensitivity for lesion detection [Dousset et al., 1999b]. 
Macrophages are effectors of the immune-mediated injury in inflammation [Raivich and 
Banati, 2004], thus visualization and quantification of the migration of these labeled 
inflammatory cells to specific brain areas is of high diagnostic relevance due to the enhanced 
probability of detecting active demylinating disease [Rausch et al., 2003]. Macrophage 
infiltration is orchestrated by other inflammatory mediators such as T lymphocytes, which 
attract circulating monocytes by secretion of cytokines. Correspondingly, labeling T cells 
[Stinissen and Raus, 1999] might provide a tool to detect inflammatory events at an even 
earlier time point,  potentially prior to the occurrence of significant tissue damage. The use of 
USPIOs for MR imaging [Weissleder et al., 1990], their ability to tag T cells [Bulte et al., 
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1996], and the possibility to track iron-tagged T cells in vivo using MRI [Yeh et al., 1995] 
have been demonstrated. The sensitivity of the technique allows detecting single T cells 
labeled with ferumoxides in vitro [Dodd et al., 1999]. In contrast to macrophages T cell 
cannot be labeled in situ by systemic administration of contrast agents due to lack of 
phagocytotic activity. Instead they have to be harvested and labeled in cell culture. Several 
methods to increase the efficiency of cell labeling using dextran-coated FeOs have been 
reported. One approach uses the Tat-peptide (Tat: transativator of transcription) of the human 
immune deficiency virus-1 (HIV-1) to introduce tagged nanoparticles into the cells 
[Josephson et al., 1999] [Lewin et al., 2000]. A more frequently used method is based on 
complexing FeOs with polycationic transfection agents (TAs) to form complexes that should 
enter cells [Frank et al., 2002]. TAs are positively charged macromolecules commonly used 
to shuttle foreign DNA into mammalian cells by formation of TA-DNA complexes [Xu and 
Szoka, 1996]. There are two principal classes of TAs available: lipid-based agents such as 
lipofectamine, Lipofectamine2000, FuGENE6, and polyamine polymers like poly-L-lysine 
(PLL) or poly-ethyleneimine (PEI). These polymers differ in size, charge, and molecular 
mass, which will affect transfection parameters and labeling efficiency. To achieve efficient 
labeling, the optimal ratio of FeO to TA that leads to the formation of stable FeO/TA 
complexes needs to be determined [Arbab et al., 2004a].  
The aim of the current study was to determine, whether by combining commonly available 
TAs and FeOs approved for clinical use, freshly extracted  and primary cultured T cells can be 
efficiently and reliably labeled to an extent sufficient for the in vivo MRI detection. The 
efficiency of this labeling technique and the labeling yield was assessed using different 
readouts including the measurement of the transverse relaxation rate R2. Physico-chemical 
properties such as particle size and Zeta Potential, a critical determinant for membrane 
permeability [Kalish et al., 2003], of each FeO/TA complex were determined. Cell 
physiological measurements were carried out to assess the potential of labeled T cells to exert 
their function, i.e. to become activated upon stimulation, and to evaluate eventual toxic effects 
of the label. Finally, labeling of T cells was confirmed under the microscope. 
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9.1.3 Material and Methods  
 
Ferumoxides particles Labeling experiments were carried out with two kinds of negatively 
charged FeO particles: Endorem particles (Guerbet®, France) are approximately 140 nm in 
size according to the supplier, and Sinerem (Guerbet®, France) that have the same shape but 
smaller in size (40 nm in diameter). A stock solution of each compound was stored at 11.2 mg 
iron/ml. In order to determine the optimal FeO/TA ratio to form stable FeO/TA complexes, 
different concentrations of FeOs (µg/ml) were tested.   
 
Transfection agents FuGene6® (Roche, Switzerland) is a lipidic multi-component 
transfection agent designed to shuttle DNA inside eukaryotic cells by forming vesicles. The 
concentration of the active transfecting substance in FuGene6 is not disclosed by the 
manufacturer. According to the transfection rate (1 µg/µl of DNA to 2-3 µl of FuGene6) 
suggested in the user manual, we assumed that the stock solution contain at least 1 mg/ml of 
active reagent. 
Poly-L-Lysin is a poly-amine TA (Sigma-Alderich, Buchs, Switzerland). Different molecular 
weights ranging from 16 kD to 250 kD have been used to form FeO/PLL complexes. We 
tested four mixtures containing the following PLL molecules: 16 to 30 kD, 30 to 70 kD, 72 to 
84 kD, and 125 to 250 kD. A stock solution of 1 mg/ml for each mixture was stored frozen at 
-20°C until requirement. 
Lipofectamine™ 2000 (Invitrogen) is a lipid-based TA widely used to transfect eukaryotic 
cells. The stock solution is supplied at a concentration of 1 mg/ml. 
Poly-Ethylene-Imine (PEI) (Sigma-Alderich, Buchs, Switzerland) was supplied at 1 mg/mL. 
The polymer molecular weight was between 25 and 75 kD. 
 
FeO/TA complexes preparation FeOs and TAs were always mixed apart from cell medium to 
allow complex formation. FeO/TA mixes were prepared in advance by mixing FeOs and TAs 
in RPMI medium without serum. For all labeling experiments, the volume of Endorem or 
Sinerem stock solution was calculated to have a final concentration of 22.5 µg iron/ml in 
FeO/TA mix.  
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Different concentrations for each TAs were tested. The final FeO/TA mixture volume was 
always 100 µL. The FeO/TA mixture remained under gently agitation during 60 min before 
adding it into cell-culture complete medium. 
 
Cell culture and labeling conditions T lymphocytes were extracted from young Lewis rat’s 
spleen few days before labeling. Organs were destroyed using a Potter homogenizer and the 
solution was filtered several times through cell strainer with pores of 100, 70 and 40µm in 
diameter. After the last wash (centrifugation with phosphate-buffer), rat pan T cell was 
selected by the means of Miltenyi magnetic beads (Miltenyi Biotech) associated with 
antibodies against cells expressing α/β as well as γ/δ T cell receptor (TCR). An 
AutoMACS™ cell sorter was used to isolate the cells. In order to characterize MACS sorted 
cells, a FACS analysis of isolated cells has been performed on a LSR II flow cytometer 
(Bekton Dickinson, San Jose, CA, USA). using fluorescent monoclonal antibodies (BD 
Pharmingen, Franklin Lakes, NJ, USA).     
 
The R2 relaxivity of Miltenyi beads associated to T cell membrane has been measured during 
the days following the MACS selection. By culturing and washing T cell in the conditions 
described thereafter, it appears that the iron labeling due to the magnetic selection totally 
disappeared after 4 days of culture (results not shown).   
T cells were cultured in RPMI medium plus HEPES containing 1 mM Na-pyruvate, 1× MEM 
non-essential amino-acids, 50 µM 2-mercaptoethanol, 50 µM gentamicin antibiotic,  1× MEM 
vitamins, 2 mM L-glutamine and 10% Fetal Calf Serum. In order to avoid premature death 
and to stimulate T cells growth, rat T-STIM ™ solution (Becton Dickinson) was added to the 
medium for a final concentration of 5%.  
To label T cells, we added the 100 µl FeO/TA mix to 106 T cells to have a final labeling 
medium of 2 ml. We allow cells to rest in a humidified atmosphere at 37°C in 95% / 5% 
air/CO2 during the labeling process. 
 
Determination of physico-chemical properties of FeO/TA complexes The size and the Zeta 
potential (ZP) of pure FeO particle and pure TA as well as FE/TA complexes were measured 
with a Zetasizer® (Malvern, UK). Ferumoxide solutions at 22.5 µg iron/mL and TA at 5 
µg/ml were diluted in filtered, distilled water. Size and ZP of FeO/TA complexes were also 
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measured in nanopure water at a final volume of 1 ml. While the FeOs concentration remain 
the same in all the measurements (22.5 µg/mL), different concentrations of TAs were tested 
i.e. 0.5, 1, 2.5 and 5 µg/ml.  All measurements were at least repeated three times. 
 
FE / TAs toxicity and T cell activation After a certain labeling period and before each other 
application, the number of living cells was estimated under the microscope by FDA 
(Fluorescein DiAcetate) exclusion. To have a quantitative confirmation of cell viability, the 
proliferate activity of FeO/TA labeled T cells was evaluated using the MTT (3-[4,5-2-yl]-2,5-
diphenyl tetrazolium bromide) assay (Roche, Switzerland).  
To determine the toxicity of FeOs or TAs separately, T cells were seeded into 96-well plates 
and then incubated at 37°C in 95% / 5% air/CO2 with different doses of FeOs or TAs. MTT 
reagent was added 1h after mixing TAs and FEs and the whole mixture was incubated for 24h 
or 48h. Thereafter, the detergent reagent supplied within the MTT assay kit was added to each 
well and incubated in the dark at room temperature overnight. All measures were repeated 
three times and the mean value was used to make statistical studies. 
T cell activation was evaluated based on their level of IL-2 secretion. The Elispot™ assay is 
designed for the detection of IL-2 secreting cells at the single cell level. We have used this 
method to monitor cellular responses in presence of either FeOs and TAs separately or 
FeO/TA complexes.  
 
Estimation of the fraction of cells containing iron-oxide nanoparticles Cells labeled with 
superparamagnetic FeO were sorted exploiting their magnetic properties (magnetic selection). 
After labeling, T cells were centrifuged and washed three times to remove the excess of free 
FeO particles in solution. After the last centrifugation, the pellet was resuspended in 2 ml of 
phosphate buffer (PBS). Cells were counted and poured onto a magnetic column. Due to the 
magnetic field applied, FeO-labeled cells were retained in the column. The column was 
washed three times with PBS to remove unattached material. Thereafter, the magnetic field 
was switched off by removing the magnet surrounding the column and the remaining cells 
were eluted by adding 2 ml of PBS and counted by FDA staining.  
 
 
 
 121 
 
Chapter 9.1 T Cells Labeling for MRI: an In Vitro Study 
 
 
 
 
Measurement of iron content X-ray fluorescence spectroscopy by wavelength dispersion was 
used to determine traces of heavy metals like iron within the cells. After labeling, washing 
and counting, cells were suspended in distilled water with Tris buffer 0.1%. Under osmotic 
pressure and detergent activity, cells were lysed and the iron released into the in solution. The 
mass absorption coefficient of the pellet was calculated or determined by measuring of the 
scattered X-ray radiation (Compton or Rayleigh scattering) experimentally. The trace content 
of the analyte is determined from the net impulse rate of its appropriate fluorescence line and 
from the intensity of the background line(s) using a matrix normalized curve. 
 
MRI estimation of labeling efficiency After each labeling procedures, cells were washed three 
times with PBS and resuspended in 1 ml of PBS containing 3% gelatin at a concentration of 
106 cells/ml. Superparamagnetic nanoparticles such as FeOs lead to a significant increase of 
the transverse relaxation rate R2. In fact, R2 is proportional to the concentration of FeO 
particles cFeO, 
FeOFeO crRR ⋅+= ,2202        (1) 
 with R20 being the relaxation rate in the absence of the contrast agent and r2,FeO to molar 
relaxivity (in s-1mM-1) of FeO. Alternatively, we can attribute the change in relaxivity the 
number of labeled cells in the medium Ncell according to  
1
,2202
−⋅⋅+= VNrRR cellcell      (1a) 
with V being the sampling volume and  r2,cell the average relaxivity of the labeled cell.  
MRI experiments were carried out using a horizontal bore Pharmascan 70/16 spectrometer 
(Bruker Biospin GmbH, Germany) equipped with a self-shielded gradient insert of 90 mm 
inner diameter capable of switching 300 mT/m in 150µs. A 35 mm inner diameter bird-cage 
coil was used as transmitter/receiver device. The phantom consisted of a Plexiglas support 
containing Eppendorf vials filled with the corresponding cell suspensions. R2 determinations 
were based on a multi-echo Carr-Purcell-Meiboom-Gill (CPMG) sequence with the 
measurement parameters : repetition delay TR = 2034 ms, echo spacing TE = 10.25 ms, 
number of echoes NE = 16 echoes, number of averages NEX = 1 and matrix dimension MD = 
256 × 192).  In addition T1-weighted images were recorded using TR = 600 ms, TE = 8 ms, 
NEX = 4, and  MD = 256 × 128. 
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9.1.4 Results  
 
Physico-chemical properties of FeO and FeO/TA complexes Two important characteristics for 
nanoparticulate materials are the average size and the average ZP.  Almost all particles in 
contact with liquid acquire a surface charge. The ZP is an indicator of this charge predicting 
the stability of a colloidal suspension. The greater the ZP the more stable the suspension due 
to repelling forces in between particles overcoming their tendency to form aggregates. 
Average particle size and ZP for filtered FeO nanoparticles Endorem and Sinerem are given 
in the Table 1. We determined an average diameter of Endorem nanoparticles of 95nm rather 
than the 140nm as indicated by the manufacturer. Negative ZPs have been determined for 
iron-based CAs (e.g. -15 and -19 mV for Endorem and Sinerem, respectively) in agreement 
with results from Kalish et al. [Kalish et al., 2003], who found ZPs of -41.3 and -2.03 mV for 
Feridex and MION particles in water. Discrepancies between ZPs values are probably linked 
to differences in size, coating and concentrations of tested particles.  
 
 Size ( ∅ nm) Zeta Potential (mV) 
 Endorem Sinerem Endorem Sinerem 
Average value 119.49 31.58 -15.41 -19.06 
Standard deviation 58.46 83.01 0.37 1.65 
Table 1: Average and standard deviation values were calculated from a solution of iron particles (e.g. Endorem 
or Sinerem at 22.5µg iron/ml) diluted in filtered, de-ionized, distilled water at ph 7. Concerning the particle size, 
average and standard deviation calculations are weighted with particles occurrence in solution. In this case, the 
standard deviation represents the breadth of the particle-size distribution curve. 
 
When Endorem iron beads are mixed with TAs (Fig.1A), the average size of resulting 
particles is around 114 nm. However, certain mixing conditions involving lipidic TAs (e.g. 
FuGene and Lipofectamine) at low concentration (0.5 mg/mL) induce the clustering of 
Endorem particles together resulting in the formation of larger agglomerated iron clusters. In 
a same manner, aggregation of Sinerem particles was observed at low concentration of TAs 
when using polymeric TAs such as PEI25-75 kD and PLL125-250 kD (Fig.1B). For all other 
conditions an average diameter of Sinerem/TAs complexes of 64±20 nm has been determined. 
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ZP of Endorem/TA complexes was found to be almost always positive except at low 
concentration of lipid TAs (e.g. FuGene6 and Lipofectamine). The average ZP obtained is 
23.2 mV and PLL125-250 kD forms the highest positively-charged particles (Fig.1C). 
Concerning Sinerem/TA particles, the ZP is negative when using lipid TAs except for an 
excess concentration of Fugene (Fig1D). Using poly-amine TAs, ZP reach values around 17 
mV. Again, PLL125-250 kD led to the formation of the highest positively-charged particles.   
 
 
 
 
Figure 1:. Average size of Endorem (SPIO, A) and Sinerem (USPIO, B) particles, respectively, when mixed 
with different TAs. Zeta potential for the various particle-TA clusters are shown in Figs C and D.  The 
concentrations for TAs tested were 0.5, 1, 2.5 and 5µg/ml. 
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FeO labeling studies of T cells without using TAs Previous studies have shown that larger iron 
particles (e.g. Endorem) led to a better labeling efficiency [Frank et al., 2003]. To evaluate the 
effect of FeO nanoparticles on rat T cells, we carried out a series of experiments using 
Endorem as labeling substrate without adding TAs to enhance labeling efficiency.  
Our results indicated that primary cultured T cell can be labeled by just adding of FeO 
nanoparticles to the culture medium. Based on previous studies which demonstrate that 
primary hematopoietic cells incorporate iron particles after 2 hours incubation without TA 
[Hinds et al., 2003a], we decided to evaluate labeling efficiency for a time interval between 2 
to 48 hours. Figure 2A shows that the R2 relaxation rate of T cells started to increase after 2 
hours exposure to FeO nanoparticles. The results indicate that iron contents within the cells 
remained constant between 2 and 8 hours of exposure to the label, but significantly increased 
between 8 and 48 hours of labeling. Obviously, longer incubation times led to a better 
labeling of T cells. These results are in line with observations from other groups [Arbab et al., 
2004a]. As anticipated, higher concentrations of Endorem in the culture medium increased the 
amount of label incorporated in the cells. This is reflected by larger values for the R2 
relaxation rates measured for higher Endorem concentrations (Fig.2B). However, too high 
concentrations of Endorem seem to compromise the viability of the T cells (see below). 
 
 
 
 
Figure 2: Optimization of T cell labeling with SPIO alone: Influence of incubation time (A), SPIO concentration 
(B) and cell concentration (C) on FeO uptake by primary cultured T cells as reflected by the transverse 
relaxation rate. The control value shown in A) and B) is the value for the T cells in the absence of any FeO 
nanoparticles (black bars).The Y axis shows the relaxivity per cell r2,cell (in s-1) in the cell suspension. The 
number of cells were 106 cells/ml for the Figures A and B. 
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Also the cell concentration in the labeling medium had an influence on the labeling 
efficiency: the higher the cell concentration in the solution, the lesser the R2 relaxation rate 
per cell (Fig.2C). In other words, cells are labeled more efficiently when they are not too 
concentrated in solution. This phenomenon might be due to effects of the micro-environment 
conditions and was already observed when labeling lymphocytes with monocrystalline iron 
oxide nanoparticles (MION) [Schoepf et al., 1998b]. 
 
Toxicity and cell activation An important aspect in cell labeling studies is that the label or any 
of the co-added substances do not affect the normal cell physiology. Therefore potential toxic 
effects of the labeling procedures have to be carefully evaluated. A commonly used 
toxicological readout is the cell growth rate. First, we evaluated the influence of FeO 
concentration on T cell growth rate. An increase in the concentration of FeO particles 
decreased the number of cells in the culture dish indicating a cell-toxic effect at high FeO 
concentrations (Fig.3A). In comparison to smaller FeO particle (Sinerem), the negative effect 
of Endorem particles on T cell growth was more pronounced at concentrations exceeding 25 
µg iron/ml. This concentration probably allows the most efficient labeling of T cells without 
significantly affecting the cell growth rate. Based on these results and in agreement with 
published data [Arbab et al., 2003a], we decided to used nanoparticles at a iron concentration 
of 22.5 µg/ml for further labeling experiments. 
 
 
 
Figure 3: T cell toxicity of FeO nanoparticles and TAs: Assessment of cell toxic effects as a function of the FeO 
concentration (A) and the TA used (B). In the MTT assay, the absorption intensity at 560nm is proportional to 
the cell concentration in the suspension. All these experiments were carried out at the same time following 
incubation with FeO particles and TAs under the same conditions. The control value for cell cultures not 
exposed to  TA nor FeO particles is indicated by the dashed line.  
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In a second study, potential toxic effects caused by TAs were investigated (Fig.3B). After 48h 
of culturing in presence of different TAs concentrations, the MTT test showed that all TAs 
seemed to impair T cell growth and cell survival in vitro. FuGene6 and different sized PLL 
appeared less toxic than Lipofectamine and PEI. With the exception of FuGene6, a TA dose 
greater than 2 µg/ml dramatically impaired T cell survival for all TAs. For FuGene6 the 
corresponding ‘toxic’ level was reached at concentrations higher than 5 µg/ml. Toxicity 
tended to increase with higher molecular weight (MW) of PLL at concentrations between 1 
and 2 µg/mL. Analogous results were observed when labeling dendritic cells (Antigen 
Presenting Cells: LADMAC cells) with PLL and FEs [Arbab et al., 2004b]. Lipofectamine 
seemed to be the more toxic compared to the others TAs. In particular, PEI had less toxic 
effects than Lipofectamine at all concentrations tested.   
 
 
 
 
Figure 4: T cell activation by FeO nanoparticles and TAs: Il-2 production of rat T cells in the presence of 
different TAs at concentrations of 1 and 5µg/ml.The IL-2 production is proportional to T cell immune activation 
state. Black bars are the control values for IL-2 synthesis by T cells with and without SPIO. IL-2 secretion of T 
cells increases significantly following administration  of  PLL (p = 0.011) and PEI (p = 0.025) at a concentration 
of 5µg/ml.  
 
 
Thirdly, as the purpose of current work was to evaluate the feasibility of labeling rat T cells 
for imaging studies in vivo, it was primordial to test whether T cell reactivity and activation 
were altered by presence of  FeOs and/or TAs. Interleukin-2 (IL-2) is well known to play a 
critical role in T cell expansion [Nelson and Willerford, 1998] [Lin and Leonard, 1997] and to 
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participate in natural killer (NK) cell activation [Vitale et al., 1998] [Itoh et al., 1985] [Chun 
et al., 1985]. Figure 4 shows the effects of FeOs and various TAs on the degree of IL-2 
secretion by rat T lymphocytes. Compared to the native T cells, administration of Endorem 
alone to the medium did not affect Il-2 secretion. Similarly, Lipofectamine had no significant 
effect on activation on T cells as concluded from the measured IL-2 levels. Significantly 
increased IL-2 secretion was observed when T cells were exposed to poly-cationic agents 
such as PLL (p = 0.011) or PEI (p = 0.025), while FuGene6 had a minimal effect. Among the 
TAs tested, Lipofectamine had the weakest influence on rat T cell activation.  
 
Efficiency estimation of cell labeling To estimate the efficiency of cell labeling, FeO labeled T 
cells were collected using a magnetic sorting device (MiniMACS™ Separator, Miltenyi 
Biotec) exploiting the superparamagnetic properties of FeO nanoparticles. Based on the 
assumption that FeO labeled cells should be retained in the column by the applied magnet 
field, this approach is commonly used to select immune cells presenting FeO beads at their 
surface [Suda et al., 1998]. FACS analysis of MACS isolated cells demonstrated a clear 
predominance of T cells expressing only the CD3 receptor (CD3+) as well as cytotoxic T 
cells (CD3+/CD8+). As proven by the content of the negative MACS selection, the majority 
of monocytes, B cells and NK cells has been removed from our experimental sample.  
 
 
 Spleen cells MACS positive selection 
MACS negative 
selection 
T cells 27.0 48.7 17.0 
Helper T cells 17.0 5.0 10.1 
Cytotoxic T cells 10.0 43.7 6.9 
Monocytes 18.4 0.7 13.2 
B cells 23.4 1.7 27.9 
NK cells 4.2 0.3 24.9 
Table 2: FACS phenotyping of spleen and MACS isolated cells was performed by using fluorescent antibodies 
directed against receptors of CD3, CD4, CD8a, CD45RA and CD161a. Cell populations are given in percentages 
for 100% of living cells present in the sample before (first column) and after MACS selection (second and third 
column).  
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The fact that in our case the labeling FeO particles are supposed to be internalized by the 
lymphocytes should not affect the interaction between the magnetic field column and FeO 
tagged cells. As negative control, unlabeled cell have been run over the column: no retention 
of cells has been observed. Hence, retention of cells is indicative of the presence FeO label. 
Figure 5A shows the percentage of retained cells after 16h and 48h exposure to Endorem and 
different TAs. PEI yielded the highest labeling efficiency followed by PLL with up to 60% of 
the cells carrying FeO labels after 48h, and Lipofectamine. In contrast, FuGene6 did not 
increase uptake of FeO nanoparticles in comparison to FeO alone. Although other studies 
demonstrated no cell labeling in presence of FeOs without TAs after 24h incubation [Frank et 
al., 2003], we found approximately 24% of rat T cells to be labeled with iron beads even in 
the absence of TAs. Optical microscopy observation of cells stained with Prussian blue 
confirmed that fraction of cells carried FeO particles  (arrows, Fig. 5B). 
 
 
 
 
 
Figure 5: Efficiency of T cell labeling: A) Percentage of cell containing FeO nanoparticles after labeling for 16 
and 48h, respectively, for the different TAs. A magnetic selection of labeled cell has been made in order to select 
only cells doped with FeO. Black bars show control values for T cells exposed to SPIOs only. Minimal retention 
was observed for cells not exposed to iron (cells only).  
B) Microscopic image of T cells with 100x magnification after 16h labeling with SPIO in absence of TA. FeO 
nanoparticles (see arrows) appear as blue dots (Prussian blue staining) in neutral red-colored T cells.   
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Figure 6: X-ray spectroscopic evaluation of the cellular iron content after 48h of labeling for the various TAs. 
The black bar indicates the amount of iron in T cells labeled without addition of TA.  
 
 
Experiments using fluorescence spectroscopy of X-rays confirmed the efficiency of  PLL and 
PEI for labeling rat primary cultured T cells (Fig.6). A quantification of iron trace in the pellet 
of lysed T cells revealed almost five times more iron when using PLL as TA as compared to 
the non-TA enhanced uptake. This experiment demonstrated that poly-amine TAs (PLL and 
PEI) led to significantly higher FeO loading to rat T cells than other TAs (lipofectamine and 
FuGene6).  
 
MRI labeling The decrease of the echo amplitudes in the CPMG experiment followed single 
exponential characteristics described by the transverse relaxation rate; R2 values were 
obtained from regression analysis and normalized to the concentration of the cells, in the 
solution, Ncell⋅V-1 From eq. (1a) we obtain 
 
   FeOFeOcellcell crV
Nr ⋅=⋅⋅ ,2,2 1       (2) 
 
Assuming that all FeO particles within the sampling volume are sequestered in the cell, the 
total amount of FeO per cell mFeO,cell can be estimated as 
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,
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Figure 7 represents the average r2,cell values (eq. 1b) for the various FeO / TA combinations as 
derived from forty experiments carried out with different doses of TAs and different labeling 
time. The relaxivity of cells labeled with Endorem was found to be always higher than that 
measured for Sinerem labeling, supporting the notion that larger nanoparticles yield better 
labeling T cells labeled with PLL and Endorem resulted in the highest relaxivity values. Also 
for Sinerem nanoparticles, co-administration of PLL yielded the highest labeling efficiency. 
The relaxivity per cell r2,cell allows the estimation of the amount of FeO particles present in 
each cell (see eq.4): for r2,cell values in the range 2.5⋅10-6 s-1cell-1< r2,cell <3⋅10-5 s-1cell-1 the 
amount of iron per cell is estimated to be 3.5 pg(Fe)/cell < mFeO,cell < 42 pg(Fe)/cell, or 
correspondingly in molar quantities 0.06 pmole (Fe)/cell < mFeO,cell < 0.75 pmole(Fe)/cell. 
 
 
 
 
 
Figure 7: Efficiency of T cell labeling assessed via transverse relaxation rates: Measurement of the r2,cell 
relaxation rate in test vials containing a 1ml suspension of 106 cells labeled with 25µg FeO particles per ml and 2 
and 8µl TAs. Values are given as relaxivity per cell and unit volume according to eq.(1b). The relaxation rates 
reflect the amount of iron in the sample and allows to estimate the labeling efficiency (eq.3). Results have been 
obtained as the average values of ten measurements per TA either with SPIO or with USPIO. The control value 
is for cell labeled with SPIO only without TA.  
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9.1.5 Discussion 
 
The objective of this study was to compare the efficiency of the magnetic labeling of rat 
primary cultured T cell combining commonly available TAs and FeO nanoparticles. As 
magnetic tag we used superparamagnetic dextran-coated Endorem, which exert their effect on 
surrounding water molecules by increasing R2 and R2* relaxation rates. It is known that FeOs 
in presence of TAs self-assemble into complexes that can be used to label cells [Arbab et al. 
2003b]. Coating of FeO by TAs is shielding the water from the FeOs surface preventing any 
appreciable inner sphere relaxation of water molecules. As a consequence the effect of FeOs 
and FeO/TA complexes on water relaxivity is due to the local disturbance of the static 
magnetic field translating into increased of the relaxation rates R2 and R2*. Since the change 
in the transverse relaxation rate is proportional to the amount of superparamagnetic particles 
per cell (eqs. 1 and 3) R2 measurements can be used to estimate the efficiency of T cell 
labeling. From our measurements we estimated that cells were doped with 3.5 to 42 
pg(Fe)/cell depending on the labeling conditions. These values are in good agreement with 
values obtained by Matuszewski et al. [Matuszewski et al., 2005] for labeling of several 
human tumor cell lines. The structure and the self-assembling properties of the FeO/TA 
complexes depends on the surface charges on both the dextran and TA moieties [Arbab et al., 
2004a]. Complexation furthermore varies with the concentration of FeO nanoparticles and 
TA, the pH-value of the solution (all our experiments were carried out at pH=7), the 
incubation time, and the ionic strengths of environment. Correspondingly, these properties 
will also influence the ability of these complexes to label T cells.  
Based on literature data [Arbab et al., 2003b] [Frank et al., 2003] and our own in vitro results, 
we choose a concentration around 25 µg iron/ml mixed with 1 to 2 µg/ml of TA and an 
incubation time of 48h to achieve high labeling of primary cultured T cells. An Endorem 
concentration corresponding to about 25 µg iron/ml SPIO and 2 µg/ml TA (ratio TA/SPIO = 
2/25) were found to constitute thresholds for toxic effects, higher values leading to significant 
T cell toxicity as reflected by decreased growth rates and the occurrence of cell death. A cell 
loss of more than 35% has been observed when using TA doses exceeding 2 µg/ml, 
confirming results obtained by Arbab et al on TAs toxicity [Arbab et al., 2004a]. 
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Large FeO particles (Endorem) turned out to be more toxic than smaller ones (Sinerem), 
however, also led to a better direct labeling of T cells in the absence of TA. As our culture 
conditions were the same in both cases, we can assume that the size of particles is the only 
factor affecting both the cell mortality and the enhanced labeling efficiency. Provided that 
particles are taken up into the cytoplasm, bigger particle sizes would imply more efficient 
endocytosis. The calculated size of the SPIO/TA particle at a ratio of 2/25 was of the order of 
100 to 120 nm in diameter irrespective of the TA used (Fig.1A). However, the ZP of these 
particles clearly depended on the TA mixed with FeO. While PEI and different-sized PLL led 
to a positively-charged particle around with ZP ≈ +40mV. The ZP of  FeO-adducts with 
lipophilic TAs like FuGene6 and Lipofectamine was considerably smaller (ZP ≈ +10mV) or 
as in the case of Lipofectamine at concentrations less than 2 µg/ml even slightly negative 
(Fig.1C).  Two features of the FeO particles seem to be relevant for high uptake of  FeO/TA 
complexes: a particle size of the order of 100 µm (and potentially more) and reasonably high 
positive charge [Hinds et al., 2003b] [Nicholas and Jones, 1986] [Schwendener et al., 1984]. 
The latter is in line with the observation that membrane penetrating peptides comprise a large 
numbers of positively charged amino acids such as arginine [Goncalves et al., 2005]. 
Although a previous study did not observe SPIO uptake in the absence of TA [Anderson et 
al., 2004], we found that approximately 24% of the primary cultured rat T cell were loaded 
with FeO nanoparticles after 48h exposure to a culture medium containing only SPIO but no 
TA. This is probably due to the natural capacity of living cells to take up foreign complexes 
by endocytosis. Moreover, this capacity should be enhanced by the dextran-coating of iron 
particles. Indeed, DEAE-dextran (Diethylaminoethyl dextran) is widely used to transfect 
mammalian cells [Fregeau and Bleackley, 1991] leading to a remarkably reproducible inter-
experimental and intra-experimental transfection efficiency [Gulick et al., 2003]. The exact 
location of the FeO particles within the cells, however, remains unclear. Microscopic cell 
analyses revealed the occurrence of such particles both intracellular as well as extracellular, 
i.e. attached to the cell membrane (Fig. 8A). The same pattern was found for FeO/TA labeled 
cells. Although the presence of TA molecules at the surface of the FeO particles is supposed 
to enhance complex formation, thereby facilitating the penetration of cellular membranes, it 
appears that some particles remain sticking to the outer leaflet of plasma membrane. 
Concerning iron that has been internalized into cells, confocal microscopy experiments using 
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house-synthesized chimerical USPIO-Cy5.5 particles showed that iron within T cells is 
located in the cytoplasm (Fig. 8B).   
 X-ray spectroscopy experiments and NMR R2 measurements demonstrated large PLL 
polymers to be the most efficient TA for labeling of primary cultured rat T cells. On the other 
hand, the presence of PLL caused a strong T cells activation pattern as reflected by the IL-2 
secretion values. This increased activation state could explain the fact that T cells became 
adherent to culture plates and probably also to FeO/TA complexes, or from another 
perspective, the adherence of FeO/TA complexes to the T cell membrane. In presence of 
foreign antigens in the culture medium (such as the TA), primary cultured T cell become 
activated leading to the expression of adhesion proteins and cytokines synthesis [Peters and 
Ernst, 2003]. Hence, exposure of T cells to FeO/TA particles might result either in 
internalization of the particle or in the particle simply sticking to the T cell surface by 
interaction with adhesion molecules.  
It has been established that intracellular tagging of T cells with 0.02 pg iron SPIO per cell can 
be achieved [Bulte et al., 1996]. By using TAs, the ratio between FeO particles and TA 
should be defined in order to achieve a proper formation of complexes small enough for 
efficient endocytosis. In our studies the formation of aggregates between T cells and FeO/TA 
complexes has been observed over a considerable range of TAs concentrations (i.e. 0.5 and 1 
µg/ml) due to the adherent behavior of activated T cells (e.g. with PEI in the Fig.8C). While 
PEI does not form iron clustering (Fig.1 A), it had the strongest effect on the IL-2 secretion of 
T cells (Fig.4). Not surprisingly, PEI displayed the most severe toxic effect on T cell viability 
of all the TAs evaluated (Fig.3B) at low concentrations. On the other hand, labeling efficiency 
of the SPIO-PEI combination was highest, resulting in approximately 60% of T cells 
containing/presenting FeO. This indicates that the increased immune activation state of T cell 
tends to increase the labeling efficiency. This higher number of selected lymphocytes includes 
T cells with internalized iron particles but also a large number of T cells with FeO/TA 
complexes sticking to their surface. Figure 8C shows clear aggregations of activated T cells 
after SPIO-PEI labeling process. Staining of these cells with annexin-V-based fluorescent dye 
(Vybrant™ Apoptosis Assay, Molecular Probes) revealed high fluorescence intensity in such 
clusters. As annexin-V targets externalized phosphatidylserine, which migrate to the outer 
leaflet of the plasma membrane during apoptosis, the high signal intensity is indicative of 
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programmed cell death. We speculate that the formation of aggregates of activated T cells 
with FeO/TA complexes might in fact lead to premature cell death.  
Another undesired consequence of this kind of surface labeling is the ability of iron particles 
to interfere with basic function of cell surface signaling. FeO particles sticking to the outer 
membrane of the T lymphocytes could inhibit the normal immune response by steric 
hinderance of the antigen access to the cell surface receptors.   
 
In summary, our results showed that labeling of primary cultured rat T cells after a fresh 
extraction from the spleen is feasible. Mixing of TA with dextrane-coated FeO nanoparticles 
led to the formation of complexes, which enhances the labeling efficiency compared to 
spontaneous uptake in the absence of TAs. Determination of physico-chemical properties of 
the FeO/TA particles demonstrated that large polymers of PLL led to the formation of the 
highest positively-charged particles suited for efficient uptake. Moreover, qualitative and 
quantitative assessment of iron content within cells showed that the number of labeled T cells 
was highest when using large PLLs as TAs. Hence, from a practical point of view and 
balancing toxicity versus labeling efficiency, the combination of SPIO (22.5 µg/ml) 
associated with PLL (1.5 µg/ml) yielded the best results for labeling primary cultured T cells. 
Although PLL showed no toxicity at concentrations used routinely (i.e. around 1µg/ml), our 
findings revealed that the use of  poly-amine TA provoked a significant T cell activation. As a 
consequence labeling occurs not only intracellularly but also on the surface of cells.  This 
labeling is not negligible and may result in premature phagocytosis of labeled T cells by 
macrophages which could lead for instance to unspecific labeling of macrophages. By 
providing a detailed characterization of the bio-physical properties of  FeO particles coupled 
with specific TAs and their capacity to label primary cultured T cells, the results from this 
study should aid in the determination of efficient procedures to tag T cells with FeO/TA 
complexes which would allow in vivo MR visualization after adoptive transfer of cells. 
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Figure 8: Microscopy of labeled T cells: A) Different examples of primary cultured T cells labeled with SPIO + 
PLL after cytospin centrifugation. The overview image yields an estimate on the percentage of labeled cells. The 
three examples below show a cell containing FeO particles  in the cytoplasm (left), a cell with FeO particles 
sticking to the cell membrane (middle) and a dead cell full of iron (at the bottom of the right image). Prussian 
blue staining was used to visualize the iron content. 
B) Confocal image an 3D reconstruction (Imaris® Bitplane AG) of a T cell labeled with USPIO nanoparticles 
that were also labeled with the near-infrared fluorescent dye Cy5.5. FeO nanoparticles were unambiguously 
identified in the cytoplasm (blue areas). The cellular membrane and the nucleus were stained with Alexa488 
(green) and Propidium Iodide (PI, red), respectively. 
C) Clustering of T cells “glued together” by PEI vesicles containing iron. Green fluorescence signals indicates 
cells undergoing apoptotis (Molecular Probes® Apoptosis kit). 
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9.2 T Cells Labeling for NIRF Imaging 
 
 
Tracking of Cy5.5-Tat Labeled Lymphocytes by Quantitative Near 
Infra-Red Imaging during Acute Brain Inflammation in a Rat Model 
of Experimental Autoimmune Encephalomyelitis 
 
 
9.2.1 Abstract 
Inflammation in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis 
(EAE) is driven by T cells directed against myelin specific proteins. So far, in vivo imaging 
focused on downstream processes such as the infiltration of macrophages or structural 
alterations linked to inflammation and tissue damage. In this work, the infiltration of Cy5.5-
labeled T lymphocytes into the brains of EAE rats was studied by near infrared fluorescence 
imaging. T cells, extracted from the spleens of naïve and immunized rats, were cultured in 
presence of Cy5.5-Tat (100 µg/ml) and administered intravenously to Lewis rats. Four groups 
of EAE animals have been studied: rats receiving activated labeled T cells at 5, 7, and 11 days 
post immunization (dpi) as well as EAE rats receiving naïve labeled T cells. The fourth group 
received naive T cells at 7 dpi. Three control groups received either activated labeled T cells, 
naïve labeled T cells or the Cy5.5 dye only. Measurements were carried out from day 9 to 22 
using a near-infrared fluorescence imaging system. The highest fluorescence signal was 
observed for EAE animals, which received myelin-activated T cells during the acute phase of 
EAE. The temporal profile of T cell accumulation in this group paralleled the pattern of 
neurological impairment during the acute phase, the remittance and first relapse. No disease 
specific fluorescence pattern was observed for EAE animals, which received naïve T cells. 
Inoculation of myelin-activated T cells in naïve animals led to a peak of fluorescence signal 
on day 13, which was less pronounced than in the EAE group. These results demonstrate that 
Cy5.5-Tat labeling of T cells is suitable for in vivo  fluorescence imaging. This approach may 
particularly be useful for evaluation of novel anti-inflammatory therapies. Nevertheless, 
intrinsic problems for longitudinal studies is that, due to short life time of labeled T cells, 
unspecific labeling of scavenger cells (e.g. macrophages) will always occur. 
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9.2.2 Introduction 
 
Multiple Sclerosis (MS) is characterized by neurological deficits that are attributed to the 
demyelination of nerve fibers in the central nervous system (CNS) [Julien and Ferrer, 1989]. 
Inflammation processes can occur anywhere in the central nervous system (brain,  spinal cord 
or optic nerve) causing symptoms such as weakness, sensory deficits and optic neuritis 
[Miller, 1998]. MS is believed to be an auto-immune disease mediated by lymphocytes 
[Calopa et al., 1995; Goust et al., 1978] while hematogenous macrophages and microglial 
cells act as effectors degrading the myelin sheets [Benveniste, 1997]. Evidences of T 
lymphocyte initiative role in MS are for instance the presence of  many active T cells subsets 
in early CNS lesions [Babbe et al., 2000], and the fact that one of the existing method to 
induce MS animal model is to inject myelin activated T cells [Kojima et al., 1997] [Ben Nun 
et al., 1981]. Chronic-relapsing MS involves alternating phases relapsing episodes, with 
significant, frequently aggravating manifestations of neurological symptoms, and remitting 
episodes, during which patients recover partially or fully  [Barnett and Prineas, 2004]. There 
is concluding evidences that even during remission the underlying disease processes leading 
to axonal injury is still ongoing. Today there is compelling evidences that T lymphocytes as 
initiates [Hickey, 1991], orchestrate [Traugott et al., 1983a], and also effects the immune 
response in MS [Huseby et al., 2001] [Steinman, 2001]. Hence, assessment of the T cell 
immune activity, in particular during phases devoid of clinical symptoms, would be of high 
diagnostic and prognostic value and would allow the guidance of therapeutic interventions. 
Chronic experimental autoimmune encephalomyelitis (EAE) is a rodent model that mimics 
multiple aspects clinical MS [Feurer et al., 1985]. EAE is an immune-mediated disease, in 
which immune cells become reactive against myelin components leading to the destruction of 
myelin sheets. As in MS, T lymphocytes are believed to be responsible for initiating the 
immune reaction against myelin, because inflammatory CNS infiltrates were shown to contain 
predominantly T lymphocytes  [Hauser et al., 1986]. Moreover, EAE can be adoptively 
transferred to animals by intravenous injection of myelin-activated T cells [Reynolds et al., 
1996]. Both, brain resident microglia cells and blood-derived macrophages are supposed to be 
rapidly activated and recruited to sites of inflammation by the lymphocytes [Raivich and 
Banati, 2004]. These two cell types seem to be responsible for the immune-mediated myelin 
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injury, which lead to an impairment of the nerve signal transmission and as a consequence to 
the neurological deficits. 
Today, a number of non-invasive imaging approaches have been developed that allow in vivo 
monitoring of the migration of labeled cells. Magnetic resonance imaging (MRI) using e.g. 
superparamagnetic iron oxide nanoparticles as contrast agents provides excellent spatial 
resolution [Bulte et al., 1999]. This approach is limited by the inherent low sensitivity and by 
background signal of MRI. In contrast, positron emission tomography (PET) involving 
radiolabelling of cells is characterized by excellent sensitivity [Adonai et al., 2002]. PET is 
limited by low spatial resolution, the relatively short lifetime of the radiolabel preventing long 
term studies (days, weeks), as well as the study costs. Similar to PET, optical imaging using 
bioluminescent or fluorescent labels provides high sensitivity, sufficient to detect low 
numbers of cells [Doyle et al., 2004] [Edinger et al., 2003] [Lin et al., 2003]. Fluorescent 
labels are relatively stable allowing longitudinal studies. The principal limitation is spatial 
resolution due to diffuse photon propagation in tissues caused by light scattering. 
Fluorescence imaging has e.g. been applied for the detection of endocrine tumor cells by 
using a fluorescent ligand targeting somatostatin cell surface receptors [Becker et al., 2000] 
[Becker et al., 2001] or to monitor apoptotic tumor cells using fluorescently labeled annexin-
V targeting externalized phosphatidylserines [Kietselaer et al., 2003] [Petrovsky et al., 2003].  
The purpose of this study was to monitor the infiltration of  T lymphocytes into the CNS of 
rats in a model of chronic relapsing EAE using fluorescence reflectance imaging (FRI) in the 
near-infrared spectral domain. T cells were labeled ex vivo using chimerical Cy5.5-Tat 
peptide developed in house. Labeled cells were administered to EAE rats to test the feasibility 
of RFI to visualize and quantify T lymphocytes activity during the early inflammation stages 
of EAE.  
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9.2.3 Experimental Protocol 
 
Animal model  The EAE model in the Lewis rat is characterized by a first acute monophasic 
attack around eleven days post immunizing (dpi). The disease course can be prolonged by 
increasing the concentration of foreign antigens (guinea-pig spinal cord fragments) and/or 
Mycobacterium tuberculosis in the inoculum resulting in a remitting-relapsing pattern [Feurer 
et al., 1985]. In our study rats typically went through an acute inflammation period (9-15 dpi) 
followed by a remitting phase (15-20 dpi), during which the animals recovered, and a first 
relapse (20-26 dpi), during which inflammation symptoms reappeared. Brain inflammation 
was monitored only between days 9 to 22, i.e. during the acute phase up to the first relapse. 
Inbred (RT11) female Lewis rats (N=42) from Charles River (Sulzfeld, Germany) were kept 
in a temperature and humidity-controlled room in line with sawdust with access to standard 
rodent chow and water ad libitum. The rats, weighing 140-160 g, were lightly anesthetized 
with isoflurane (Abbott, Baar/Zug, Switzerland) and immunized intradermally (i.d.) at the 
dorsal tail root by injecting 100 µl of a suspension consisting of 1 part (volume:volume) 
guinea pig spinal cord emulsified in 0.9% NaCl to 1 part complete Freund’s adjuvant (CFA, 
Difco, Detroit, MI, US) supplemented with M. tuberculosis strain H37RA (Difco). The final 
inoculum per rat comprised about 66 mg Gp-sc and 2 mg mycobacterium. 
 
Neurological score: The diseased status was assessed using a scoring scale for the 
neurological state of the animals. A careful examination of animal symptoms was carried out 
on a daily basis [Rausch  et al., 2003]. Concidering the state of paralysis of each animals, 
individual scores were estimated as following: 0 = normal healthy animal; 0.5 = loss of tail 
tonus; 1 = complete tail paralysis; 2 = hind limb weakness; 3 = complete hind limb paralysis, 
incontinence; 4 = complete paralysis. 
 
Cy5.5-Tat synthesis The Tat (Twin Arginine Translocation) peptide is a fragment of protein 
from the HIV virus containing multiple arginine groups. This peptide is ferrying foreign 
proteins through the plasma membrane of a cell by an energy dependent process involving 
endocytosis [Vives et al. 2003]. In our study, the indocyanine dye Cy5.5-Mal (Amersham 
Biosciences GmbH, Otelfingen, Switzerland)  was covalently coupled to the Tat peptide in 
order to be shuttled across the plasma membrane of primary cultured T lymphocytes. 
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Coupling was achieved by adding Tat-peptide-Cys (Biosyntan GmbH, Berlin, Germany) in 
DMSO to 1 equivalent Cy5.5-Mal dissolved in DMSO and stirring the mixture for 2h at room 
temperature. The product was purified by chromatography (Biogel P-2; MWCO: 1800, bidest. 
water) and the first fraction was isolated and lyophilized. All operations were done under 
protection from excess light. For labeling of fresh T cells, a stock solution of Cy5.5-Tat was 
prepared by diluting Cy5.5-Tat powder in phosphate buffer (D-PBS, Gibco, Basel, 
Switzerland) to a concentration of 2 mg/ml. This solution was stored at 4°C until use.  
Spectral analysis in the UV/VIS domain was performed using a Lambda 19 
spectrophotometer (Perkin-Elmer AG, Schwerzenbach, Switzerland). The absorption 
spectrum was measured in the wavelength range 850-200 nm with a slit width of 2 nm, a scan 
rate of 120 nm/min and phosphate-buffered saline solution (PBS) in the reference channel.  
Fluorescence measurements were carried out using a Spex Fluorolog II (HORIBA Jobin Yvon 
Inc, Edison, USA), equipped with a 450W Xe-lamp and a cooled detector R928P (Solvias 
AG, Basel, Switzerland). Fluorescence spectra were measured with slit widths for excitation 
and emission mono-chromators set to 1.0 mm (= half width 1.8 nm). Emission spectra were 
measured for excitation at two wavelengths, 678 nm and 630 nm, respectively, 678 nm 
corresponding to the absorption maxima. Excitation spectra were measured by setting the 
detector to 697 nm (fluorescence maximum). Quantum yields were determined in reference to 
cresylvioletperchlorate in methanol, for which a quantum yield of 0.54 was assumed, and 
which has been excited at 594 nm. 
 
T cell preparation Splenocytes were extracted from Lewis rat’s spleens. Organs were 
destroyed in Hanks’ balanced salt solution (Gibco AG, Basel, Switzerland) using a Potter 
homogenizer. The mixture obtained was filtered several times through cell strainers with 
pores sizes of 100 µm, 70 µm and 40 µm in diameter. After the last centrifugation, 
erythrocytes were lysed by resuspending the cell pellet in 0.13 M ammonium chloride. 
Remaining white blood cells were incubated in a 25 cm2 cell culture flask (Falcon®, Becton 
Dickinson Discovery Labware, Basel, Switzerland) in complete medium (CM) composed of 
RPMI medium plus HEPES buffer, 1 mM Na-pyruvate, 1× MEM non-essential amino-acids 
(Gibco AG, Basel, Switzerland), 50 µM 2-mercaptoethanol, 50 µM gentamicin antibiotic,  1× 
MEM vitamins (Gibco AG, Basel, Switzerland), 2 mM L-glutamine, 10% fetal calf serum and 
interleukin-2 (IL-2) stimulating factor (5% rat T-STIM™ solution, Becton Dickinson 
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Biosciences, CA, USA). To remove the majority of monocytes/macrophage population, the 
non-adherent cell population was transferred into a new flask. This method yielded a cell 
population containing about 95% lymphocytes, as determined by morphology analysis 
[Schoepf et al., 1998a]. Rat pan T cells were isolated by immunomagnetic bead selection 
(Miltenyi Biotec Inc, Auburn, CA) according to the manufacturer instruction. A FACS 
analysis of MACS isolated cells was performed to confirm the only presence of T cells in the 
isolated population (results not shown). 
 
Cell labeling Rat pan T cells was resuspended in 1 ml CM at a final concentration of 106 
cells/ml and incubated with Cy5.5-Tat for 1, 2, 4h or overnight at 37°C in 95% / 5% air / CO2. 
Different concentrations of Cy5.5-Tat ranging from 5 µg/ml to 200 µg/ml have been tested. 
To remove free fluorescent probes in solution, cells were washed three times after labeling 
with Hanks’ balanced salt solution (HBSS), counted with Fluorescein Di-Acetate (FDA) 
exclusion method and used for in vivo adoptive transfer, FACS experiments or confocal 
microscopy. 
 
Confocal and FACS analysis  Confocal microscopy was performed using a Leica TCS SP II 
(Leica Microsystems AG, Glattbrugg, Switzerland). Cy5.5-Tat labeled cells were dumped on 
glass slices, allowed to dry and incubated with a immunostaining mixture composed of PBS, 
0.1% Triton X-100 (Sigma, Buchs, Switzerland), an anti-CD3 monoclonal antibody coupled 
to the Alexa488 dye (Molecular Probes, Invitrogen AG, Basel, Switzerland), and propidium 
iodide (PI) for nucleus staining. 
Fluorescence automated cell sorting (FACS) experiments were carried out using a LSR II 
flow cytometer (Becton Dickinson, San Jose, CA, USA). The FACS buffer used was 
composed of PBS with 3% fetal bovine serum (FBS) and 0.02% sodium azide.  
For FACS analyses and confocal microscopy studies the Cy5.5-Tat peptide was excited at 678 
nm and the emitted fluorescence was detected at 698 nm. 
 
Immunolabeling To phenotype splenocytes by FACS, labeled monoclonal antibodies have 
been used. Helper T cells were targeted using an anti-rat CD4 antibody coupled with 
phycoerythrin (PE) (Pharmingen, San Diego, CA, USA), cytotoxic T cells using an anti-rat 
CD8-peridinin chlorophyll protein (perCP), and pan T cells using an anti-rat CD3-
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allophycocyanin (APC) antibody. Cells were incubated for 20 min at 4°C with the antibody at 
the appropriate concentration according to the instructions of the manufacturer. Four-channel 
FACS analysis was performed using the LSR II cytometer.  
 
Cell uptake measurement After washing centrifugations, cell suspensions (106 rat pan T cells) 
were transferred into plastic tubes containing 1 ml PBS. To determine the retention of Cy5.5-
Tat peptide in cells as a function of time; the fluorescence signal of cell suspensions was 
measured using bonSAI FRI prototype device (Siemens AG, Medical Solutions, Erlangen, 
Germany). The fluorescence intensity of reference concentrations of the pure Cy5.5-Tat dye 
were measured in parallel enabling an estimate of the Cy5.5-Tat concentration per T cell. 
 
T cells adoptive transfer and in vivo protocol Prior to FRI measurements, animals were 
anesthetized using isoflurane (2% volume) in nitrous oxide / oxygen. A cannula was placed in 
the tail vein using a catheter (0.5×25 mm, Becton-Dickinson Discovery Labware, Basel, 
Switzerland) for infusion of Cy5.5 labeled T cells. Ten millions (107) cells suspended in PBS 
were injected intravenously. Animals were placed on a heated support, allowing maintaining 
body temperature at 37°C using warm air. FRI measurements were carried out once per day 
for two weeks, starting at 1 day after T cell injection. Whole body scans were carried out for 
all animals at the first and second day after T cell injection to monitor the  unspecific signal 
contribution due to free label or labeled cells in blood circulation (and peripheral organs).  
EAE rats were divided into four groups of 6 animals:  E-AT-5, E-NT-7, E-AT-7, and E-AT-
11. Three groups of six naïve rats each have been used as controls: N-AT-7, N-NT-7, and N-
Cy5.5. The nomenclature is such that the first letter correspond to the type of animal used (E 
= EAE,  N = naïve rat), the second term describes the type of cells the animal received (AT = 
Cy5.5-Tat tagged activated T cells and NT = Cy5.5-Tat tagged naïve T cells), while the 
number correspond to the day of T cell injection. All T cells injected have been labeled with 
Cy5.5-Tat, the activated T cells originated from EAE animals, whereas of naïve cell were 
derived from healthy animals. The experiment setup is summarized in Table 1.  
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Group name Animal Injected cells Day of injection 
E-AT-5 EAE Cy5.5 Activated T cells 5 dpi 
E-NT-7 EAE Cy5.5 Naïve T cell 7 dpi 
E-AT-7 EAE Cy5.5 Activated T cells 7 dpi 
E-AT-11 EAE Cy5.5 Activated T cells 11 dpi 
N-AT-7 naïve Cy5.5 Activated T cells 7 dpi 
N-NT-7 naïve Cy5.5 Naïve T cell 7 dpi 
N-Cy5.5 naïve Cy5.5-Tat peptide 7 dpi 
Table 1: Experimental setup of the in vivo experiment. Cy5.5 labeled activated T cells and Cy5.5 labeled naïve 
T cell were extracted respectively from the spleen of EAE animals and naïve animals, respectively. Cells were 
injected i.v. in the tail vein. The injection days are either 5, 7 or 11 days post EAE immunization (dpi). 
 
 
In vivo NIRF imaging For FRI experiments, rats were anaesthetized using 1.5% isoflurane 
(Abott) in nitrous oxide (2:1) administered with a facemask. Total FRI scanning time was 5 
min per rat. To avoid problems caused by light scattering due to the fur, we shaved animals 
for the FRI experiments.  
 
For time-resolved in vivo brain imaging, a eXplore Optics™ (GE Healthcare) small animal 
imager was used. A laser at 670 nm powered at 4.4 mW and pulsed at repetition rate of 80 
MHz with pulse durations of 60 psec was used for fluorescence excitation. The fluorescent 
light emitted from the sample (rat) was detected by a photo-multiplier tube (PMT-detector) at 
700 nm. FRI images have been analyzed quantitatively on a ROI basis using the same 
software tool provided by the manufacturer. 
Whole body and ex vivo organ imaging were performed with the bonSAI FRI system. For 
fluorescence excitation, three laser diodes at 660 nm with a total power of 10 mW/cm2 have 
been used yielding a uniform illumination of the whole animal. The fluorescent light emitted 
from the sample (rat) was detected by a charged-coupled device (CCD) camera (Hamamatsu 
ORCA, Solothurn, Switzerland) equipped with a focusing lens system (macro lens 60 mm, 
1:2.8, Nikon, Egg/ZH, Switzerland). The image matrix comprised 532 × 256 pixels. A 
bandpass filter was used for the selection of the detection wavelength (698 nm). Experiments 
were controlled by a PC using the Siemens SYNGO software. Autofluorescence measured 
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immediately before cell adoptive transfer turned out to be negligible. All experiments were in 
strict concordance to the Swiss Federal law for animal protection. 
 
Ex vivo analysis and histopathology One animal of each group has been sacrificed at 12 and 
22 dpi. For group N-Cy5.5 three more rats have been sacrificed at one, two and four hours 
after Cy5.5-Tat injection in order to visualize the bio-distribution of the probe in healthy 
animals (results not shown). Rats were killed by an overdose of isoflurane immediately after 
FRI studies. Animals were perfused intracardiacly 5 minutes with a D-PBS to clear organs 
from blood. Thereafter a solution of 4% formalin (4 mg in 100 ml) was infused during 10 
minutes to fix organs. Ex vivo imaging of the brain and the spleen of each animal was 
performed before embedding them in paraffin. Semi-serial slices of 5µm thickness were cut in 
brain areas displaying Cy5.5 signals in vivo. Slices were first treated with a classical 
hematoxylline-eosin (H&E) stain to localize inflamed areas. Morphometric analyses were 
performed on sections stained immunohistochemically (IHC) for ED-1 (macrophages) and 
CD3 (T cells) using the Histolab™ software (Microvision Instruments, Evry, France). Stained 
slides were examined with a light microscope (Eclipse E600, Nikon, Egg/ZH, Switzerland) 
connected to a 3CDD color video camera (DXC-970MD, Sony, Tokyo, Japan). After 
capturing of the total surface of the brain slice, at x20 magnification, the color corresponding 
to each IHC staining (ED1 and CD3 respectively) was extracted by threshold settings and the 
occupied area automatically calculated. The results were expressed as percentage values, 
describing the fraction of the total surface area displaying IHC labeling. Another set of 
histological sections has been stained with monoclonal antibodies directed against CD3 
(coupled to Alexa488) and against ED-1 receptors (coupled to Alexa496), respectively, for 
confocal microscopic analysis. 
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9.2.4 Results and Discussion 
 
Dye description The UVVIS-spectrum of the Cy5.5-Tat complex is shown in Fig.1. The 
corresponding absorbance values for wavelengths  λ = 278 nm, 630 nm and 678 nm are listed 
in Table 2 together with the fluorescence quantum yields determined for excitation 
wavelengths 678 nm and at 630 nm.   
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Figure 1: (A) Molecular structure of Cy5.5-Tat  (B) Absorption and emission spectra. Spectrum for a Cy5.5-Tat  
at a concentration of 1g/ml and pathlength d = 1cm. Fluorescence excited at 678nm. 
 
 
 Absorbance [g⋅ml-1⋅cm-1] Quantum Yield 
wavelength 278nm 630nm 678nm 
Excitation at 
630nm 
Excitation at 
678nm 
Cy5.5-Tat 1.775 2.875 6.576 0.17 0.22 
Table 2: Absorbance and quantum yield value of the Cy5.5-Tat biomolecules when excited at 278, 630 and 
678nm 
 
Estimation of cellular uptake The in vitro fluorescence intensity was found to be proportional 
to the incubation concentration of the Cy5.5-Tat probe (Fig.2).  In addition, Fig.2b shows the 
relationship between the number of living T cells following the labeling procedure as counted 
by FDA exclusion. When using low concentrations of Cy5.5-Tat concentrations in the range 1 
to 50 µg/ml cell viability was not affected. However, concentrations of Cy5.5-Tat exceeding  
100 µg/ml displayed dose-dependent toxicity resulting in a diminution of surviving cells by 
10 to 30% respectively.  
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Figure 2: In vitro cell fluorescence. T cells near infrared fluorescence (A) after overnight incubation with 5, 10, 
20, 50, 100 and 200 µg/ml of Cy5.5-Tat peptide. The fluorescence was quantified by comparing to a standard 
concentration of 0.01% of pure Cy5.5-Tat (0.01g in 100ml distilled water). (B) NIRF intensity as a function of 
Cy5.5-Tat concentration (circles) compared with the number of living T cells remaining in solution after the 
overnight incubation (black squares). 
 
 
Although the total number of viable cells decreased significantly for [Cy5.5-Tat] = 200 µg/ml 
the total fluorescence signal of the T cell suspension still increased as compared to 100 µg/ml 
indicating that the amount of dye complexes per cell increases when incubating with high 
concentration of Cy5.5-Tat. The dose dependence of the fluorescence intensity deviates from 
linearity (Fig.2b), which may reflect saturation of the labeling process or non-linear optical 
effects such a fluorescence quenching at high concentration or a combination of both.  In 
reference to the standard fluorescence (0.01% = 10 mg in 100 ml; long tube in Figure 2a), the 
amount of Cy5.5-Tat peptide present in one T cells is estimated to be in the range 5pg to 50pg 
for an overnight incubation complex concentrations between 5 and 200 µg/ml respectively.  
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In order to further investigate both labeling efficiency as well as the toxic effect of the dye, a 
kinetic study of Cy5.5-Tat uptake was performed and analyzed using FACS. Isolated T cells 
were incubated during 1h, 2h, 4h and 12h with a solution of Cy5.5-Tat complexes at a 
concentration of 200 µg/ml. Fig. 3 shows FACS data of the T cell population that was 
incubated for 12h. Pie charts show the fractions of helper and cytotoxic T lymphocytes that 
were tagged with Cy5.5-Tat, as well as of dead and unlabeled T cells. After incubating for 1h, 
19.5% of the living population of lymphocytes was already labeled. This fraction increases up 
to 36.4% for overnight incubation (12h). In parallel, the population of dead lymphocytes, 
identified on the basis of propidium iodide incorporation, increases from 12.3% to 34.2% of 
the total population. The value is in agreement with data displayed in Fig.2b showing a 
decrease of the number of living cells to 70% after incubating overnight.  
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Figure 3: Kinetic of  Cy5.5-Tat uptake by FACS analysis. FACS data (on the left) represent dual color flow-
cytometry analysis of Cy5.5-Tat labeled T cells after 12h incubation. The y-axis represents the mean intensity of 
Cy5.5 fluorescence, whereas the x-axis refers to conjugated immunoglobulins controls for non-specific labeling 
of T cells (top), CD4-PE for specific labeling of T-helper (middle) and CD8-PerCP for cytotoxic T cells 
(bottom).  
Pie charts represent the sub-populations in 100% of T lymphocytes after 1h, 2h, 4h and 12h incubation with 
Cy5.5-Tat dye (at 200µg/ml). Dead cells (identified by PI staining) are represented in black. Populations of 
living helper (CD4+) and cytotoxic (CD8+) lymphocytes are represented by grey and dashed sectors 
respectively. White sectors represent the population of unlabeled lymphocytes. 
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Even after an exposure of 12h, one third of the total T cell population did not show a 
fluorescent signal, i.e. these cells have not been labeled. We speculate that  either these cells 
represent sub-population of T cells that are not sensible to Tat sequence penetration or that the 
label has been degraded in these cell, e.g. due to the cleavage of the sulfide Mal-Tat bond 
leading to the release/destruction of the cyanine dye. Alternatively, the Cy5.5-Tat probe might 
be released into the cell culture medium, as described by Ensoli et al. [Ensoli et al., 1993]. 
Confocal microscopy analysis confirmed the main intracellular localization of the dye within 
the T cells is the cytoplasmic compartment (Fig.4). Nevertheless, in some cells a significant 
nuclear staining has been observed consistent with previous reports using different Tat 
peptide-derived sequences in Hela cells and mouse splenocytes [Schimmelpfennig et al., 
2005] [Lewin et al., 2000]. Cytoplasmic staining was visible after 1h as described by Fawell 
et al. [Fawell et al., 1994]. Referring to these previous studies, we presume that Tat-mediated 
uptake by T cells occurs via adsorptive endocytosis [Fawell et al., 1994] [Mann and Frankel, 
1991].  
 
 
 
 
Figure 4: Confocal microscopy of labeled T lymphocytes. Confocal raw image (left) of labeled lymphocyte and 
3D reconstruction (middle and right) with the Imaris® software (Bitplane AG, Switzerland). A schematic view 
of the cell is represented on the top of confocal images. Lymphocytes have been incubated with Cy5.5-Tat 
(200µg/ml) for 1h. The cytoplasmic membrane and the nucleus were stained with CD3-Alexa488 (green) and 
Propidium Iodide (red) respectively. The Cy5.5 dye (blue) was mainly localized in the cytoplasm but also within 
the nucleus.  
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T cells adoptive transfer in immunized animals Fig. 5a displays the average neurological score 
of EAE rats as function of time following immunization. Animals showed neurological 
impairment up to a score of 3 in the interval 10 to 12 dpi. The acute phase was followed by a 
remitting phase (15 to 20 dpi), during which the neurological status returned almost 
completely to normal. During the first relapse (21 to 26 dpi), neurological impairment resulted 
in a average score of 0.85, i.e. the symptoms were significantly weaker as during the acute 
stage. 
 
Figure 5: (A) Neurological score of animals 
during the different phases of EAE. Animals 
display neurological impairment during the 
acute phase and the first relapse, while they 
show almost complete remission between the 
two periods. The acute inflammatory phase 
ranges from 9 to 15 dpi, the remitting phase 
from 15 and 20 dpi, and the first relapse from 
21 to 26 dpi.  
(B) NIR fluorescence signal evolution in rat 
brain based on T cell activation state. In this 
experiment, Cy5.5-Tat labeled T cells were 
transferred adoptively at 7 dpi. Animals from 
groups E-AT-7 and N-AT-7 received myelin-
activated T cell while rats from groups E-
NT-7 and N-NT-7 received naïve T cells. 
The NIR fluorescence intensity is given in 
percentage of the initial value at 8 dpi, i.e. 
one day after cell transfer (not shown). 
(C) NIR fluorescence  signal evolution in rat 
brain based on the time of adoptive transfer. 
Similarly to the previous diagram, NIR 
fluorescence intensity is given in percentage 
of the initial value. This value is 5 dpi for the 
group E-AT-5, 7 dpi for E-AT-7 and 11 dpi 
for E-AT-11. All animals received myelin-
activated T cells preliminary labeled with 
Cy5.5-Tat.  
 
 150 
 
Chapter 9.2  T Cells Labeling for NIRF Imaging 
 
 
 
 
 
Rats received intravenously 107 T lymphocytes at 5, 7 and 11 dpi. For all groups, an intense 
fluorescence signal could be detected in the brain immediately following the injection. This 
signal decreased to a lower signal for control groups (N-AT-7, N-NT-7 and N-CY5.5) one 
day after injection. For these animals, no fluorescence signal was detectable in brain and 
peripheral organs one day after T cell transfer with the except for spleen and liver (result not 
shown). The fluorescence signals of organs harvested from the group N-CY5.5 suggest that 
i.v. injected dye redistributes to spleen and liver during the next hours in agreement with 
published data [Schimmelpfennig et al., 2005] [Basse, 1995].  
 
In vivo FRI imaging FRI measurements were carried on from day 1 following T cells injection 
until the middle of the first relapsing phase (22 dpi). Semi quantitative information of the 
fluorescence signal evolution was derived from FRI images by normalizing in a region of 
interest comprising the brain actual fluorescence intensity to that of the first measurement 
(=100%) recorded 1 day after T cell injection [Hintersteiner et al., 2005]. A significant 
difference in the NIRF signal has been found between EAE groups (E-AT-5, E-NT-7, E-AT-7 
and E-AT-11) and control groups (N-AT-7, N-NT-7 and N-CY5.5) throughout the duration of 
the experiment. While EAE groups revealed large differences in fluorescence intensity as a 
function of time, the signal in control animals remained essentially constant at lower intensity. 
The brain fluorescence measured in animals of the group N-CY5.5 (results not shown) was 
equal to the background signal within error limits.  
The role of lymphocyte activation state on their migratory properties towards sites of 
inflammation has been analyzed by comparing groups which received either activated or 
naïve T cells (E-NT-7 versus E-AT-7, N-AT-7 versus N-NT-7). Fig. 5b shows the progression 
of the fluorescence intensity in both EAE and naïve animals following the injection of either 
myelin-activated or naïve T lymphocytes. Animals in the group E-AT-7 show the strongest 
signal during the acute phase up to 90% of the initial value. Transferred lymphocytes must 
find their way towards their target (i.e. myelin) by the means of a chemotactic gradient 
[Hickey, 1991], taking part in the already-activated endogenous immune response [Carrithers 
et al., 2000]. Although animals from group N-AT-7 were healthy, adoptive transfer of myelin-
activated T cell led to a 50% NIR signal in the time period 12 to 15dpi, which decreased 
subsequently. It is known that transfer of myelin activated T lymphocytes may prompt an 
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immune response in immuno-deficient mice and induce EAE [Lafaille et al., 1997]. Since 
Lewis rats we used for this experiment were not immuno-deficient, this response is 
considerably weaker than in the EAE model (i.e. the fluorescence signal in N-AT-7 rats was 
significantly weaker than the group E-AT-7). Control groups E-NT-7 and N-NT-7 showed no 
significant changes in fluorescence signal following lymphocyte transfer.   
Another aspect that might influence the migration of labeled T cells to the brain parenchyma 
is the time point of injection. Fig. 5c shows the fluorescence signal in rat brain following 
adoptive transfer of T cell at different time points (i.e. 5, 7 and 11 dpi). For the groups E-AT-
5, E-AT-7 and E-AT-11, the highest fluorescent intensity was reached at the end of the acute 
phase (15 dpi) followed by a decrease of fluorescence intensity during the remitting period. 
During the acute phase, a significant increase of the fluorescence intensity to an average value 
of 80% of the initial signal irrespective of the time point of T cell injection. During the 
remitting and relapsing phase, the brain fluorescence signals followed course of the 
neurological state decreasing to 32% at 19 dpi. During the first relapse, when increasing 
migration of labeled T cells to the CNS occurs (at 20 dpi) the average fluorescence intensity 
increased concomitantly to reach 50% of the initial value. Data in the Figure 6 illustrate that 
the fluorescence signals, reflecting the amount of labeled T cells in the brain, correlate with 
the neurological state of animals, which is linked to the cellular and molecular activity of the 
immune system within the parenchymal brain tissues [Tabira, 1989].  
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Figure 6: Correlation diagram. The NIRF intensity is represented as a function of the neurological scoring of 
animals. Numbers beside points correspond to dpi.  
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In the EAE groups, the fluorescence signal paralleled course of the EAE disease. Correlation 
of the E-AT-7 fluorescence data with the neurological (Fig. 6) score yielded a correlation 
coefficient of R2=0.75, indicating that the fluorescence intensity is linked to the immune 
activity in the brain. We presume that this increase of fluorescence prior to the onset of 
symptoms (at 9 dpi) reflects the accumulation of myelin-activated T cells in inflammation 
sites, which trigger the infiltration of activated monocytes causing tissue damage and thereby 
neurological deficits. Fluorescence peaks at 11 dpi indicating increasing recruitment of 
activated T cells involved in the immune reaction against myelin [Babbe et al., 2000]. These 
data obtained from non-invasive imaging are in line with previous EAE studies demonstrating 
the initiative role of T lymphocytes, which recognize the major histocompatibility complex 
(MHC) complex expressed by affected brain cells [Neumann et al., 2002] and myelin antigens 
[Hartung and Rieckmann, 1997]. A small increase in the fluorescence signal intensity is 
observed at the beginning of the first relapse phase (20 dpi), the origin of which is not 
unambiguously revealed. It rather difficult to attribute this signal to T lymphocytes because T 
cells that are present in acute brain lesions seem to undergo apoptosis when EAE animals 
recover (i.e. remitting phase) [Schmied et al., 1993] [Gold et al., 1997]. Although, T cell 
apoptosis appear to be restricted to cells located in the neuroectodermal parenchyma [Bauer et 
al., 1998], we speculate that this signal increase arises either from unharmed labeled T cells 
present in the brain’s connecting tissue compartments or from macrophages entering brain 
parenchyma that have been labeled by phagocytozing apoptotic T cells and accordingly the 
Cy5.5-Tat probes. It has been shown that both microglial cells and hematogenous 
macrophages that interact closely with T cells influence their susceptibility to apoptosis 
[Pender and Rist, 2001] and also participate in the phagocytosis of apoptotic lymphocytes in 
the CNS [Nguyen and Pender, 1998].   
 
Ex vivo imaging and correlative histology In vivo results were confirmed by ex vivo 
fluorescence measurements on brains excised at 12 and 22 dpi. Ex vivo imaging and 
fluorescence microscopy demonstrated the presence of Cy5.5 fluorescence signal in the brains 
of animals from groups E-AT-5, E-AT-7 and E-AT-11 and N-AT-7 whereas signals from 
groups E-NT-7 and N-NT-7 were significantly weaker or not observed at all. Fig. 7 illustrates  
the ex vivo analysis procedure. After in vivo localization of the region of interest, the 
corresponding histological brain section was selected, immunohistochemically stained in 
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order to identify T lymphocytes and macrophages. Histo-morphometrical analyses showed the 
exact co-localization of CD3 and ED1 tracers in the periphery of the medulla (Fig.7b) 
confirming the predominant infiltration of these cells into EAE lesions [Hauser et al., 1986]. 
Confocal images (Fig.7c) revealed more detailed information on inflamed areas 
demonstrating labeling of both rat T lymphocytes and macrophages with Cy5.5-Tat. Clearly, 
labeled T cells had been taken up by activated monocytes.  
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Figure 7: (A) In vivo raw image of the Cy5.5-Tat fluorescence signal in the brain. The exact localization of ex 
vivo and histological investigation has been define in the medulla where the signal was the strongest (white line). 
In this case, the animal belong to the group E-AT-11 and histological investigations were performed on day 12 
dpi. 
(B) Histological correlation. Peroxidase staining of T lymphocytes (CD3+) and macrophages (ED1) present in 
the brain has been performed. T cells and macrophages colocalize unambiguously in inflammation areas (i.e. 
periphery of the medulla). For all measurements, the area occupied by T cells was approximately half of the area 
occupied by macrophage 
(C) Confocal microscopy. Cy5.5-Tat fluorescence, CD3+ and ED1 labeling appear in blue, green and red 
respectively. Lymphocytes but also macrophages are labeled with Cy5.5.  
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In summary, our study demonstrated that the indocyanine dye Cy5.5 can be shuttle into 
primary cultured T lymphocytes using the Tat peptide as vector. The Cy5.5-Tat complex 
exhibits low toxicity and a sufficiently high fluorescence quantum yield  for in vivo detection 
of labeled cells after intravenous injection. Microscopic analyses of labeled cells revealed 
probe presence in the cytoplasm after 1h incubation, and to a lesser extent in the nucleus. 
Adoptive transfer of labeled T cells permitted visualization of T cell infiltration into the brain 
parenchyma during the acute inflammation episode of EAE. This approach allows studying 
mechanistic aspects of the immune response, in particular the early lymphocyte infiltration 
leading to the recruitment of effector cells. In later phases, phagocytosis of dead T cells by 
macrophages will lead to unspecific labeling of the latter. However, removal of dead cells 
reflects a normal activity of the immune system, and irrespective of the cell type and label 
used, unspecific labeling of macrophages might occurs in every longitudinal studies.  
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Important developments in computer sciences in the past decade have provided powerful tools 
to improve imaging technologies. Advances in the imaging sciences could change the face of 
medicine, making possible to non-invasively detect, diagnose and guide therapy for a large 
variety of diseases. Positron emission tomography (PET), magnetic resonance imaging (MRI), 
fluorescence optical tomography or nuclear medicine techniques are examples of the detection 
methodologies used with molecular probes and contrast agents that typify the powerful new 
field of molecular imaging. Although the science of molecular imaging needs further 
development to be used as a routine clinical tool, imaging technologies such as MRI and 
computed tomography (CT) scanning have become standard tests in disease detection and 
patient management. As a consequence, new clinical modalities with improved sensitivity 
such as brain imaging for the characterization of neurological diseases are on the horizon. In 
order to enhance the ability to detect disease at its early stages, scientists must determine how 
to define disease better in terms of the specific biological (i.e. molecular and genetic) 
abnormalities underlying symptoms.  
 
In the EAE rat model of neuroinflammation, blood derived macrophages and microglia 
activity in brain lesions is directly linked to the destruction of myelin sheets [Bauer et al. 
1994]. Longitudinal imaging of  macrophages by MRI can thus allow a non-invasive 
localization of active myelin degradation spots in the brain. The protocol to tag macrophages 
with iron consist on injecting ultra small particles of iron oxide (USPIOs) intravenously 24h 
hours before MR measurements [Rausch et al. 2001]. As we discussed it in our first report 
[Berger et al. 2006], we attribute the decrease in the T2 to the recruitement of iron-labeled 
blood-born macrophages because passive diffusion of USPIOs (around 30 nm) across 
inflamed BBB fenestration (20 nm) [Rapoport 2000] can not be expected. However, it is still 
not clear whether the internalization of iron particles occurs exclusively in the blood by 
hematogenous macrophages or on inflamed lesions by microglial cells and brain-resident 
macrophages [Modo et al. 2005]. The main problem arises from the broad size-distribution of 
iron particles which can influence their physicochemical and pharmacokinetic properties 
[Wang et al. 2001]. For instance, although manufacturers indicate a size of 20-40 nm for 
SINEREM particles, we measured an average size of 31 nm with values ranging from less 
than 10 nm up to 75 nm. As the rate of internalization by macrophages is determined by 
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particle size [Rogers and Basu 2005], size discrepancies of USPIOs may not only lead to 
labeling of macrophages but also to penetrate brain parenchyma (i.e. particle smaller than 20 
nm passing through the impaired BBB). In this context, further kinetic uptake measurements 
of iron particles by phagocytic leukocytes and an estimation of free iron particles entering 
brain parenchyma should be analyzed.  
A new kind of contrast agents for MR investigation are dendrimers [Kobayashi and Brechbiel 
2004]. As these macromolecules complexes are polymeric compounds synthesized through a 
sequence of iterative reactions, it is possible to control their size, shape and surface chemistry 
at the molecular level [Tomalia et al. 1990]. By coupling dendrimers with the adequate size to 
Gd ions, it should be possible to label macrophages for T1 imaging.  
Strategies to improve the specificity of cell labeling for MR imaging have been investigated. 
An other way to target contrast agent to inflammation zones is to couple them with molecules 
specific for immune activity. The expression of adhesion proteins such as selectin [Bernardes-
Silva et al. 2001] or apoptosis marker like annexine-V [Kietselaer et al. 2003] are 
characteristic for ongoing inflammation processes. Experiments, carried out recently, relate 
the possibility to synthesize and characterize new generation of Gd-chelates contrast agents 
coupled to the sialyl Lewis X molecule, which bind to E-selectin [Laurent et al. 2004]. 
Dendrimers which present multiple terminal reactive groups on the exterior of the molecule 
[Venditto et al. 2005] are also potential macromolecular contrast agents  that can be 
associated to inflammation markers.  
An other challenge in the molecular imaging field is to label non-phagocytotic cells. Due to 
their high therapeutic implications, stem cells have been studied extensively for in vivo 
tracking [Hoehn et al. 2002] by labeling them using magnetodendrimers [Bulte et al. 2001] or 
iron oxide particles combined with commonly available transfection agents [Frank et al. 
2003]. The results we have obtained in this thesis show that it is possible to translate this 
technique to T cells labeling for T2 MR imaging. Recent in vivo results have shown the 
possibility to monitor such cells in the spleen [Dodd et al. 2001], in tumors [Kircher et al. 
2003], but also in the spinal cord [Anderson et al. 2004] and in the brain [Pirko et al. 2003] of 
neurodegenerative animal models. However, the MRI technique lacks sensitivity and i.v. 
injected labeled cells diluted in the blood circulation and redistribute mainly to the liver and 
the spleen [Schimmelpfennig et al. 2005] [Basse 1995]. To overcome these problems, contrast 
agents exhibiting a higher tissue discrimination potential (e.g. T1 paramagnetic CAs) 
[Rudelius et al. 2003] or bimodal imaging properties can be used to corroborate in vivo 
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visualization of cells by correlative histology [Huber et al. 1998] should be used to label T 
cells. The use of bimodal agents (MRI / fluorescence) has the further advantage of 
complementing the high spatial resolution of structural information given by MRI by a more 
sensitive detection using optical imaging technology [Modo, Hoehn, and Bulte, 2005]. A new 
promising technique in this regard is near infrared fluorescence imaging that exploits the 
narrow window in the 700-900 nm range which allows a very sensitive display of changes at 
the cellular level to depths of several millimeters [Wolbarst and Hendee 2006]. Results 
presented in the thesis confirmed the ability to monitor immune cells movement within the rat 
brain during acute inflammation.  
However, despite the versatility of contrast agents, a large number of CA molecule are needed 
in each cell to allow a clear in vivo visualization. Heavily labeling cells can lead to CA 
induced cell toxicity and thus to the premature death of such labeled cells. Consequently, 
unspecific labeling of phagocytic cells such as macrophages may be inevitable as they will 
internalize fragments from dead CA labeled cells.  
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